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Abstract 
The use of polar anti-solvents for the crystallisation of lactose from 10% (w/v) aqueous solutions 
has been investigated.  Crystal growth was observed at 50-65% antisolvent content and showed a 
morphological transition from polyhedral to needle-like habit with increasing antisolvent content, 
which coincided with a polymorphic transition from alpha lactose monohydrate (L.H2O) to beta 
lactose (L.  Where anhydrous dehydrating antisolvents were employed such as methanol and 
ethanol, evidence of L.H2O dehydration to form stable anhydrous alpha lactose (LS) was also 
observed at 95% antisolvent content.  Powder X-ray diffraction (PXRD) analysis of the samples 
highlighted the preferred orientation effects exhibited by large crystals of this kind, indicating the 
difficulties experienced by the non-specialist when performing phase identification of lactose 
polymorphs by PXRD.  Application of the same crystallisation procedures to a racemic mixture of 
the active pharmaceutical ingredient (API) salbutamol sulfate (SS) indicated that some conditions 
can promote the formation of solvated SS. 
 
Ethanolic suspensions of spray dried and micronised L.H2O, with average particle size between 3 
and 200m, were prepared by static and reflux methods and compared with sub-micron lactose 
(SML) suspension prepared by a high pressure homogenisation approach.  Dehydration behaviour 
as a function of time was investigated by 
13
C CP MAS NMR spectroscopy and in all cases, 
indicated that suspensions contained LS.  Several approaches were employed to remove ethanol 
from these suspensions and the products were analysed by PXRD and scanning electron 
microscopy (SEM).  For samples with mean particle size greater than one micron, LS was retained 
on removal of the ethanol, although differences in the morphology and particle size of the crystals 
were apparent. These data imply that while SML is stable under dry conditions it is more 
susceptible to rehydration than standard LS with particle size between 3 and 200m.  In-situ 
13
C 
CP MAS NMR spectroscopy, employing hand-made glass inserts, was used to investigate the 
dehydration behaviour of L.H2O to LS in ethanolic suspension.  Strong ethanol 
13
C resonances 
were observed for some samples, indicating a liquid-solid interaction between the ethanol and 
lactose surface.  Replacement of ethanol with anhydrous methanol, n-butanol and 3-methylbutan-
2-ol implied that the solvent mediated dehydration is sterically controlled. 
 
13
C CP MAS NMR studies of SS, fluticasone propionate (FP) and salmeterol xinafoate (SX) 
showed that both SS and FP exhibit very short relaxation times for a solid material (~2s).  This 
liquid-like behaviour is particularly beneficial pharmaceutically, as these APIs are often mixed with 
an excess of lactose in inhaled formulations.  Lactose behaves as a typical crystalline solid, and 
therefore experiences significantly longer relaxation times (~360s).  Signals from SS and FP were 
successfully isolated from lactose/API blends (98%/2%) simply by reducing the delay times used 
within the 
13
C CP MAS NMR experiment. 
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Inhalation therapy is an effective means for the treatment of asthma and chronic obstructive 
pulmonary disease (COPD).  There are two main systems which provide respirable dosages for the 
treatment of such conditions, dry powder inhalers (DPIs) and pressurised metered dose inhalers 
(pMDIs).   
  
While the inhaler system is commonly associated with the treatment of asthma, it is important to 
note that the technology is expanding to include other drugs that are poorly absorbed by other 
means or to improve methods of drug administration.  Research is becoming ever popular in the 
field of protein and peptide drug delivery via the lungs, and in particular, the inhalation of insulin as 
a means to avoid subcutaneous injections for the treatment of diabetes [1-3].  Pfizer released 
inhalable insulin (Exubera®), though in October 2007 it was removed from the market following 
claims that this method of insulin administration had links to lung cancer in smoking patients [4], 
however Pfizer claimed that the removal was purely due to economic factors.  Following the 
product removal, further investigation into inhaled insulin continued as Pfizer collaborated with 
MannKind Corporation to produce Technosphere® Insulin [5,6].      
 
The main obstacle for inhalation therapy lies with the natural ability of the airways to filter out 
particulate matter to avoid damage to the lower airways.  The viscous mucus that lines the airways 
attracts aerosolised particles, and the natural bifurcation of the airways increases the probability of 
inertial impaction and hence failure to reach the peripheral airways.  This protective system cannot 
distinguish between dust particles and beneficial drugs, so the design of inhaled pharmaceuticals 
must be specific enough to combat these effects.   
 
What follows in this introduction, is an account of inhalation technology currently available to 
provide a background for the discussions presented.  The different types of inhalers, components 
of formulations and the means of production of particles to be delivered to the lungs are 
considered.  Characterisation of these particles is also a necessity and therefore the methods 
employed to collect these data are also discussed. 
 
1.1 Formulation for inhalation 
 
The material contained within an inhaler canister is known as the formulation.  It is a common 
misconception that the canister of an inhaler contains only the drug (also referred to as the active 
pharmaceutical ingredient; API), as when a dose is expelled only powder is observed.  However, 
there are various other components required to produce this aerosolised powder, which work 
alongside the inhaler technology to maximise drug delivery to the lung.  The formulation 
components and their importance will be discussed here for both DPIs and pMDIs. 
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1.1.1 Dry powder inhaler (DPI) 
 
A DPI chamber normally consists only of the medication formulation in powder form.  There are 
many advantages to this system, for example in most modern inhalers the dose is breath activated 
and consequently hand-lung coordination to synchronize dose discharge and inhalation is no 
longer a necessity.   
 
There are many types of DPI systems, ranging from single dose loading, to multiple dose 
capability.  The diagram shown in Figure 1.1 [7] is an example of a multiple dose system; there are 
obvious similarities in appearance to that of the pMDI (section 1.1.2).   
 
 
Figure 1.1  Schematic of a DPI 
 
pMDI systems make use of a propellant to aid API aerosolisation.  Due to the lack of propellant in 
the DPI system, it is of paramount importance that the properties of the formulation are optimised 
such that dose success is high, therefore a number of research groups have focussed on the need 
for an effective delivery system [8-12]. 
 
DPI systems are usually based around an API/excipient binary system.  This is where the drug in 
question (e.g. beclomethasone diproprionate, fluticasone propionate (corticosteroids), or 
salbutamol sulfate (a bronchodilator), is mixed with an excipient or carrier, typically alpha lactose 
monohydrate (LH2O) in a standard ratio of 1:67.5 w/w [13].  Research has shown that there are 
three main areas which benefit from these types of system [14]: 
 
1. The release of the API from the carrier particles is promoted; 
2. Powder flowability is improved (i.e. aerodynamic properties); 
3. Moisture resistance and storage stability is improved. 
 
These effects not only improve deep lung penetration, but also reproducibility in terms of dosage as 
the drug dose required is so small that the inhaler systems have insufficient accuracy to administer 
Overcap
Bulk chamber cover
Bulk chamber
Metering cylinder
Dust cap
Mouthpiece
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such small quantities.  Dose accuracy seems to improve with volume dispensed which can vary 
depending on the inhaler type (and efficiency), drug dispensed and dosage required [15].  The 
excipient not only acts as a carrier, but also a diluent for the drug, allowing for larger volume 
dispensations per dose.  
 
1.1.1.1 Inhalable particles 
 
Both drug and excipient must meet regulatory requirements (set by the Food and Drug 
Administration, FDA) to be suitable for use as an inhalation product.  The powders contained within 
the inhaler system must comply with regulations controlling which compounds are suitable for 
inhalation, as well as particle size guidelines.  
  
API particles in the order of 1-5m in diameter are considered to be within the “respirable range” 
[16-18].  Particles larger than 5m are considered too large for inhalation.  For deposition in the 
central airways, particle size must be a maximum of 5m, however to achieve the desired deep 
lung/alveolar penetration a particle size of 2-3m is preferred.  A common misconception is that 
particles below 1m are simply exhaled.  This is not always the case, though the probability of 
exhalation increases as the particle size decreases, and particles below ~0.5m in diameter are 
more likely to be exhaled [19].   
 
It must be acknowledged that particle size control alone is not sufficient in the behavioural control 
of a powder formulation.  Chan and Chew [14], Buckton [8] and Malcolmson and Embleton [19] 
suggested that there are many other factors, such as morphology and surface roughness,  that 
affect powder flowability and deep lung penetration, while Bosquillon et al. [20] showed that the 
presence of a larger “carrier particle” or excipient also proves beneficial.  These studies contributed 
to the development of the binary system.  In a binary system, the small (1-5m) API particles 
adhere to the surface of larger (63-90m [13,21-24]) excipient particles, most commonly LH2O.  
The basis of this combination is that on inhalation, the turbulent air from the inhaler and inhaled 
breath causes the two species to separate [25].  The carrier particles are then deposited in the 
oropharyngeal region, while the smaller APIs enter the lungs [13,26].  
 
In order for this system to be effective, it is important that the binary formulation exhibits two main 
properties [27]: 
 
1. The powder (API and excipient formulation) must be free flowing and non-cohesive; 
2. Drug/carrier interactions must be weak enough to avoid permanent agglomeration and to 
allow drug deposition. 
 
Electrostatic charges play a large role in these two properties.  When particles collide with each 
other or surfaces, charge transfer takes place, leading to accumulation of a net charge on the small 
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particles [21].  This increases the chances of agglomerate (larger masses of small particles) 
formation during the early production processes as well as within the inhaler canister.  These 
electrostatic charges can also have a detrimental effect on particle deposition in the respiratory 
tract, as well as the separation of the drug/carrier binary.  It is because of these problems that 
ternary systems were introduced. 
 
A ternary system is a combination of API and excipient with the addition of a third species referred 
to as “fines”.  These are small particles that are added to the formulation to occupy high energy 
adhesion sites on the carrier, therefore inhibiting the binding of the API in these positions, leaving 
only lower energy regions.  API/excipient adhesion forces are reduced and therefore, separation of 
the API on inhalation is facilitated [27].  The fines are usually in the particle size range of 4-7m 
and represent only a minority of the formulation, typically 1.5-10% by weight [28].  The similarity in 
particle size to the API aids the competitive nature of their function.  Fines are also usually LH2O 
as the use of an already established inhalable material avoids toxicological issues associated with 
the addition of a third species [13]. 
 
While the addition of fines overcomes the problem of electrostatic forces within the formulation, 
they also have associated disadvantages.  Ternary systems may result in poorer powder 
aerodynamic properties, which to an extent, opposes the theoretical basis for the use of excipients.  
The addition of fines also increases the probability of undesirable penetration of peripheral airways 
by small LH2O particles.  Each of these factors must be considered throughout the formulation 
process, such that the efficiency of drug delivery to the lungs is improved, without affecting the flow 
properties or introducing excessive amounts of lactose to the lungs [13].   
 
As the flow properties of inhalable powders make such an impact on dose delivery, particles for 
inhalation are often characterised according to their aerodynamic diameter (dA).  This is defined as 
“the diameter of a sphere of unit density, which reaches the same velocity in the air stream as a 
non-spherical particle of arbitrary density” [29].  This diameter essentially is used to define the 
mechanism of particle deposition within the respiratory system.  This dA is dependent not only on 
air flow (constant for an inhaler system) but also particulate properties for example size, shape and 
density, each of which contributes to powder flow properties. 
 
Further attempts to improve dose delivery to the lung resulted in the use of propellants to aid 
aerodynamic flow of the API.  This technological advance saw the production of the first 
commercial pMDI in 1955 by Riker Laboratories Inc. (now 3M Health Care Ltd) [30]. 
 
1.1.2 Pressurised metered dose inhaler (pMDI) 
 
A pMDI typically exists in the arrangement shown in Figure 1.2 [7]. 
 
 
Chapter 1  Introduction 
Page | 6  
 
 
Figure 1.2  Schematic of a pMDI 
 
As in the DPI, the canister featured acts as a storage device for the formulation, however in pMDIs 
the formulation differs significantly.  Where a DPI formulation consists only of an excipient/API 
mixture, pMDI formulations usually consist of micronised drug suspended or dissolved in liquefied 
propellant, a co-solvent (also suitable for inhalation, such as ethanol) and surfactant [31].  More 
recently lactose has also been added to suspended formulations as a suspension aid [32-34]. 
 
1.1.2.1 Propellant 
 
Propellants used in formulations are liquids, typically halogenated hydrocarbons, of low boiling 
point.  These may be mixed with co-solvents such as ethanol to reduce the vapour pressure of the 
propellant, and produce a suspension of the desired solvency of the API.  When the dose is 
expelled, the pressure difference between the sealed canister and the mouth piece results in rapid 
expansion of the propellant.  This physical effect forces aggregates apart and disperses the liquid 
formulation to form droplets.  The further evaporation of the propellant/co-solvent blend results in a 
powder aerosol for inhalation.  The use of such propellants is thought to increase deep lung 
penetration, making the pMDI more efficient than the DPI system [35]. 
 
Halogenated hydrocarbons (chlorofluorocarbons (CFCs) and more recently hydrofluoroalkanes 
(HFAs)) are preferred as propellants owing to their low toxicity, non-flammable nature and poor 
solubilising ability of most APIs.  From the release of the first pMDI in 1955 until ~1985, propellants 
were typically CFCs.  Due to environmental considerations, these were phased out (following the 
“Vienna Convention for the Protection of the Ozone Layer followed by the Montreal Protocol on 
Substances that Deplete the Ozone Layer in 1987” [36]) and replaced with ozone benign HFAs.  
These propellants were selected as they have similar properties to the original CFCs but also have 
good availability, are compatible with inhaler components and have been shown to inhibit the 
growth of microorganisms.  The most commonly used propellant is given the name HFA 134a 
(Figure 1.3).   
 
Canister
Actuator
Metering valve
Actuator nozzle
Actuator seat
Formulation
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HFA 134a
Boiling point -26.5oC
 
Figure 1.3  HFA 134a 
  
As a result of the low boiling point of these propellants, inhaler canisters are filled by a process 
called “cold filling”, where the propellant is chilled to a point below its boiling point (such that it 
remains liquefied) to allow for the blending of APIs, excipients, co-solvents and surfactants. 
 
1.1.2.2 Active pharmaceutical ingredient (API) 
 
As with DPI formulations, the API used within suspension pMDIs must be within the designated 
respirable range (1-5m).  Methods of micronisation for pharmaceutical use are discussed in detail 
in section 1.2, but specifically for pMDIs, API/excipient micronisation is usually carried out by 
means of fluid energy milling with compressed air.   
 
The solubility of the small API particles in the propellant is particularly important.  Where an API is 
completely soluble or completely insoluble in a given propellant, the formulation can achieve long 
term stability.  In the case of partial solubility, crystal growth can occur.  This has detrimental 
effects on the delivery of the API to the lung, as particles can grow to sizes out of the respirable 
range and may cause obstructions in the inhaler spray orifice, completely preventing dose 
expulsion.  API/propellant suspensions are the preferred mode of formulation, as in most cases 
stability (i.e. with respect to polymorphism, particle growth) of the API is greater in solid form.  The 
solubility of excipients under pMDI formulation conditions must also be monitored for the same 
reasons.  Suspended formulations, are of interest as these are relevant to the studies presented in 
this thesis.  
 
1.1.2.3 Surfactant 
 
A surfactant, or “surface active agent”, is a material that is attracted to and absorbed at an 
interface.  With respect to inhaler technology, this means at the interface between solid 
API/excipient particle and propellant/co-solvent.  The role of the surfactant, which is usually 
vegetable based, such as lecithin, is essentially to aid dispersion of suspended particles.  Particles 
of API and excipient can often be electrostatically charged as a result of the micronisation process 
and so the use of a surfactant aids the wetting of solid particles and hence promotes dispersion.  
The surfactant also coats the particles and imparts a thermodynamic stabilisation as the electrically 
charged surfaces repel, therefore reducing coagulation and flocculation.  This stabilisation aids the 
maintenance of dose reproducibility as the formulation remains homogenous for an extended 
period of time (up to 5 years).  Some surfactants are also selected on the basis of lubrication [37], 
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as conditioning of the metering valve is necessary to ensure that the mechanism functions 
efficiently for ~200 doses. 
 
1.1.2.4 Formulation stability 
 
The term “stability” can be sub-divided into chemical and physical stability.  Chemical stability 
refers to the potential for drug polymorphism and solubilisation whilst under formulation conditions.  
This is a major concern such that full characterisation of APIs has ensued.   
 
As most pMDI formulations exist in suspension form, the main physical stability factor lies with 
flocculation and aggregation of the suspended particles (particles settling at the bottom of the 
suspension).  Flocculation can be described by the DLVO (Deryaguin, Landau, Verwey and 
Overbeek) theory (Figure 1.4 [30,38]), which described changes in potential energy as suspended 
particles approach each other. 
 
 
Figure 1.4  Graphical representation of inter-particle interactions in suspensions 
 
As the distance (d) between suspended particles becomes smaller, the particles experience a net 
attraction (van der Waals forces).  Where these forces are sufficiently strong, a permanent 
attraction is observed and coagulation results (curve VA).  In closer proximity, there is an electrical 
repulsion between suspended particles owing to the repulsion of like-charged species.  The 
strength of this repulsion governs the interactions represented by curve VR where the suspension 
remains stable.   
 
For a typical pMDI suspension, curve VT is considered to give an accurate account of particle 
behaviour.  As suspended particles approach each other, a small net attraction is observed (point 
X) due to van der Waals forces.  This loose aggregation of particles or flocculation can be easily re-
dispersed by shaking the inhaler device.  As the interparticular distance continues to decrease, the 
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particles experience a net repulsion (point Y) due to electrical repulsion of like-charged species.  
The height of this potential energy barrier determines the long term physical stability of the 
formulation.  Where the energy barrier is high, the suspension remains homogenous and physically 
stable.  Where the energy barrier is low, the net attraction due to van der Waals forces dominates 
and a permanent aggregation is formed, known as coalescence, the result of which is represented 
by point Z.  Upon further decrease of interparticle distance, electronic repulsion occurs, raising the 
potential energy dramatically. 
 
The rate of sedimentation of particles out of suspension has also described by Stoke's Law: 
 
 
9
2 21
2 ddgr
U

                Equation 1.1  Stoke's Law 
 
Where U is the rate of sedimentation (ms-1), 
1d  and 2d  are the densities of the drug powder and 
the propellant respectively (kgm
-3
), r  is the radius (m) of the dispersed particle (API), g  is the 
acceleration due to gravity (ms
-2
) and   is the viscosity of the propellant (kgm-1s-1).  This 
relationship highlights that where densities of API and propellant are similar, stability of the 
dispersion can be maintained. 
 
Due to the need for progressively more sophisticated powder formulations, whether binary or 
ternary systems, processes capable of producing these powders to exact specifications are 
increasingly required.  Not only are processes required that have the potential to produce powders 
within the desired particle size range, but equally important is the characterisation of these powders 
to understand their behaviour under DPI and pMDI conditions.  For inhalation therapy to achieve its 
true potential, these techniques had to be developed and mastered to enable their effective use.  
The following sections consider the major technologies used for particle engineering, and the key 
areas of particle characterisation. 
 
1.2 Particle engineering for inhalation 
 
The previous sections gave an outline of the components that inhaled formulations comprise.  The 
techniques discussed here are those most common in the manufacture of particles suitable for 
pharmaceutical formulations.  An outline of each technique is given, along with a brief discussion of 
the theory behind the technology and examples of use for previous research into inhalation 
products. 
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1.2.1 Crystallisation from aqueous solutions 
 
Crystallisation is a major processing tool in the production of pharmaceuticals and the direct link 
between processing and the drug release properties of final dosage forms is significant.  It is 
important to note that while common ideas of the term “crystallisation” involve the precipitation of 
crystals from a solution, solid-state transitions between polymorphs may also be a result of the 
process (discussed further in Chapter 3).  
 
1.2.1.1 Crystal formation 
 
An ideal crystal can be described as “an indefinitely large system consisting of a regularly spaced 
lattice, at each point of which there are identical particles or identical groups of particles” [39].  The 
particles described may be atoms, ions or molecules, and the process by which these ideal crystals 
are formed is termed crystallisation. 
 
Crystallisation from solutions occurs in four phases: 
 
1. The preparation of a supersaturated solution; 
2. Crystal nucleation; 
3. Precipitation; 
4. Possible recrystallisation and crystal growth. 
 
Solutions can exist in three forms.  An unsaturated solution is one where the dissolution of crystals 
is enabled.  In a saturated solution the solid and liquid content are in an equilibrated state (i.e. no 
dissolution and no precipitation occurs).  Finally, a supersaturated solution exists where the 
concentration of the solution is greater than that at the point of saturation (Figure 1.5).  
Supersaturation is an obligatory state in crystallisation from solutions which can be promoted by 
cooling, evaporation of solvent, or with the addition of an alternative solvent (an antisolvent) that is 
miscible with the original solvent, but in which the solute is insoluble [40].  The addition of 
antisolvents reduces the solubility of the solute, and hence increases the rate of nucleation.  This 
method of antisolvent crystallisation may be considered under the same category as “salting-out” 
[41], where solid material is added to the crystallisation liquor in the same manner. 
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Figure 1.5  Schematic of crystallisation from saturated solutions 
 
The formation of crystals from solutions is the process by which a new phase is formed.  This 
process is termed nucleation and occurs when a nucleus of definite volume and boundary is 
formed, such that the old and new phases are separated.  A nucleus is defined as the minimum 
amount of a new phase capable of existence without re-dissolution into the solution, and is 
therefore the crystallisation centre for a new phase [39]. 
 
It is the growth of these nuclei that governs particle precipitation (what most refer to as “crystal 
growth”).  The rate of this growth is governed by the diffusion of particles in solution to the surface 
of nuclei formed, and the rate of their incorporation into the crystal structure of the lattice. 
 
1.2.1.2 Crystallisation of pharmaceuticals 
 
It has been reported that “over 90% of all pharmaceutical products, such as tablets, aerosols, 
capsules, suspensions and suppositories contain drug in particulate, usually crystalline, form” [42].  
This statement brings into context the requirement for a firm understanding of the crystallisation of 
actives and excipients alike. 
 
Crystallisation conditions typically define the properties of the material formed.  This can be 
beneficial when crystallising pharmaceutical products, as the crystallisation conditions can be 
controlled to generate the desired particles that are fit-for-purpose, and so reduces the need for 
expensive and time consuming processing.  The effect of crystallisation processes on drug or 
excipient materials are summarised in Table 1.1 [42]. 
  
L.H2O
Unsaturated Saturated
Undissolved
L.H2O
Nucleation
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Solid-state properties  
Effect on drug substance and/or drug 
product 
   
Structural   
Crystallinity (existence of amorphous and  
Physical and chemical stability 
semi-crystalline forms)  
   
Polymorphs  
% Relative humidity (RH) profile 
(hygroscopicity) 
Solvates and hydrates  
Solubility profile and dissolution rate 
Salts  
Crystal defects  All aspects of processing 
   
Chemical   
Organic and inorganic impurities, residual 
solvent and decomposition products 
 
Toxicity 
 
   
Chiral forms and chiral separation  Chemical, physical and enantiomeric stability 
Sterility (microbial limits)   
   
Dimensional   
Particle size distribution  Processing behaviour: bulk density, 
agglomeration, flow/rheology, compaction   
Particle morphology  Particle permeability (i.e. particle adsorption) 
   
Particle surface structure  Bioavailability (drug absorption) 
  
Consistency and uniformity of the dosage 
form 
   
Mechanical   
Brittle/ductile transitions, fracture stress, 
indentation hardness, stress/strain relaxation, 
yield pressure, Young's modulus 
 
Milling and tableting behaviour  
 
   
Electrical   
Electrostatic charge distribution  Agglomeration and flow properties 
Table 1.1  The effect of crystallisation processes on solid-state properties 
 
Another common misconception is that crystallisation techniques produce purely crystalline 
materials, however, the degree of crystallinity relies heavily on the techniques employed.  One 
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such example is the spray drying of lactose [43-46].  Particles generated as a result of spray drying 
are typically spheroidal with surface indentations (Figure 1.6) and there is an inherent amorphicity 
associated with particles produced by this method, despite being formed from a feed solution [47].  
Amorphous (non-crystalline, i.e. no long range order in crystal structure) lactose has a higher 
solubility than crystalline lactose, and as such would result in undesired solubilisation under pMDI 
formulation conditions.  While this increase in solubility is disadvantageous for pMDI excipients and 
suspended APIs, it can be beneficial for solution formulations as improved solubility can improve 
bioavailability. 
 
 
Figure 1.6  SEM micrograph of spray dried L.H2O showing rough surface morphology and 
spherical shape 
 
Minor changes in crystallisation conditions can be in the form of supersaturation, temperature, the 
presence of impurities or cooling regime.  These inconsistencies can result in batch to batch 
variations such as particle size variation (most commonly), shape, purity or defects in crystals.  
Perhaps more significant is the effect on drug (or excipient) polymorphism, given that the majority 
of drugs used in modern medicines do not exist as single polymorphs. 
 
In a similar way to lactose, APIs can exhibit polymorphism under different crystallisation conditions 
(for example solvent).  With changes in polymorph come changes in physical and chemical 
properties such as solubility and stability, which directly affect bioavailability.  It was previously 
mentioned in reference to inhaled pharmaceutics that the FDA set guidelines for what is deemed 
acceptable for use as a pharmaceutical (for inhalation this includes particle size as well as API and 
excipient polymorph specificity).  This applies to all drugs of all forms, whether in tablet, inhalable, 
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or suspension form and as a result, characterisation of drug polymorphs must be in depth, and 
therefore understanding the crystallisation conditions which lead to their formation is a must.   
 
These (potential) crystallisation complications must be taken into account during the formulation 
stages in both DPIs and pMDIs.  The dA of API and excipient particles is particularly at risk in DPI 
formulations, and the potential for recrystallisation, agglomeration and crystal growth in pMDIs is 
particularly prominent.  The susceptibility of lactose, in particular, to changes in crystallisation 
environment has enhanced the need for alternative particle size reduction methods such as 
micronisation to generate particles of reliable behaviour and stability, despite the possibility for 
inclusion of amorphous material. 
  
1.2.2 Micronisation 
 
Micronisation is a term generally applied to the process of particle size reduction as a result of 
friction.  Considered under this category are techniques such as milling and grinding, which in 
terms of methodology are very similar.  The success of milling techniques relies on the suitability of 
the material in terms of the following [48]; 
 
1.  Crack propagation (relating to toughness of the material)   
Localised stresses produce inter-particulate strains large enough to cause bond rupture.  
Crack propagation results and hence the destruction of the particle ensues; 
2.  Surface Hardness 
Hard materials are, in general, more difficult to comminute than softer materials.  Hard 
materials can result in the wear of mill components which in turn may be responsible for 
the contamination of later samples.  It is much easier to consider this issue in terms of 
materials other than actives and excipients.  For example, diamond is considerably harder 
than talc. 
 
Particle size reduction, or comminution, can be performed by cutting, compression, impact or 
attrition methods, or some combination thereof.  While it is possible for these techniques to 
generate different particle sizes, it is important to note that the overall effect is predominantly 
dependent on the duration of the milling cycle. 
 
L.H2O has been the subject of both roller compaction and vibrational milling studies [49,50].  The 
research concluded that the effect of milling conditions was also heavily dependent on material 
properties for example crystallinity, particle size and particle morphology.   
 
Combined impact and attrition mills, for example the fluid energy (jet) mills are those most 
commonly used today for pharmaceutical material comminution.  Attrition is defined as a type of 
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wear caused by friction.  Essentially, attrition is observed as the result of two solid materials coming 
into contact in a “rubbing” manner, such that abrasion is caused. 
 
1.2.2.1 Fluid energy (jet) milling 
 
Due to the methods of comminution employed, jet milling typically produces particles irregular in 
shape with rough surfaces (Figure 1.7).   
 
 
Figure 1.7  SEM micrograph of micronised L.H2O 
 
Air is entered into the loop (Figure 1.8) at high pressure, causing areas of turbulence, into which 
the solid is fed.  The high kinetic energy of the air allows for inter-particulate collision, which causes 
the particles to fracture due to impact and attrition.  The particles remain in the system until a 
sufficiently small particle size is achieved (recognised by a particle size detector), at which point 
they are exhausted from the system along with the fluid (usually compressed air).  A collection 
device is then employed to retain the yield. 
 
Instrumental variations of this technique may include the presence of horizontally opposed jets in 
place of the turbulence system, or the presence of a target plate into which a single jet of fluid 
carrying the solid is propelled.  Both arrangements result in the same generation of impact 
comminution of the powder.    
 
 
Chapter 1  Introduction 
Page | 16  
 
 
Figure 1.8  Schematic of a fluid energy (jet) mill 
 
Fluid energy milling has also shown potential for the production of inhalable drug/LH2O blends 
incorporating highly cohesive actives.  Giry et al. report that the active, fusafungine, when co-
micronised with carrier (LH2O), showed enhanced aerosolisation properties [27].  The data 
collected were compared to the traditional method of dry powder production by jet milling, which 
involves the individual micronisation of the active, followed by blending with the carrier.  The 
traditional method produced a respirable fraction of only 10%, whereas co-micronisation yielded a 
respirable fraction of 23%. 
 
1.3 Polymorphism in APIs and excipients 
 
1.3.1 Polymorphism of lactose 
 
“The polymorphism of any element or compound is its ability to crystallise as more than one distinct 
crystal species” [51,52] i.e. polymorphism occurs where different crystalline forms of the same pure 
chemical compound exist.  Lactose as an excipient has been heavily researched, hence it is well 
documented that it exists as four polymorphs [53].  Alpha lactose monohydrate (L.H2O, Figure 
1.9) consists of two sugar moieties, -galactose and -glucose bonded via a beta 1-4 glycosidic 
link.  LH2O has an anhydrous anomer in the form of beta lactose (L).  This consists of a -
glucose anomer along with the -galactose as in LH2O.  There are also two alpha, anhydrous 
polymorphs.  One of these polymorphs is stable in the anhydrous state (LS), while the other is 
Centrifugal force throws large 
particles outwards
Classifier removes fine particles 
and fluid
Solids inlet
Fluid inlet jets
Zone of 
turbulence
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hygroscopic (LH).  While the term polymorph does not strictly apply to these different forms 
(anomers and hydrates, the latter of which technically falls under the classification of 
pseudopolymorph), the nomenclature has been used for more than 50 years and so is maintained 
throughout these discussions. 
 
.H2O
 
Figure 1.9  Structural representation of L.H2O 
 
The preparation of each of these polymorphs from LH2O has been discussed elsewhere [53].  
The standards used throughout these studies were prepared by the methods outlined: 
 
L is prepared as described by Parrish et al. [54]; LH2O is refluxed in at least eight times the 
amount (w/v) of 0.014M methanolic potassium methoxide for a minimum of 3h.  L is also formed 
by the natural mutarotation of LH2O in water to form a 60:40 mixture of LLH2O.   
 
The preparation of LS has shown to be possible by two means.  The first, outlined by Lim and 
Nickerson [55,56] shows dehydration of LH2O following reflux for 24h in at least ten times the 
amount (w/v) of dehydrating solvent (methanol or ethanol), previously dried over molecular sieves.  
Garnier et al. [57] also showed a thermal dehydration of LH2O to LS by heating to 160
o
C for 16h.   
 
LH, the hygroscopic polymorph, is produced by similar thermal methods to LS [58] whereby 
LH2O is heated in vacuo to 120
o
C for 16h.  It should also be noted that while these crystalline 
polymorphic forms exist, it is also possible to produce lactose in the amorphous state.  
 
Structural information for of each of the lactose polymorphs has been determined previously: 
 
 
 
 
 
 
 
 
Chapter 1  Introduction 
Page | 18  
 
Polymorph System 
Space 
group 
Cell data 
         (Å)                    (
o
) 
Typical 
morphology 
LH2O Monoclinic P21 
a 
b 
c 
4.783 
21.54 
7.759     


 
90 
105.911 
90 
[59] 
Tomahawk 
[60,61] 
         
L Monoclinic P21 
a 
b 
c 
4.932 
13.27 
10.779    


 
90 
91.554 
90 
[57] 
Needle 
[62] 
         
LS Triclinic P1 
a 
b 
c 
7.652 
19.863 
4.987  


 
92.027 
106.261 
97.152 
[63] 
Tape 
[64] 
         
LH Monoclinic P21 
a 
b 
c 
7.779 
19.693 
4.906  


 
90 
103.691 
90 
[65] Unavailable 
Table 1.2  Structural data for the polymorphs of lactose 
 
1.3.2 Polymorphism in pharmaceuticals 
 
When molecules arrange themselves into different crystal structures, it follows that a variance in 
intermolecular interactions occurs, such as van der Waals forces or hydrogen bonding.  It is 
therefore feasible that different polymorphs of a species will have different properties such as 
solubility, stability or density.  As such, it is perfectly understandable that lactose exist as a stable 
anhydrous and hygroscopic anhydrous form of the same anomer.   
 
When polymorphic materials are used within drug formulations, these variations in properties pose 
potential problems in terms of stability and bioavailability of the drugs, so it is important to fully 
understand the polymorphism of both excipients and APIs, and their susceptibilities to formulation 
conditions.  An example of the effect of polymorphism on inhaled formulation has been 
documented by Traini et al. [66] who showed the difference in binding properties of the stable 
lactose polymorphs in salbutamol sulfate formulation.  Where LH2O was substituted for L or LS, 
the drug delivery capabilities of the formulation were significantly reduced.  Similarly, salbutamol 
sulfate itself exists as two enantiomers, and of the active R-form, two polymorphs have been 
documented [67].  Further discussion of salbutamol sulfate is found in Chapter 6.    
 
Having a complete understanding of the polymorphs or phases present within a drug formulation is 
a necessity before any assumptions of stability can be made.  As a result, the pharmaceutical 
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industry is heavily reliant on characterisation techniques capable of providing this type of 
information.  
 
1.4 Aims and objectives 
 
The background information provided in this chapter gives an insight into the formulation processes 
involved in the production of inhaled pharmaceuticals.  Typically investigation into these products 
has focussed on the individual components of a formulation, and more prominently, the flow 
properties of inhaled formulations and therefore dose delivery success.  In order to carry out these 
analytical investigations, sample manipulation is often necessary (i.e. recovery from an inhaler 
canister), which poses the potential for sample compromise.   
 
The studies presented within this thesis give various approaches to the analysis of inhaled 
formulations in-situ.  Analyses are applied to both DPI and suspended pMDI formulations, in an 
attempt to provide detailed characterisation of the pharmaceuticals present, without the potential 
for compromise of the sample.  A discussion of the susceptibility of these pharmaceuticals (both 
API and excipient) to solvent environment is also presented. 
 
 
 
    
  
 
Chapter 1  Introduction 
Page | 20  
 
1.5 References 
 
[1] A Adjei, P Gupta. Pulmonary delivery of therapeutic peptides and proteins, J.Control.Release. 
29 (1994) 361-373. 
 
[2] C Uherek, W Wels. DNA-carrier proteins for targeted gene delivery, Adv.Drug Deliv.Rev. 44 
(2000) 153-166. 
 
[3] C Klingler, BW Mueller, H Steckel. Insulin-micro- and nanoparticles for pulmonary delivery, 
Int.J.Pharm. 377 (2009) 173-179. 
 
[4] R Siekmeier, G Scheuch. Inhaled Insulin - does it become reality? J.Physiol.Pharmacol. 59 
(2008) 81-113. 
 
[5] JJ Neumiller, RK Campbell, LD Wood. A review of inhaled Technosphere insulin, 
Ann.Pharmacother. 44 (2010) 1231-1239. 
 
[6] JJ Neumiller, RK Campbell. Technosphere® insulin. An inhaled prandial insulin product, 
Biodrugs. 24 (2010) 165-172. 
 
[7] 3M Health Care Ltd, personal communication. 
 
[8] G Buckton. Characterisation of small changes in the physical properties of powders of 
significance for dry powder inhaler formulations, Adv.Drug Deliv.Rev. 26 (1997) 17-27. 
 
[9] DI Daniher, J Zhu. Dry powder platform for pulmonary drug delivery, Particuology. 6 (2008) 225-
238. 
 
[10] PM Young, D Traini, M Coates, H Chan. Recent advances in understanding the influence of 
composite-formulation properties on the performance of dry powder inhalers, Physica B: 
Condensed Matter. 394 (2007) 315-319. 
 
[11] R Price, PM Young, S Edge, JN Staniforth. The influence of relative humidity on particulate 
interactions in carrier-based dry powder inhaler formulations, Int.J.Pharm. 246 (2002) 47-59. 
 
[12] E Guenette, A Barrett, D Kraus, R Brody, L Harding, G Magee. Understanding the effect of 
lactose particle size on the properties of DPI formulations using experimental design, Int.J.Pharm. 
380 (2009) 80-88. 
 
 
Chapter 1  Introduction 
Page | 21  
 
[13] XM Zeng, GP Martin, S Tee, AA Ghoush, C Marriott. Effects of particle size and adding 
sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation, 
Int.J.Pharm. 182 (1999) 133-144. 
 
[14] H Chan, NYK Chew. Novel alternative methods for the delivery of drugs for the treatment of 
asthma, Adv.Drug Deliv.Rev. 55 (2003) 793-805. 
 
[15] LA Hannemann. What is new in asthma: New dry powder inhalers, J.Pediatr.Health Care. 13 
(1999) 159-165. 
 
[16] K Iida, Y Inagaki, H Todo, H Okamoto, K Danjo, H Luenberger. Effects of surface processing 
of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate, 
Chem.Pharm.Bull. 52 (2004) 938-942. 
 
[17] SP Newman, SW Clarke. Therapeutic Aerosols 1. Physical and practical considerations, 
Thorax. 38 (1983) 881-886. 
 
[18] I Gonda. Aerosols for delivery of therapeutic and diagnostic agents to the respiratory-tract, 
Crit.Rev.Ther.Drug Carrier Syst. 6 (1990) 273-313. 
 
[19] RJ Malcolmson, JK Embleton. Dry powder formulations for pulmonary delivery, 
Pharm.Sci.Technol.Today. 1 (1998) 394-398. 
 
[20] C Bosquillon, C Lombry, V Préat, R Vanbever. Influence of formulation excipients and physical 
characteristics of inhalation dry powders on their aerosolization performance, J.Control.Release. 70 
(2001) 329-339. 
 
[21] A Elajnaf, P Carter, G Rowley. Electrostatic characterisation of inhaled powders: Effect of 
contact surface and relative humidity, Eur.J.Pharm.Sci. 29 (2006) 375-384. 
 
[22] H Larhrib, XM Zeng, GP Martin, C Marriott, J Pritchard. The use of different grades of lactose 
as a carrier for aerosolised salbutamol sulphate, Int.J.Pharm. 191 (1999) 1-14. 
 
[23] JH Bell, PS Hartley, JSG Cox. Dry Powder Aerosols .1. New powder inhalation device, 
J.Pharm.Sci. 60 (1971) 1559-&. 
 
[24] MP Timsina, GP Martin, C Marriott, D Ganderton, M Yianneskis. Drug-delivery to the 
respiratory-tract using dry powder inhalers, Int.J.Pharm. 101 (1994) 1-13. 
 
 
Chapter 1  Introduction 
Page | 22  
 
[25] TM Crowder, JA Rosati, JD Schroeter, AJ Hickey, TB Martonen. Fundamental effects of 
particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry 
powder inhaler formulation and development, Pharm.Res. 19 (2002) 239-245. 
 
[26] XM Zeng, KH Pandhal, GP Martin. The influence of lactose carrier on the content homogeneity 
and dispersibility of beclomethasone dipropionate from dry powder aerosols, Int.J.Pharm. 197 
(2000) 41-52. 
 
[27] K Giry, JM Péan, L Giraud, S Marsas, H Rolland, P Wüthrich. Drug/lactose co-micronization by 
jet milling to improve aerosolization properties of a powder for inhalation, Int.J.Pharm. 321 (2006) 
162-166. 
 
[28] MD Jones, R Price. The influence of fine excipient particles on the performance of carrier-
based dry powder inhalation formulations, Pharm.Res. 23 (2006) 1665-1674. 
 
[29] AHL Chow, HHY Tong, P Chattopadhyay, BY Shekunov. Particle engineering for pulmonary 
drug delivery, Pharm.Res. 24 (2007) 411-437. 
 
[30] TS Purewal, DJW Grant, Metered dose inhaler technology, Interpharm Press, Inc, USA, 1998. 
 
[31] LA Dellamary, TE Tarara, DJ Smith, CH Woelk, A Adractas, ML Costello, et al. Hollow porous 
particles in metered dose inhalers, Pharm.Res. 17 (2000) 168-174. 
 
[32] P Jinks, Preparation and utility of sub-micron lactose, a novel excipient for HFA MDI 
suspension formulations, Drug Deliv. Lungs XIV. (2003) 199-202. 
 
[33] PA Jinks, L McKenzie, JT Lister.  Medicinal aerosol formulations.  Patent WO2002/030 394 
(2006). 
 
[34] J James, B Crean, M Davies, R Toon, P Jinks, CJ Roberts. The surface characterisation and 
comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension 
formulations in metered dose inhalers, Int.J.Pharm. 361 (2008) 209-221. 
 
[35] XM Zeng, GP Martin, C Marriott, J Pritchard. Lactose as a carrier in dry powder formulations: 
The influence of surface characteristics on drug delivery, J.Pharm.Sci. 90 (2001) 1424-1434. 
 
[36] PJ Aucamp. Questions and answers about the effects of the depletion of the ozone layer on 
humans and the environment, Photochem.Photobiol.Sci. 6 (2007) 319-330. 
 
 
Chapter 1  Introduction 
Page | 23  
 
[37] D Traini, PM Young, P Rogueda, R Price. Investigation into the influence of polymeric 
stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers, Int.J.Pharm. 
320 (2006) 58-63. 
 
[38] DJ Shaw, Introduction to colloid and surface chemistry, 4th ed., Butterworth-Heinemann, 
Oxford, 1992. 
 
[39] TG Petrov, EB Treivus, AP Kasatkin, Growing crystals from solutions, Consultants Bureau, 
New York, 1969. 
 
[40] ABN Brito, M Giulietti. Study of lactose crystallization in water-acetone solutions, 
Cryst.Res.Technol. 42 (2007) 583-588. 
 
[41] RK Bund, AB Pandit. Sonocrystallization: Effect on lactose recovery and crystal habit, 
Ultrason.Sonochem. 14 (2007) 143-152. 
 
[42] BY Shekunov, P York. Crystallization processes in pharmaceutical technology and drug 
delivery design, J.Cryst.Growth. 211 (2000) 122-136. 
 
[43] D Chiou, TAG Langrish, R Braham. The effect of temperature on the crystallinity of lactose 
powders produced by spray drying, J.Food Eng. 86 (2008) 288-293. 
 
[44] MK Haque, YH Roos. Crystallization and X-ray diffraction of spray-dried and freeze-dried 
amorphous lactose, Carbohydr.Res. 340 (2005) 293-301. 
 
[45] R Vehring, WR Foss, D Lechuga-Ballesteros. Particle formation in spray drying, J.Aerosol Sci. 
38 (2007) 728-746. 
 
[46] SA Shoyele, S Cawthorne. Particle engineering techniques for inhaled biopharmaceuticals, 
Adv.Drug Deliv.Rev. 58 (2006) 1009-1029. 
 
[47] A Chawla, KMG Taylor, JM Newton, MCR Johnson. Production of spray dried salbutamol 
sulphate for use in dry powder aerosol formulation, Int.J.Pharm. 108 (1994) 233-240. 
 
[48] ME Aulton, Pharmaceutics.  The science of dosage form design, Churchill Livingstone, 
London, 2000. 
 
[49] S Inghelbrecht, J Paul Remon. The roller compaction of different types of lactose, Int.J.Pharm. 
166 (1998) 135-144. 
 
 
Chapter 1  Introduction 
Page | 24  
 
[50] I Krycer, JA Hersey. Grinding and granulation in a vibratory ball mill, Powder Technol. 28 
(1981) 91-95. 
 
[51] W Mccrone, in: Fox D, Labes MM, Weissberger A (Eds.), Physics and chemistry of the organic 
solid state, Interscience, New York, 1965. 
 
[52] R Hilfiker, F Blatter, M von Raumer, Relevance of solid-state properties for pharmaceutical 
products, in: Hilfiker R (Ed.), Polymorphism: in the pharmaceutical industry, Wiley-VCH, Germany, 
2006. 
 
[53] JH Kirk, SE Dann, CG Blatchford. Lactose: A definitive guide to polymorph determination, 
Int.J.Pharm. 334 (2007) 103-114. 
 
[54] FW Parrish, KD Ross, T D Simpson. Formation of β-lactose from α- and β-lactose 
octaacetates, and from α-lactose monohydrate, Carbohydr.Res. 71 (1979) 322-326. 
 
[55] SG Lim, TA Nickerson. Effect of methanol on various forms of lactose, J.Dairy Sci. 56 (1973) 
843-848. 
 
[56] TA Nickerson, SG Lim. Effect of various alcohols on lactose, J.Dairy Sci. 57 (1974) 1320-1324. 
 
[57] S Garnier, S Petit, G Coquerel. Dehydration mechanism and crystallisation behaviour of 
lactose, J.Therm.Anal.Calorim. 68 (2002) 489-502. 
 
[58] LO Figura, M Epple. Anhydrous alpha-Lactose - a Study with DSC and TXRD, J.Therm.Anal. 
44 (1995) 45-53. 
 
[59] JH Smith, SE Dann, MRJ Elsegood, SH Dale, CG Blatchford. -Lactose monohydrate: a 
redetermination at 150 K, Acta Cryst.E. 61 (2005) 2499-2501. 
 
[60] SL Raghavan, RI Ristic, DB Sheen, JN Sherwood, L Trowbridge, P York. Morphology of 
crystals of alpha-lactose hydrate grown from aqueous solution, J.Phys.Chem.B. 104 (2000) 12256-
12262. 
 
[61] SL Raghavan, RI Ristic, DB Sheen, JN Sherwood. The bulk crystallization of alpha-lactose 
monohydrate from aqueous solution, J.Pharm.Sci. 90 (2001) 823-832. 
 
[62] JL Crisp, SE Dann, CG Blatchford. Antisolvent crystallization of pharmaceutical excipients from 
aqueous solutions and the use of preferred orientation in phase identification by powder X-ray 
diffraction, Eur.J.Pharm.Sci. 42 (2011) 568-577. 
 
Chapter 1  Introduction 
Page | 25  
 
[63] C Platteau, J Lefebvre, F Affouard, JF Willart, P Derollez, F Mallet. Structure determination of 
the stable anhydrous phase of alpha-lactose from X-ray powder diffraction, Acta Cryst.B. 61 (2005) 
185-191. 
 
[64] JL Crisp, SE Dann, M Edgar, CG Blatchford. The effect of particle size on the 
dehydration/rehydration behaviour of lactose, Int.J.Pharm. 391 (2010) 38-47. 
 
[65] C Platteau, J Lefebvre, F Affouard, P Derollez. Ab initio structure determination of the 
hygroscopic anhydrous form of -lactose by powder X-ray diffraction, Acta Cryst.B. 60 (2004) 453-
460. 
 
[66] D Traini, PM Young, F Thielmann, M Acharya. The influence of lactose pseudopolymorphic 
form on salbutamol sulfate-lactose interactions in DPI formulations, Drug Dev.Ind.Pharm. 34 (2008) 
992-1001. 
 
[67] MA Palacio, S Cuffini, R Badini, A Karlsson, SM Palacios. Solid-state characterization of two 
polymorphic forms of R-albuterol sulfate, J.Pharm.Biomed.Anal. 43 (2007) 1531-1534. 
 
Solvent-Mediated Polymorphism and Characterisation of Inhaled Pharmaceuticals 
 
Page | 26  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2.  Characterisation of inhalable 
particles 
  
 
Chapter 2  Characterisation of inhalable particles 
Page | 27  
 
The characterisation of solid materials within these studies was performed using a number of 
physical techniques which fall under the categories of diffraction, microscopy and spectroscopy.  A 
brief discussion of the techniques employed is provided here, including the experimental 
parameters used throughout.  Any deviation from these parameters is highlighted in the relevant 
sections. 
 
2.1 X-ray diffraction (XRD) 
 
X-ray diffraction (XRD) relies on the interaction between X-rays and solid materials to provide 
information relating to the arrangement of atoms in space (and therefore structural information) for 
a given sample.  XRD also has applications in the phase identification, the detection of phase 
changes and crystallite size determination. 
 
Samples for X-ray diffraction may come in the form of single crystals or powders, however powder 
X-ray diffraction (PXRD) is by far the more commonly used technique, and more prevalent in these 
studies and as such will be described in more detail than single crystal diffraction.  
 
2.1.1 Principles of a PXRD experiment 
 
Essentially, there are three components required for a diffraction experiment to take place 
successfully; an X-ray source, a sample for analysis and device suitable for the detection of 
diffracted X-rays (a detector) (Figure 2.1).   
 
 
Figure 2.1  Schematic of a PXRD experiment 
 
In reality diffractometers are much more complex than this (a typical arrangement shown in Figure 
2.2 [1]) however, in order to give a brief overview, a simplified system will be discussed. 
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Figure 2.2  Schematic of a powder X-ray diffractometer (reflection geometry) 
 
2.1.2 Generation of X-rays  
 
The X-ray tube is the source of X-ray radiation (Figure 2.3a).  A tungsten filament is heated to 
produce an electron beam, which is accelerated towards an anode by a high potential difference.  
A metal target (typically copper) is situated at the anode, which is struck by the electron beam and 
results in the ejection of a 1s electron from the copper atoms.  As electrons in higher energy shells 
relax to fully occupy the 1s shell, excess energy is released in the form of X-rays (Figure 2.3b).  
These X-rays have different wavelengths depending on the process of relaxation from which they 
are formed, for example, a 2p to 1s transition, K has an intensity weighted average wavelength of 
1.5418Å (specific to the copper source).  The relaxation of 2p electrons to the 1s shell actually 
gives a doublet (K1, 1.5406Å and K2, 1.5444Å) as there are two energy states depending on the 
spin state of the 2p electron filling the vacancy.  Where relaxation occurs from the 3p to 1s shells, 
K radiation is observed with an average wavelength of 1.3922Å [2]. 
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Figure 2.3  (a) Schematic of an X-ray tube (b) Generation of K Cu X-rays 
 
The chamber of the X-ray tube is under vacuum to avoid electron collision with air particles and to 
prevent the oxidisation of the tungsten filament.  The X-rays produced leave the tube via beryllium 
windows. 
 
2.1.3 Interaction of X-rays with solid materials 
 
Diffraction data are generated as X-rays interact with atoms in a solid material, resulting in 
scattering.  This scattering is then detected, and used to generate a diffraction pattern (plot of 
intensity versus 2θ). 
 
Scattering occurs as a result of the interaction of X-ray photons and the electron clouds of the 
sample [3].  The degree of scattering is proportional to the number of electrons present in the 
atoms, meaning that scattering is dependent on the atoms present.  This contributes to sample 
identification. 
 
One of the main uses of PXRD is in the analysis of crystalline (or polycrystalline) materials, which 
are considered to have long-range order i.e. a single repeating unit over a long range (infinitely).  
The simplest repeating unit which represents the full symmetry of the system is referred to as the 
unit cell.  Where multiple repeating units exist, the translational symmetry is described by planes.  
These planes (called Miller planes) are characterised with the use of Miller indices (h, k, l) by their 
positions within the 3D lattice.  Parallel planes have the same Miller indices and are separated by a 
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distance, dhkl, known as a d-spacing.  X-ray diffraction is able to measure these d-spacings to 
depict the type of planes present within a system. 
 
Bragg’s law is the most common approach to diffraction, and describes the reflection of X-rays from 
these Miller planes.  Figure 2.4 [1] shows two, parallel Miller planes separated by d-spacing, dhkl.  
The incident X-rays are scattered by atoms in the planes (X and Z).  The scattered X-rays must be 
in phase to generate intensity in the diffraction pattern (known as constructive interference).  Where 
the scattered X-rays are totally out of phase, cancellation of the diffraction data occurs.  The Bragg 
equation outlines the conditions under which the two incident X-ray beams are in phase.    
 
 
Figure 2.4  Diffraction from parallel Miller planes 
 
The lower of the two X-ray beams travels a greater distance than the upper beam, with a difference 
of WXY.  For the reflected beams to be in phase, this extra distance must equate to a whole 
number of wavelengths.  The d-spacing between planes, angle of incidence (or Bragg angle, θ) 
and the WX distance are related such that Bragg’s law can be defined: 
 
q nd sin2                Equation 2.1  Bragg's Law 
                  
When the Bragg law is satisfied, constructive interference occurs and reflections are present in the 
diffraction pattern. 
 
Bragg’s law can be applied in different methodologies to produce powder diffraction data.   
 
1. Fixed wavelength radiation and variable angle of incidence. 
2. Fixed incident angle and variable wavelength. 
 
For the purpose of these studies, diffraction data were collected using a fixed wavelength (1.54Å, 
K1). 
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2.1.4 Diffraction patterns 
 
Multiple examples of powder diffraction data are given in subsequent chapters, each of which 
provides valuable phase identification for a given sample.  Powder patterns are determined by two 
key factors; the size and shape of the unit cell and the atomic number and positions of atoms in 
that cell [2].  The positions of reflections in the patterns are governed by the diffraction from Miller 
planes, each of which show a diffraction maximum at a particular Bragg angle (2θ) or d-spacing.  
The intensities of the reflections are also of equal importance, particularly for quantitative analysis.  
Each atom has its own scattering factor (f) which contributes to the intensity of the observed 
reflections, however sample preparation factors can also influence intensities, and as such, 
quantitative analysis by PXRD should be performed with great care.  Sample effects on PXRD 
patterns are discussed further in Chapter 3.   
 
Once diffraction data are collected for a given sample, it is commonplace to compare these data to 
a database, typically the International Centre for Diffraction Data Powder Diffraction File (ICDD-
PDF), for phase identification.  Diffraction data are akin to a fingerprint in that no two crystalline 
compounds show the same reflections and intensities, and as such, comparison to the ICDD 
database allows the rapid identification of phases present in a sample.   
 
2.1.5 PXRD experimental parameters 
 
For the purpose of these studies, samples were analysed with a Bruker D8 Advance diffractometer, 
fitted with a germanium double single crystal monochromator producing CuK1 radiation at = 
1.5406Å.  Perspex flat plate sample holders were used to mount the samples.  Results are 
presented as a plot of 2θ against relative intensity unless otherwise stated. 
 
Two methods of data collection were employed: 
 
2.1.5.1 Continuous scan 
 
Phase identification was performed using a continuous scan between the 2θrange of 5-35
o
 (unless 
otherwise stated) using 0.014767
o
 steps over a period of 25min with a position sensitive detector 
(PSD).  During a continuous scan, data are integrated over a small 2θ range (8
o
), meaning 
collection remains continuous throughout the experiment. 
 
Data collection parameters were optimised for collection time by comparison of a series of datasets 
collected under varied step size and time/step (Table 2.1).  The quality of pattern produced was 
then assessed (Figure 2.5).  File 3 generated data of a sufficient quality (good signal-to-noise ratio) 
in a shorter experiment time and so was favourable in comparison to the other parameters.  
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File number Range (
o
2θ) Step size (
o
2θ) Time/step (s) Total run time (min) 
1 5-35 0.007 0.5 44 
2 5-35 0.007 1.0 88 
3 5-35 0.014 0.5 22 
4 5-35 0.014 1.0 44 
5 5-35 0.014 2.0 88 
Table 2.1  Optimisation of PXRD parameters 
 
 
Figure 2.5  Optimisation of continuous scan PXRD parameters 
 
2.1.5.2 Stepped scan 
 
Multiple contributions to reflections were resolved using a stepped scan covering the 2θrange 
required, with 0.001
o
 steps every 10s and scintillation counter detection.  Stepped scans generate 
well-resolved data (though are collected over a significantly longer period of time) as data are 
integrated at each datum point. 
 
Similarly to the continuous scans, data collection parameters for the stepped scans were optimised 
by comparison of a series of datasets collected under varied step size and time/step (Table 2.2).  
The quality of pattern produced was then assessed (Figure 2.6 and Figure 2.7).  
 
2-Theta - Scale
5 10 20 30
2-Theta Scale
5 10 15 20 25 30 35
5
4
3
2
1
 
Chapter 2  Characterisation of inhalable particles 
Page | 33  
 
 
File number Range (
o
2θ) Step size (
o
2θ) Time/step (s) Total run time (min) 
1 18-21 0.02 1.0 2.5 
2 18-21 0.02 5.0 13 
3 18-21 0.02 10.0 25 
4 18-21 0.01 10.0 50 
5 18-21 0.001 10.0 500 
6 18-21 0.0005 10.0 1020 
Table 2.2  Optimisation of stepped scan PXRD parameters 
 
 
Figure 2.6  Optimisation of stepped scan time/step parameters (2θ vs counts) 
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Figure 2.7  Optimisation of stepped scan step size parameters (2θ vs counts) 
 
Results indicated that a time/step of 10s and a step size of 0.001
o
 (as per file 5) gave good 
resolution of reflections without the need to extend the experiment time considerably. 
 
2.1.6 Single crystal X-ray diffraction 
 
Where powder diffraction data are commonly used to determine phase purity of samples, or identify 
polymorphism, single crystal XRD is predominantly used for crystal structure determination.  Single 
crystal XRD differs from powder diffraction as only one crystal is used, which has implications on 
the method of data collection.  It is also possible that the crystal selected for analysis may not be 
representative of the bulk properties of the sample, so care must be taken to ensure that artefacts 
are not misinterpreted.   
 
The advantage of analysis of powder samples is that due to their nature, random orientation of 
crystals allows each of the Miller planes to be observed as the sample is scanned by the detector.  
This is not the case in single crystal diffraction, where the crystal itself is orientated specifically to 
result in diffraction from particular planes.  If the crystal is not aligned correctly, diffraction is not 
observed.   
 
Again, unlike powder diffraction data where a plot of intensity versus 2θ is produced, single crystal 
data are presented as a three-dimensional electron density map, which essentially shows the 
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atomic positions of each of the atoms within the unit cell.  Once diffraction data are collected, a 
number of mathematical functions can be applied to allow structural determination to take place. 
 
2.1.7 Single crystal diffraction experimental parameters 
 
Crystal data were collected on a Bruker APEX 2 CCD diffractometer using narrow slice 0.3° ω-
scans (angular scanning relative to incident beam).  Data were corrected for Lorentz polarisation 
factor (Lp) effects and for absorption, based on repeated and symmetry equivalent reflections, and 
solved by direct methods.  Structures were refined by full matrix least squares on F
2
 [4].  Non-H 
atoms were refined anistropically unless otherwise stated.  H atoms were included in a riding 
model.  Hydrogen atom Uiso values were constrained to be 120% of that of the carrier atom except 
for methyl and hydroxyl-H (150%). 
 
2.1.8 Neutron diffraction 
 
Neutron diffraction offers a wealth of information that cannot be achieved with the use of X-rays.  
Essentially the principles of the experiment are similar, in that a source, a sample and some form of 
detector are required, however in this instance a neutron source is required. 
 
The interaction between neutrons and solid materials occurs in the nucleus, unlike X-rays where 
scattering occurs from electron clouds.  Where X-ray scattering increases with the number of 
electrons present, neutron diffraction shows similar scattering for each of the elements, as it is 
predominantly dependent on nucleus size.  As a result neutron diffraction may be able to detect the 
presence of light elements in the presence of heavier elements (if scattering lengths are different, 
one area in particular where X-rays fail), and even distinguish between isotopes of elements.  For 
the purpose of these studies, neutron diffraction was used to indirectly observe hydrogen content 
as anhydrous lactose samples rehydrated, a study which would not have been possible with the 
use of X-rays.  
 
2.1.9 Neutron diffraction experimental parameters 
 
Neutron diffraction was carried out at The Institut Laue-Langevin (ILL) in Grenoble, using the high-
flux powder diffraction instrument D20, operating in its high take-off angle configuration at a fixed 
wavelength of 1.86Å.  
 
2.2 Scanning electron microscopy (SEM) 
 
Traditionally, microscopy is used for surface observation of a subject, however technological 
advances have allowed for the use of microscopy in the determination of elemental composition. 
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Since the invention of the scanning electron microscope (SEM), sample imagery has been possible 
to much higher magnifications than traditional optical microscopy, such that particle recognition and 
characterisation has reached new levels.  SEM is hugely popular owing to its large depth of field 
and therefore ability to produce “three dimensional” images of sample surfaces on the nanometre 
to micrometre scale [5]. 
 
Such high resolution is achieved due to the use of electrons (instead of light photons) to form an 
image.  Essentially, the sample is subjected to a finely focussed electron beam, which is either 
raster scanned across the surface of the sample, or focussed on one particular point.  The 
electrons are generated from an electron gun and lenses are used to focus the beam, usually to a 
spot size of less than 10nm [5].  As the electrons come into contact with each atom in the sample, 
they generate some type of interaction from which a detectable signal is produced.  This may be 
from secondary electrons, backscattered electrons, X-rays, or other photons of various energies.  
On detection, these are then used to generate an image of the sample.  Secondary and 
backscattered electrons are of most interest as these are directly related to changes in sample 
topography [5].   
 
Due to the use of electrons as the imaging medium, it is necessary for the sample chamber to be 
under vacuum.  This can generate limitations in terms of sample suitability, though low vacuum 
modes of operation are also possible.  It is also a requirement that the sample is conductive to 
avoid charging.  This is commonly achieved for non-conducting samples with the use of gold 
(sputter) coating.   
 
SEM is also used quantitatively in the application of energy dispersive X-ray analysis (EDX) as a 
means for non-destructive, quantitative elemental analysis of a sample.  The technique makes use 
of the characteristic X-rays produced as a result of electron beam interaction with the sample (as in 
the X-ray tube).  These X-rays are specific to the element from which they are produced, and 
hence the amount produced is directly related to the amount of said atom present (providing the 
sample is flat, topographic variance can cause stoichiometric inaccuracies).  The detection of these 
X-rays therefore provides an accurate quantitative analysis of elemental composition, and can be 
performed in a matter of seconds.   
 
There are, however, limitations to this method of analysis.  It is only possible to detect elements 
above atomic number 4 (beryllium) [5], and it is possible that elements in small concentrations may 
be masked by those more prominent. 
 
2.2.1 SEM experimental parameters 
 
Micrographs were produced on a Carl Zeiss 1530 VP Field Emission Gun Scanning Electron 
Microscope (FEG-SEM) with an EDAX Pheonix EDX X-ray microanalysis system.  Powder 
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samples were mounted onto 12mm aluminium stubs with the use of carbon “sticky tabs” (Agar 
scientific).  Sputter coating was carried out using an Emitech SC7640 gold/palladium sputter coater 
with a typical coating time of ~1.30min. 
 
3D SEM work was carried out using a Nova Nanolab 600 Dual Beam Focussed Ion Beam/FEG-
SEM with an EDAX Silicon Drift Detector (SDD) Apollo XL. 
 
2.3 Solid state nuclear magnetic resonance (SSNMR) spectroscopy 
 
Solid-state nuclear magnetic resonance (SSNMR) spectroscopy is able to provide detailed 
structural information at a molecular level, and provides an insight into the long-range and short-
range order of a sample.  There are significant advantages to using SSNMR in the study of lactose 
as sample preparation in solution is made more complex owing to the natural muta-rotation of 
lactose in aqueous solution (60:40 L(beta lactose):L.H2O).  As a result, solvents in which lactose 
is soluble would have to be scrupulously dried to avoid this muta-rotation which would 
consequently result in false representation of polymorphic content.  Modern SSNMR has improved 
in recent years, and a combination of high magnetic field, fast spinning speeds and efficient proton-
decoupling allow high quality, high resolution 
13
C SSNMR spectra to be recorded.  Therefore it is 
no longer necessary to dissolve samples subject to compromise or change in the solution-state in 
order to use liquid NMR techniques.  The obvious advantages here are that the material studied is 
therefore not modified from its natural state, and also that it is recoverable post analysis. 
 
NMR spectroscopy is based on the concept that within a molecule, there are a number of nuclei, 
each with a magnetic moment (spin).  When associated by bond or by spatial proximity, these 
spins will interact with each other, however, they will also interact with an applied magnetic field 
(Bo).  When a spin system is subjected to a strong magnetic field, a net magnetisation (M) is 
observed as the individual nuclear magnetic moments align preferentially to the applied field 
(Figure 2.8) [6].  NMR spectroscopy uses an alternating orthogonal magnetic field, typically an 
electromagnetic wave such as a radiofrequency, in order to manipulate, filter and ultimately 
measure this net magnetisation in the form of a spectrum. 
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Figure 2.8  Vector representation of spin alignment with a magnetic field (Bo) 
 
SSNMR spectroscopy is an analytical technique that is increasingly popular in the pharmaceutical 
industry, mainly owing to the modern technical advances that allow increasing ability to generate 
high-resolution spectra.  Provided here is a brief introduction into the theory behind the production 
of these solid-state spectra. 
 
2.3.1 Magic angle spinning (MAS) 
 
In a typical solution-state NMR spectrum, resonances appear as very sharp lines, which means 
that for very complex compounds, signals rarely overlap and therefore lots of information can be 
extracted from the spectrum.  The sharpness of these lines is mainly attributed to the random, 
rapidly “tumbling” nature of molecules within a liquid sample, which results in the averaging of 
dipolar couplings and anisotropic interactions.  This tumbling is not possible in solid-state samples, 
therefore the dipole-dipole couplings dominate the NMR spectrum.  In particular, it must be noted 
that protons can couple to other protons in the same molecule, but also via hydrogen bonding to 
protons in neighbouring molecules in the crystal lattice.  In order to reduce these couplings, the 
tumbling of solution-state molecules is mimicked in order to produce high-resolution spectra. 
 
The term “anisotropic interactions” can be further categorised to include chemical shift anisotropy 
(CSA) and dipolar coupling effects, both of which describe the interaction of NMR active nuclei 
spins with each other.  In order to suppress the effects of these interactions in SSNMR, magic-
angle spinning (MAS [7,8]) is employed [6].   
 
Dipolar interactions (D) are governed by three key factors: 
 
D  1/r
3
   The distance between the nuclei concerned 
D  A.  The nuclei (A and B) involved and their gyromagnetic ratios () 
D  3cos
2
θ – 1 The angle that the interacting nuclei make relative to the external magnetic 
field 
Bo
M
No magnetic field applied
No net magnetisation
Magnetic field applied
Net magnetisation, M
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Modification of samples to effect the first two terms is difficult, and so it is the final expression which 
provides a method by which dipolar couplings are removed which contributes to the intensity of the 
peaks observed.  In the case of a simple molecule, with two nuclei that are aligned, rotating the 
single crystal relative to the applied field effects a change in the size of the coupling interaction.  
Returning to the expression “D  3cos
2
θ – 1”, the dipolar coupling is equal to zero where θis equal 
to 54.74
o
, and hence this value was named the magic angle. 
 
The sample within the rotor is spun at the magic angle (54.74
o 
with respect to the applied magnetic 
field) which replicates the rapid tumbling of molecules within the solution system (Figure 2.9) [9].  If 
these interactions were not removed, little spectral detail would be obtained, however, with the use 
of this decoupling method, spectral resolution can be improved to rival that of solution-state NMR. 
 
 
Figure 2.9  Magic-angle spinning 
 
The probability of being at the magic angle is further reduced when considering that most solid-
state samples consist of polycrystalline powders, not the single crystal example discussed so far.  
In the case of multiple NMR active nuclei within a molecule (which is part of a polycrystalline 
sample), it is probable that the vast majority of nuclei will not be orientated to the magic angle.  
Take for example, the hypothetical structure shown in Figure 2.10 (consider it to be part of some 
compound, where the remaining atoms are not shown).  It is clear that one proton is orientated at 
the preferred magic angle, whereas the other is aligned closer to the applied field.  For the 
hydrogen that is not aligned with the magic angle, a single rotation of the rotor about the magic 
angle will carve out a cone shaped path, the geometric average of which is the magic angle.  By 
spinning the sample at high speeds (typically upwards of 10kHz), non-orientated spin pairs will be 
subjected to what can be described as the effective MAS, meaning that the same effect is 
achieved, providing the spinning speed is sufficiently high.  It is by this method that anisotropic 
interactions are effectively removed from the spectra collected. 
 
Bo
54.74o
Cap
Rotor
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Figure 2.10  MAS removal of anisotropic interactions 
 
CSA cannot be removed by decoupling, this contribution to the NMR spectrum can only be 
removed by MAS.  CSA can also be very large, particularly for anisotropic environments such as 
carbonyl groups, in comparison to the more symmetric environments of CH, CH2 and CH3 groups.  
If the spinning speeds are not high enough to completely remove CSA, a series of spinning side 
bands (SSBs) are observed at repeating distances of the spinning frequency from the true 
resonance.  These SSBs are usually “spun out” by increasing spinning speeds, however, where 
this is not possible, SSB suppression pulse programs may be used.  SSBs are easily identified by 
repeat measurement of a sample at a different spinning speed.  Under these circumstances, the 
true resonance remains in the same place, whereas SSBs move to repeating distances of the new 
spinning frequency. 
 
2.3.2 Cross polarisation 
 
In order to obtain acceptable signal-to-noise in a SSNMR experiment, many scans are acquired 
and signals build up coherently as the noise averages.  However, the time delay (D1) between 
each scan is important; too short and the magnetisation becomes saturated (no signal can be 
recorded), too long, and the experiment becomes an inefficient use of instrument time.  The NMR 
pulse program has a relaxation delay that allows a state of equilibrium to be established.  For a 
solid organic crystalline material, this delay can be typically 10-300s for 
1
H, and 60-3000s for 
13
C.  
For poorly crystalline or amorphous materials this delay is reduced to 1-30s for 
1
H and 2-60s for 
13
C.  Directly observing 
13
C requires the use of long delays, generating excessively long experiment 
times (often weeks to obtain good signal-to-noise).  Indirectly observing 
13
C via the abundant 
1
H 
spins allows the use of much shorter relaxation delays. 
 
This idea of indirect observation of a nucleus is also applicable where particular nuclei produce a 
low intensity signal owing to low abundance (for example, 
13
C; relative abundance 1.1%).  In these 
instances, a technique known as cross polarisation (CP) can be employed to indirectly observe 
these nuclei.  Magnetisation transfer from a nucleus with high abundance for example, 
1
H; relative 
Bo
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abundance 100% to one of lower abundance enables signal enhancement, and hence an 
improvement in spectral resolution for that nucleus. 
 
A CP experiment can be described by a number of steps outlined in Figure 2.11 [9].  The starting 
point of the experiment shows a sample with a net magnetisation with the applied field (1).  First, a 
90
o
 pulse is applied to the magnetisation of 
1
H (2).  Next the cross polarisation step occurs (CP).  A 
ramp is used to cover a range of frequencies (3a), such that transfer is achieved for all types of C-
H interaction (frequencies are different depending on the environment of the proton and carbon 
nuclei in question).  The result of the CP is magnetised 
13
C nuclei (3b).  During the final stage of 
the experiment, two activities occur simultaneously.  The protons are decoupled (DEC) such the 
remaining dipolar coupling interaction with the 
13
C nuclei is removed (4a).  At the same time, the 
free induction decay (FID) is collected for 
13
C (4b).  Coupling between 
13
C is unlikely due to its low 
natural abundance, giving little opportunity for spectral complication due to coupling. 
 
 
Figure 2.11  Cross polarisation experiment 
 
Pulse programs such as the CP experiment are discussed further in Chapter 5. 
 
2.3.3 SSNMR experimental parameters 
 
Solid-state NMR spectra were recorded on a Bruker Avance 500 MHz NMR spectrometer.  Spectra 
for the suspensions were recorded with a 4mm MAS HX probe, 100W proton amplifier and 500W 
13
C amplifier.  Cross-polarisation used a 
1
H pulse of 3.2s (at -6.0dB), a ramped-proton cross 
polarisation (CP) pulse of 2ms (at -5.0dB) and a carbon CP pulse of 2ms (at +1.0dB).  TPPM15 
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proton decoupling was applied during the 30ms acquisition time.  Solid reference materials were 
recorded with a 2.5mm MAS HX probe, cross-polarisation used a 
1
H pulse of 2s (at -5.5dB), a 
ramped-proton cross polarisation (CP) pulse of 2ms (at -4.0dB) and a carbon CP pulse of 2ms (at -
3.1dB).  TPPM15 proton decoupling was applied during the 30ms acquisition time.  Side-band 
suppression was achieved using a Total suppression of spinning sidebands (TOSS-B) sequence 
with 5kHz sample rotation for suspensions and 15kHz for solid reference materials.  A relaxation 
delay of 60s was used between each scan and 4000 scans were acquired.  FIDs contain 3000 data 
points which were Fourier transformed into 16000 data points, no function was applied to the FID.  
Line fitting and deconvolution was performed using Bruker Solid Line-Shape Analysis program.  
Spectra were referenced to external adamantane and the magic angle was fixed using KBr.  
Optimisation of the relaxation delay was carried out by a series of experiments of increasing D1 
time.  Poor quality spectra were recorded when a relaxation delay of 10s was used, however, a 
delay of 60s showed good quality spectra that were equivalent to test spectra recorded using 300s 
delay, therefore a D1 time of 60s was selected.  Estimates of the 
1
H and 
13
C T1 values were 
obtained using saturation-recovery and Torchia [10,11] methods respectively. 
 
Direct polarisation (DP MAS) 
1
H spectra were recorded with 16 scans covering 200ppm and DP 
MAS 
13
C{
1
H} spectra were recorded covering 350ppm using 64 scans, spinal-64 decoupling and a 
relaxation delay of 60s.  
 
2.4 Vibrational spectroscopy 
 
Infrared (IR) and Raman spectroscopy are classified together under the category “vibrational 
spectroscopy” because each technique provides images of molecular vibrations of the analyte.  
This allows the use of both techniques in a complimentary manner, though it must be understood 
that there are significant differences between the techniques, as discussed in the following 
sections. 
 
2.4.1 IR spectroscopy 
 
IR spectroscopy makes use of a portion of the electromagnetic spectrum known as the infrared 
region.  This area ranges between 14000-10cm
-1
 and is generally split into three regions; near- 
(14000-4000cm
-1
), mid- (4000-400cm
-1
) and far- (400-10cm
-1
) infrared. 
 
At standard room temperatures, molecules are in a continuous state of vibration.  Each bond of the 
molecule has characteristic bending and stretching frequencies (as seen in the example of a simple 
triatomic molecule, CH2, in Figure 2.12 [12]), which are capable of absorbing light at those 
frequencies.   
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Figure 2.12  Vibrational modes in CH2 groups (+ and - indicate movement in to and out of the 
page respectively) 
 
These vibrational frequencies can be calculated using the following equation; 
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Equation 2.2  Hooke's law 
 
where  = frequency, k= constant related to force constant of the bond and m1 and m2 = mass of 
the two atoms) [12], which states that the amount of deformity within the material is directly related 
to the force causing the deformity (i.e. strain is linearly related to stress).   
 
As light is passed through the sample, some frequencies are absorbed and some are transmitted 
through the sample.  This results in the generation of the IR spectrum, represented as a plot of 
percentage absorbance or transmittance against frequency (cm
-1
) [12].  The spectrum displays 
absorption bands which are characteristic in their appearance and position to distinct motions of a 
molecule.  For example it is common that an alkyl C-H stretch is indicated by an absorption band at 
approximately 3000cm
-1
.   
 
In order for a molecule to show IR absorptions, it must follow a selection rule, and for IR 
spectroscopy, it states that the electric dipole moment of the molecule must change during 
vibration.  Examples of IR active molecules include symmetric stretches of heteronuclear diatomic 
molecules (for example HCl) but exclude the same for homonuclear diatomics as there is no 
change in dipole [13].  
 
 
 
Stretching modes
symmetric asymmetric
Bending modes
scissor rock
+ +-+
twist wag
In-plane Out-of-plane
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2.4.2 IR experimental parameters 
 
Data were collected on a Shimadzu FTIR-8400s Fourier Transform Infrared Spectrophotometer.  
The spectrophotometer was set to a resolution value of 1.0cm
-1
 and 30 scans were performed per 
sample in the range of 400-4000cm
-1
.  Sample preparation was as a caesium iodide disc pressed 
to ~10t using a 13mm die.  Spectra were analysed using Shimadzu IRSolution software v1.30.   
 
2.4.3 Raman spectroscopy 
 
When light is passed through a material, a small amount is always scattered.  In the case of 
Raman spectroscopy, this is advantageous as it is this light which is used to generate a spectrum.   
 
Most of the scattering that occurs is known as Rayleigh scattering.  Rayleigh scattering is elastic, 
i.e. an incident photon is directly reflected back in the same direction with the same energy.  The 
scattering of interest is that which is inelastic, otherwise known as Raman scattering.  This means 
that there is some interaction between the incident photon (from the light source) and the electron 
clouds of the interacting matter.  It is the manner in which this interaction occurs that generates two 
different types of Raman scattering (Figure 2.13).  If an electron is in a ground state (v = 0) on 
interaction, it will be excited to a virtual energy level, and on relaxation will remain in a higher 
vibrational energy state (v = 1).  This is Stokes Raman scattering and results in the loss of energy 
to the incident photon.  If the interaction occurs with an electron already in an excited vibrational 
state, excitation to a virtual state occurs, followed by relaxation to a ground state.  This is known as 
anti-Stokes Raman scattering and results in the gain in energy of the incident photon [14].  This 
scattering is dependent on the vibration of the molecule, and hence can be used to generate a 
spectrum similar to that produced by IR. 
 
 
Figure 2.13  Schematic of photon scattering in Raman spectroscopy 
 
The selection rules for Raman activity state that molecules must be anisotropically polarisable 
(Figure 2.14).  This means that the vibration or stretching mode of the molecule must generate a 
change in polarisation to be detected.  
Incident 
Photon
Incident 
Photon
Scattered 
Photon
Scattered 
Photon
V=0
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Virtual State
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Figure 2.14  Anisotropic polarisation of a homonuclear diatomic molecule (where arrows 
represent directions of polarisation) 
 
In order for the Raman process to be successful, it is necessary to have an intense monochromatic 
light source.  It is for this reason that most modern Raman spectrometers make use of laser light 
sources [14].   
 
The main interference observed with Raman spectroscopy is that of fluorescence which can 
frequently mask and therefore be confused for the Raman signal.  As a result of this problem, there 
have been introductions of Raman alternatives which reduce the interference of fluorescence.  The 
main technique if this kind is known as coherent anti-Stokes Raman spectroscopy (CARS).  This 
technique enhances the intensity of the Raman scattering observed with the use of a two laser 
beam system [15]. 
 
Raman spectroscopy has also proven itself as an analytical tool in the pharmaceutical field.  
Similarly to IR, there is scope for the use of this technique in the identification of polymorphs of 
active pharmaceutical ingredients, as well as the evaluation of amorphous content.  This is 
particularly important as many of the micronisation processes used in the production of inhalable 
drugs result in the formation of amorphous material.  The use of Raman in this field has been 
demonstrated with the analysis of spray dried lactose [16]. 
 
Raman mapping and chemical imaging is also gaining popularity, particularly in the field of drug 
aerosolisation.  The ability of mapping to identify a single minor element in a mixture makes it 
suitable for the analysis of formulations such as nasal sprays [17] and for the evaluation of in-vitro 
deposition of drugs [18].  
 
2.4.4 Raman experimental parameters 
 
Data were collected on a Horiba Jobin Yvon LabRAM HR800 spectrometer using a 632.8nm HeNe 
laser with 600 grating and 50x objective.  The hole size used was 1000m and the slit aperture 
150m.  Multiscan collections were performed, with each 200cm
-1
 scan comprising of 20 
accumulations, each of 20s exposure.  The full range of each scan was 200-1500cm
-1
.  Data were 
analysed using LabSpec software v5.25. 
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2.5 Thermal analysis 
 
Thermal analysis is defined as the measurement of changes in a physical property of a substance 
as a function of temperature whilst the sample is subjected to a controlled temperature programme 
[19].  Pharmaceutically, the most commonly used thermal analysis techniques include 
thermogravimetric analysis (TGA), differential thermal analysis (DTA) and differential scanning 
calorimetry (DSC).  There are various events that can be assessed via these methods, depending 
on the behaviour of the sample under the experimental (thermal) conditions.  The main thermal 
events observed for a pure solid material, A, when heated in an inert atmosphere are summarised 
in Table 2.3 [20]. 
 
Start End Transition 
A(s1) 
A(s2) Phase Transition 
A(l) Melting 
A(g) Sublimation 
B(s) + gases 
Decomposition 
(Thermal) 
Gases (Radiolytic) 
A(glass) A(rubber) Glass Transition 
A(s) + B(g) C(s) 
Oxidation 
Tarnishing 
A(s) + B(g) Gases 
Combustion 
Volatilisation 
A(s) + (gases)1 A(s) + (gases)2 Heterogeneous Catalysis 
A(s) + B(s) AB(s) Addition 
AB(s) + CD(s) AD(s) + CB(s) Double Decomposition 
Table 2.3  Summary of thermal transitions 
 
TGA involves the measurement of changes of sample mass with temperature.  The data collected 
are presented in the form of a thermogravimetric curve; a plot of temperature against mass.  TGA 
is often used as a comparative medium for groups of samples, however a number of conclusions 
can be drawn from the data acquired.  For example, in the analysis of bovine serum albumin (BSA) 
and the effects of particle corrugation on powder aerosolisation, TGA was used as a means of 
moisture content determination, and results indicated that moisture content was higher in the non-
corrugated particles [21].  
 
DTA is a technique in which a sample and an inert reference are heated (or cooled) under identical 
conditions.  Any temperature difference as a result is recorded and plotted against time to generate 
a DTA plot.  DSC measures changes in the difference in the heat flow rate between a sample and 
reference while they are subjected to a controlled temperature program [22].  DSC is often 
classified alongside DTA as the instruments are essentially the same in their function, and very 
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similar in instrumental arrangement.  The sample is placed into a pan and heated alongside an 
empty reference pan.  However, in the case of DSC, it is the differential amount of power required 
to heat the sample that is measured.  Hence a plot of heat flow against temperature is produced 
(compared to temperature differential against temperature for DTA).  This type of plot is capable of 
providing information of first order transitions (melting and crystallisation) and second order 
transitions (glass transition temperatures) [23]. 
 
One main difference between the data produced by DTA and DSC is the convention in which they 
are graphically represented.  Each type of plot demonstrates where energy differences occur, 
however in DSC endothermic responses are usually represented as a positive signal, i.e. above the 
baseline (in DTA analysis endotherms appear as a negative signal).  Regardless of this, the peaks 
are still produced as a result of whether more or less energy was required to heat the sample, 
relative to the reference pan.  
 
Advances in DSC have seen the introduction of Hyper-DSC (HDSC), which uses an increased 
scanning rate (100-500
o
C/min) to generate improved sample through-put and increased sensitivity.  
The technique has shown great potential in the quantification of amorphous material in 
predominantly crystalline samples [24].  By increasing scan rate, the detection of the glass 
transition (Tg) improves.  When at high scan rates (500
o
C/min), it is also possible for analysis to be 
carried out on very small samples (ca. 1mg) without reducing the detection of Tg.  It is this property 
that aids the quantification of amorphous material, even when present in amounts as low as 1.5%. 
 
2.5.1 Thermal analysis experimental parameters 
 
Thermal analysis in the form of thermogravimetric analysis and differential thermal analysis were 
carried out using a TA Instruments 2960 SDT instrument.  The samples were heated at 10
o
C/min in 
air.  Each sample was analysed once and data were plotted using Microsoft Excel.  
 
2.6 Summary 
 
The techniques described are those which have found common usage in the physical 
characterisation of pharmaceuticals.  For the purpose of these studies, techniques employed 
include PXRD and SSNMR for phase identification and SEM for particle characterisation.  
 
PXRD and SSNMR were selected for phase identification purposes in preference to IR or Raman 
analysis based on their non-destructive nature and improved detection of small amounts of 
polymorph transformations.  Most of the studies included here involve the characterisation of 
lactose polymorphs, and due to the close proximity of absorption bands in the IR spectra [25], it 
can be difficult to identify mixed phase samples.  PXRD and SSNMR also offer a smaller sampling 
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error due to the increase in sample mass required for analysis (PXRD and SSNMR ~0.5g, IR 
~0.02g). 
 
SEM was selected in preference to optical microscopy as ultra high magnification allows the 
observation of fine structural detail of small particles and agglomerates as well as particle shape 
and size.  
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3.1 Introduction 
 
Crystallisation is a traditional technique commonly used in chemical synthesis to generate a 
reaction product or to improve the purity of a given material.  This technique has also been 
exploited commercially by the pharmaceutical industry as a means of pre-formulation particle 
engineering for excipients such as lactose [1,2].   
 
Along with the obvious size restrictions necessary to enable therapeutic APIs to enter the lung (1-
5m, see Chapter 1), particle shape has a surprisingly large effect on the amount of active that 
achieves deep lung penetration.  Before specified particle engineering less than 10% of API doses 
reached the lungs, however with the use of particle engineering technologies, now over 50% 
delivery is achieved [3].  Improved drug delivery relies on aerodynamics and active-excipient 
binding, each of which partially relies on particle morphology.  Research has shown that particles of 
spherical or at least rounded shape with a rough surface morphology provide better aerodynamic 
properties and binding ability than smooth surfaced particles [4-6].  Surface imperfections and 
craters allow effective binding by API particles, and rounded morphologies exhibit less 
aerodynamic resistance.  As a result the crystallisation of L.H2O from aqueous solution has been 
previously investigated [7-14].   
 
Existing research shows that crystallisation conditions heavily influence the properties of lactose 
crystals.  Generally, crystals are of polar morphology, meaning that they adopt an asymmetric 
shape, though the specific shape varies significantly.  They are termed “polar” as the crystals are 
polarised as a result of molecular dipole alignment to a crystallographic direction.  It has also been 
proven that anisotropic growth is observed in the polar directions, such that in extreme cases, 
growth in other directions can be significantly inhibited.  It is for these reasons that the traditional 
“tomahawk” shaped crystal (Figure 3.1) is expected as a crystallisation product.  Nucleation begins 
at the narrow tip end and the polar growth direction is towards the broader base of the crystal [12]. 
 
Chapter 3  Crystallisation of pharmaceutical excipients 
from aqueous solutions 
Page | 53  
 
 
Figure 3.1  (a) Representation of a tomahawk morphology (b) SEM micrograph of a 
tomahawk shaped L.H2O crystal 
 
Despite the well researched and generally acknowledged mode of crystal growth, there are various 
grades of L.H2O commercially available (excluding those micronised or spray dried) that do not 
show the expected tomahawk particle shape exclusively (Figure 3.2 where (a) shows the presence 
of a single tomahawk, and (b) shows multiple tomahawks in the presence of other polyhedral 
morphologies). 
 
 
Figure 3.2  SEM micrographs of (a) Lactochem crystals (b) Lactochem extra fine crystals 
(250x magnification) 
 
The main concern with any pharmaceutical particle engineering technique is that the processing 
conditions may result in polymorphism.  For lactose, this is a major issue, as there are four 
“polymorphs” commonly accepted [15], three of which are stable under ambient conditions.  
Polymorphism is a concern in formulation studies, as each of the lactose polymorphs can produce 
different properties in terms of mechanical properties, drug binding/release, solubility and stability.  
For example, for inhalation therapy applications, L.H2O has been shown to have preferable flow 
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and carrier properties in comparison to the other stable polymorphs [16].  There is also the 
possibility of producing amorphous material during processing, particularly in the case of 
micronisation where high energy shear forces indiscriminately cleave the crystals.  This is highly 
undesirable during the drug formulation process, as amorphous materials exhibit increased 
solubility and reactivity properties in comparison to crystalline materials which can potentially pose 
problems in terms of stability of the formulation.  Recrystallisation of amorphous material also 
provides the means for crystal growth, which is again undesirable in drug formulations.   
 
The conditions required to result in polymorphic transitions of L.H2O have been discussed 
previously (Chapter 1).  The most important consideration for crystallisation from aqueous solutions 
is the muta-rotation of L.H2O to L that naturally occurs in water.  This mutarotation immediately 
gives the possibility of producing a mixed phase product from the crystallisation process.  The 
inclusion of an antisolvent to the crystallisation mixture can also give this material means for further 
polymorphism effects. 
 
Antisolvents are a group of solvents that may be added to a crystallisation mixture in order to 
facilitate crystallisation.  In order to fulfil the properties required for antisolvent crystallisation to be 
successful, the solvent must be miscible with the mother liquor (here, water), but in which the 
solute (here, L.H2O) is insoluble.  Under these conditions, an environment is created such that the 
effective solubility of L.H2O is reduced, but not completely inhibited.  Consequently, by increasing 
the antisolvent content within the crystallisation mixture, crystallisation is increasingly induced.     
 
The antisolvent most commonly investigated in lactose crystallisation is acetone, however other 
water miscible polar solvents are suitable for use under these conditions.  Previous investigation 
into crystallisations of lactose from aqueous solutions with the use of alcohol antisolvents have only 
used small proportions, typically 10% by volume [17-19].  Given the already acknowledged 
dehydrating nature of short chain alcohols [20,21], it is logical to extend the investigation to include 
higher proportions of alcohol antisolvents, and dehydrating solvents such as these, are a good 
example of how crystallisation conditions affect the number of phases present in the final product. 
 
Further polar antisolvents were employed throughout this study to investigate antisolvent effects on 
morphology and polymorphism of lactose in comparison to other dehydrating sugars (hydrates 
capable of water loss) for example raffinose pentahydrate and trehalose dihydrate and non-
dehydrating sugars (those which do not exist as a hydrate in their most stable form) for example 
mannitol. 
 
The excipients selected for comparison to lactose are all capable of polymorphic or 
pseudopolymorphic transitions, and have been selected based on the extent to which these 
transitions are prominent.  For example, raffinose exists in a stable pentahydrate form.  When 
treated thermally, dehydration occurs to lower states of hydration, though these have only been 
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shown to be metastable [22].  Trehalose, as a dihydrate, is also capable of dehydration however, 
unlike raffinose, a stable anhydrous polymorph is known [23].  Conversely, mannitol exists as an 
anhydrous species capable of hydration and polymorphism in a manner similar to lactose.  In its 
anhydrous form, there are three polymorphic forms commonly accepted (alpha, beta and delta), 
though a further two have been postulated [24,25].  These properties are comparable to those of 
lactose and its polymorphs, and as such these excipients are applicable to the terms of this 
investigation. 
   
In addition, the effect of morphology of large crystals on PXRD analysis, and subsequently on 
lactose polymorph identification is discussed due to previous inconclusive studies.  An ideal sample 
for PXRD analysis consists of a large number of very small crystals that are randomly oriented with 
respect to each other.  Where samples comprise inhomogeneous powders or large polycrystalline 
samples, preferred orientation can influence the diffraction patterns obtained.  Despite these 
issues, various methods have been employed in an attempt to use PXRD quantitatively [26].  
Preparation of single phase materials for the calibration measurements is more challenging in the 
case of lactose than for mineralogical samples where the methodology is common place.  This is 
simply because this excipient is very sensitive to preparative conditions and most standard 
methods of characterisation themselves can cause changes in polymorphism or crystallinity. 
 
Preferred orientation presents itself as increased intensity in certain reflections in the PXRD 
pattern, and therefore the concomitant suppression of others.  This effect comes as a result of 
crystal morphology as well as size.  For example, where flat plate-like crystals exist, a tendency 
towards orientation of the flat surfaces will occur within the sample, exposing these planes 
preferentially to the X-ray beam (in reflection geometry), giving increased reflection intensity.  The 
orientation of crystals in this manner therefore reduces probability of scattering from the shorter 
“end planes” of the crystals, reducing the intensity of their associated reflections.  In extreme 
cases, this reduction can be to zero, and the reflection is not observed at all.  
 
3.2 Experimental 
 
3.2.1 Crystallisation of lactose from saturated solutions 
 
Initial crystallisations involved the use of a saturated solution.  L.H2O (Figure 3.3(a), Fluka 
Biochemica, Cat. No. 61340), used without further purification, was added to 100ml heated water 
(distilled, 50
o
C) until dissolution ceased (i.e. the point of saturation was reached).  At this point, any 
non-dissolved, excess L.H2O was separated from the solution.  The solution was cooled by two 
means, slow cooled (5
o
C/h) or quenched, and any crystals produced were then filtered.  The 
crystals produced were characterised by SEM and PXRD. 
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3.2.2 Antisolvent crystallisation of lactose 
 
L.H2O was dissolved in distilled water (1:10 w/v) at room temperature.  The lactose solution was 
added to five different antisolvents (without stirring or agitation) such that the antisolvents occupied 
45-95% (v/v) of the total crystallisation volume (40ml).  The crystallisation vessels were covered to 
avoid solvent evaporation, and left undisturbed for three days to allow crystallisation to occur.  After 
three days, the crystals were recovered and analyzed for particle morphology and size by SEM, 
and lactose polymorphism was identified by PXRD.  Antisolvents must be miscible with water to 
allow the solubility of lactose to be sufficiently reduced such that crystallisation ensues, therefore 
acetone, tetrahydrofuran, acetonitrile (all polar aprotic), ethanol, methanol and ethylene glycol (all 
polar protic) (Fisher scientific Ltd.) were selected. 
 
For comparison purposes, the crystallisation period was also varied (1h-4w) to determine any effect 
this had on particle shape and size. 
 
3.2.3 Application to other pharmaceutical excipients 
 
These crystallisation procedures were applied to raffinose pentahydrate, trehalose dihydrate and 
mannitol (Figure 3.3(b), (c) and (d) respectively) in order to assess their susceptibility to antisolvent 
crystallisations, i.e. any resulting polymorphism or change in hydration. 
 
 
Figure 3.3  Structural representations of pharmaceutical excipients (a) L.H2O, (b) raffinose 
pentahydrate (c) trehalose dihydrate and (d) mannitol 
.H2O
(a)
.5H2O
(b)
.2H2O
(c) (d)
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3.3 Results and discussion 
 
3.3.1 SEM investigation of the morphological transitions in lactose 
 
3.3.1.1 Crystallisation of lactose from saturated solutions 
 
SEM analysis of the slow cooled crystallisation indicated a larger particle size (relative to the 
starting material) of ~600m with smooth surface morphology and flat faces (Figure 3.4), whereas 
the quenched crystallisation (faster cooling rate, Figure 3.5) showed a much smaller particle size, 
though a wider particle size distribution (10-90m).  It can also be seen that in comparison to the 
slow cooled method, the particles produced do not have the same flat surfaces and smooth edges.  
The quenched, rapid cool crystallisation process yields particles that appear more similar in 
appearance to those resulting from a micronisation process (Figure 3.6). 
 
 
Figure 3.4  SEM micrograph showing lactose crystallised from a saturated solution with a 
slow cooling rate 
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Figure 3.5  SEM micrograph showing lactose crystallised from a quenched saturated 
solution 
 
 
Figure 3.6  SEM micrograph of micronised L.H2O 
 
The micrographs shown above indicate that neither of the methods employed exclusively 
generated the “expected” tomahawk morphology. 
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3.3.1.2 Antisolvent crystallisation of lactose 
 
Crystal growth followed the same general trend independent of antisolvent used; at lower 
proportions of antisolvent the crystals produced were larger in size (typically 100-200m) than 
those formed at higher proportions of antisolvent and showed a polyhedral habit.  As antisolvent 
content increased, much smaller (<100m), flatter, needle shaped crystals were observed.  The 
transition from smooth-surfaced, large particles to needle shaped crystals was via a fractured 
intermediate, whereby the surface of the larger crystals became roughened and showed signs of 
cracking.  While this trend was adopted by each crystallisation set, it must be highlighted that there 
were significant differences between the crystals formed by each of the antisolvents, for example, 
some crystals grew as defined single crystals, while in other cases growth from multiple nucleation 
sites resulted in crystals joining and growing together to give large agglomerates.   
 
While the morphological trend observed appears to be independent of antisolvent employed, the 
onset of crystallisation varied between antisolvents.  The addition of lower quantities of antisolvent 
did not induce crystallisation of lactose, however at ~40-50% and above, crystallisation was 
observed (after the three day crystallisation period), with the exception of ethylene glycol which did 
not induce any crystal formation.  The investigations with acetone antisolvent indicated 
concurrence with previous crystallisation studies [27] where crystal growth occurred at 50-65% 
acetone.  Solubility is variable with temperature and as such, temperature plays a significant role in 
the crystallisation process.  It is therefore highly feasible that the variance in the onset of 
crystallisation was a function of temperature fluctuation, though the interaction between lactose 
solution and antisolvent is also a limiting factor.   
 
The particle morphologies produced in these crystallisations imply that the antisolvent restricts 
polar growth in one particular direction.  It is for this reason that needle shaped crystals are 
produced at higher quantities of antisolvent.  SEM analysis of the crystals highlighted similarities in 
size and morphology when crystallised from methanol and ethanol antisolvents and similarly those 
from tetrahydrofuran and acetonitrile antisolvents.  Comparison of these to the acetone 
crystallisations showed that the onset of needle shaped crystal formation occurred at lower 
proportions of antisolvent (typically 75% acetone) in comparison to the remaining antisolvents (80-
85% antisolvent).  A summary of the particle characteristics produced as percentage antisolvent 
changes is given in Table 3.1. 
 
It is also important to consider the effect of L formation in aqueous solution.  When L.H2O is 
dissolved in water a natural equilibrium is reached, whereby a 40:60 ratio of L.H2O:L is obtained 
by muta-rotation.  The effect of this L presence also has an effect on L.H2O crystallisation, and it 
is thought that it may act as a nucleation inhibitor and habit modifier.  This theory is responsible for 
the queries over the typical tomahawk morphology and whether it is in fact a result of extreme 
crystallisation conditions [12].   
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90 
 
 
 
 
 
 
 
 
 
 
95 
     
Table 3.1  SEM micrograph comparison of antisolvent crystallisation of L.H2O as a function of %antisolvent in the total volume (40ml) (250x 
magnification, solutions where crystal growth was not observed are indicated by “-”)  
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The crystallisation method outlined disregards concentration effects on crystallisation.  Under these 
experimental conditions, as antisolvent proportion increases, to maintain constant crystallisation 
volume, lactose solution proportion decreases, meaning lactose concentration is effectively 
reduced.  To ensure that this change in concentration did not pose question over the particle 
morphologies produced, a separate experiment was performed using constant lactose solution 
volume (and therefore concentration), and variable crystallisation volume.  Results indicated that 
particle morphology and lactose polymorphism was not affected by concentration (Figure 3.7).  
Where significantly more lactose was used in the crystallisation, the result was simply an increased 
yield of crystals. 
 
 
Figure 3.7  SEM micrographs showing crystallisation of lactose from varied total volumes 
(200x magnification) 
 
3.3.1.3 Crystal growth with time 
 
Previous experiments used a crystallisation period of three days, which was varied to determine 
the effect of time on crystal growth.  The saturated solution experiments have already shown that a 
huge difference in crystal size can be obtained by cooling the solutions slowly.  With this in mind, 
Total volume 40ml
Acetone content 50%
Total volume 50ml
Acetone content 60%
Total volume 60ml
Acetone content 66%
Total volume 70ml
Acetone content 71%
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crystal size would be expected to further increase as crystal growth is permitted over a longer 
period of time. 
 
Raghavan et al. [12] claim that tomahawk shaped crystals are exclusively produced in a 10% 
L.H2O solution containing 65% acetone antisolvent after a 12h crystallisation period.  Repeat 
crystallisations under these conditions (Figure 3.8) did not produce the expected tomahawk, or any 
evidence of its formation.  
 
Figure 3.8  SEM micrographs for products of repeat acetone antisolvent crystallisations, 
65% acetone, 12h crystallisation period (150x magnification) 
 
The crystallisation period was increased to 4w to determine whether the elusive tomahawk 
morphology could be prepared over a longer crystallisation period, however, results again showed 
no sign of this particular morphology exclusively (Figure 3.9).  The SEM micrographs show 
evidence of multiple crystal growth from a single nucleation point, and the individual “lobes” of 
these agglomerates are, in places, in the tomahawk shape.  It is possible that at some point 
throughout the 4w isolated tomahawk shaped crystals were present, which agglomerated as the 
nucleation points proliferated. 
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Figure 3.9  SEM micrographs for products of repeat acetone antisolvent crystallisations, 
65% acetone, 4w crystallisation period (150x magnification) 
 
Following these results, crystal formation was observed, using the same quantities, on an hourly 
basis (Figure 3.10 and Figure 3.11).  The 10% L.H2O stock solution was prepared from two 
different particle sizes to determine any effect on crystals produced. 
 
 
Figure 3.10  SEM micrographs (hourly) of development of crystals from an acetone 
antisolvent crystallisation (65% acetone) with Lactochem extra fine crystals starting 
material (250x magnification) 
 
1h 2h 3h
4h 5h 6h
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Figure 3.11  SEM micrographs (hourly) of development of crystals from an acetone 
antisolvent crystallisation (65% acetone) with Fluka L.H2O starting material (250x 
magnification) 
 
Different grades (average particle size) of lactose should not affect the particles produced during 
crystallisation, as once in solution, only crystallisation conditions (which remained constant for each 
set of crystallisations) can affect crystal morphology.  However, Figure 3.10 shows that while the 
overall shapes of the particles produced are very similar, the distinguishing fine structural detail in 
crystals produced from the Lactochem extra fine crystals L.H2O is unique (Figure 3.12). 
 
1h 2h 3h
4h 5h 6h
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Figure 3.12  SEM micrograph showing the development of crystals from an acetone 
antisolvent crystallisation (65% acetone) with Lactochem extra fine crystals starting 
material  
 
Crystallisations of 5-95% acetone antisolvent were also allowed to grow for an extended period of 
4w.  Tomahawks, or aggregates of tomahawk shaped crystals were observed at 35% acetone 
(confirmed by multiple repeat crystallisations, Figure 3.13), whereas no crystals were observed 
after 3d at this proportion of acetone.   
  
 
Figure 3.13  SEM micrographs of the products of an acetone antisolvent crystallisation, 35% 
acetone, 4w crystallisation period (200x magnification) 
 
These results have failed to confirm the exact conditions under which the tomahawk morphology is 
produced, therefore posing questions over the methodologies outlined in the literature. 
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3.3.2 PXRD characterisation of lactose crystallisation products 
 
3.3.2.1 Crystallisation from saturated solutions 
 
PXRD data were collected for crystallisation products from both quenched and slow cooled 
saturated solutions, showed that the products were phase pure in the L.H2O form with no 
indication of L presence (Figure 3.14). 
 
 
Figure 3.14  PXRD patterns for material produced by slow cooled and quenched 
crystallisation methods 
 
3.3.2.2 Antisolvent crystallisation of lactose from aqueous solutions 
 
PXRD data were collected for each crystallisation product, from which it could be seen that the use 
of an antisolvent emphasised the polymorphic nature of lactose (Figure 3.15 to Figure 3.19).   
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Figure 3.15  Comparison of PXRD patterns for acetone antisolvent crystallisation 
 
 
Figure 3.16  Comparison of PXRD patterns for tetrahydrofuran antisolvent crystallisation 
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Figure 3.17  Comparison of PXRD patterns for acetonitrile antisolvent crystallisation 
 
 
Figure 3.18  Comparison of PXRD patterns for ethanol antisolvent crystallisation 
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Figure 3.19  Comparison of PXRD patterns for methanol antisolvent crystallisation 
 
The natural mutarotation of lactose in aqueous solution to form a 40:60 mixture of L.H2O: L has 
already been discussed.  L is more water-soluble than L.H2O and as such, in the presence of 
low antisolvent content, the formation of single phase L.H2O was as expected.  L increased in 
dominance with increasing antisolvent content due to L.H2O nucleation inhibition by L [12].  The 
onset of L formation also varied depending on antisolvent, however this may also be attributed to 
temperature factors.  L has also been referred to as a “habit modifier” [28] in that it reduces crystal 
growth in polar directions.  It is for this reason that the tendency towards needle shaped crystals is 
observed with increasing antisolvent.   
 
Furthermore, in the presence of dehydrating antisolvents such as methanol and ethanol, 
dehydration of existing L.H2O to form the stable anhydrous polymorph, LS, is observed to 
generate tertiary phase products (Figure 3.20).  While dehydration would not normally be expected 
under aqueous conditions, high proportions of antisolvent (LS formation occurs at 90 and 95% 
methanol or ethanol) in comparison to water allows dehydration to be the dominant process.   
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Figure 3.20  PXRD patterns of crystals produced from high proportions of ethanol and 
methanol antisolvents 
 
Evidence suggests that dehydration occurs following L.H2O crystal nucleation.  SEM images 
collected show signs of the dendritic growth commonly associated with ethanolic dehydration of 
L.H2O to LS [29,30], though this can be mistaken for the needle-like crystals of L, which is the 
dominant species (Figure 3.21). 
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Figure 3.21  (a) Formation of LS dendrites from L.H2O (b) crystals produced from 90% 
methanol (LS present, left) and 95% tetrahydrofuran (L dominant) 
 
It should be noted that phase identification by PXRD characterised the bulk material only.  It is 
possible, due to the nature of crystallisation conditions that some surface modification of the 
crystals occurred.  Following nucleation and crystal growth, the crystals remain in contact with the 
surrounding crystallisation liquor.  The surface of these crystals are therefore subject to 
mutarotation or dehydration depending on antisolvent employed.  Determination of these effects 
would require surface specific analysis, for example Raman spectroscopy or attenuated total 
reflectance mode FT-IR. 
  
3.3.3 Preferred orientation effects in PXRD of lactose crystals 
 
Close scrutiny of the PXRD data collected shows irregularities in the intensities of the reflections 
observed.  This is not an experimental artefact, but a consequence of the properties of the crystals 
produced via this method of particle engineering.  
  
PXRD relies on randomly orientated crystals within a powder sample, such that an average of each 
of the crystallographic planes within the sample can be represented simultaneously.  Where 
crystallisation conditions force the production of large crystals of distinctive, consistent 
morphologies, a randomly orientated sample cannot be obtained.  It is under these conditions 
where preferred orientation affects the intensities of reflections; the preferred hkl planes produce 
increased intensity reflections, whereas other, non-preferred planes may have reflections that show 
(a)
(b)
Anhydrous 
ethanol
Static
Room Temp.
Chapter 3  Crystallisation of pharmaceutical excipients 
from aqueous solutions 
Page | 75  
 
almost zero intensity.  This effect has both advantages and disadvantages when examining 
samples of lactose.  While preferred orientation can be useful in enhancing the intensity of some of 
the data, indicating perhaps the presence of a minority phase which would not be apparent if the 
orientation of the crystals were random, it means that quantification methods which essentially use 
calibrated intensity profiles cannot be used.  Each polymorph of lactose has a low intensity, unique 
reflection at low angle, and these have been used in previous studies to both identify and quantify 
[26] phases present within mixtures of polymorphs.  As these reflections lie in well separated 
regions, they are at first sight the best reflections to choose for quantification studies.  However, 
some caution should be exercised as the intensities of these reflections are those most affected by 
preferred orientation due to the needle-like crystal morphology.  Homogenisation of lactose 
samples can result in changes in these intensities in the PXRD data and removal of the preferred 
orientation, leaving only the region 15-25
o
 2θ, which contains many overlapping reflections, to 
perform phase identification and quantification.  This can generate different challenges associated 
with deconvolution of overlapping reflections and anisotropic broadening of the reflections 
associated with the different phases. 
  
This study outlines the problems of preferred orientation in lactose well.  Where L.H2O crystals 
are dominant, the antisolvent process formed polyhedral crystals.  As a result, the (01-1), (040) and 
(04-1) planes are dominant, resulting in preferred orientation in the PXRD patterns in reflections at 
12.55, 16.46 and 20.34
o
 2θ, which corresponds to d-spacings of 7.05, 5.38 and 4.37Å respectively 
(Figure 3.22).  As L becomes increasingly dominant with increasing antisolvent content (where the 
antisolvent is non-dehydrating), the morphological transition towards needle shaped crystals is 
shown in the preferred orientation of the (110) and (200) reflections at 10.51 and 16.35
o
 2θ, 
corresponding to d-spacings of 8.41 and 5.41Å respectively (Figure 3.23). 
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Figure 3.22  PXRD pattern showing preferred orientation of the (01-1), (040) and (04-1) 
L.H2O reflections at 12.55, 16.46 and 20.34
o
 2θ 
 
 
Figure 3.23  PXRD pattern showing preferred orientation of the (110) and (200) L reflections 
at 10.51 and 16.35
o
 2θ 
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 The cause of this preferred orientation is made clear when paying closer attention to the shape of 
the crystals produced.  The SEM micrographs shown in Figure 3.24 show the preferred planes for, 
and the directional growth in L.H2O and L phases. 
 
Figure 3.24  L.H2O crystal (left) showing the (01-1) and (04-1) planes and L crystal (right) 
showing the (110) and (200) planes 
  
The preferred orientation effect can be reduced by a number of different methods including sample 
homogenisation or sample sieving, however both these methods generate their own issues.  For 
example, homogenisation by grinding or milling can change the amorphous content.  Furthermore, 
grinding can facilitate both polymorphic changes and dehydration due to localised heating.  Sieving 
often results in preferential removal of one phase over another due to the crystal habit/size effects 
in that phase.  In addition there are also numerous experimental methods available to the PXRD 
expert with multiple instruments and no time constraints to reduce the effects of preferred 
orientation in PXRD analysis, for example by rotation of the sample in a capillary.  However the 
standard laboratory arrangement for a PXRD experiment normally employs flat plate sample 
holders and a short collection time (1h or less) typically with the instrument in reflection rather than 
transmission mode, as used throughout these studies.  This investigation therefore clearly 
highlights the potential downfalls associated with phase identification and quantification by these 
means, and as such, the method of analysis employed should be carefully considered when using 
PXRD as a quantification tool. 
  
Figure 3.25 shows the PXRD pattern produced from the mixed phase (determined in Figure 3.15) 
crystallisation product of the 80% acetone crystallisation using a continuous scan.  The same 
sample was analysed via a stepped scan method, such that the accurate positions of the 
reflections present could be obtained due to the improved resolution of data collected by these 
means.  Close scrutiny of the pattern produced show multiple contributions to reflections, but this is 
most obvious at 10.5
o
 2, where a distinct doublet is observed (note that this effect was observed 
in multiple samples, and not unique to one specific sample).   
 
110
Chapter 3  Crystallisation of pharmaceutical excipients 
from aqueous solutions 
Page | 78  
 
 
Figure 3.25  PXRD pattern of crystals produced from 80% acetone, analysed using a 
continuous scan (top) and stepped scan compared to L and L.H2O (bottom)    
 
This splitting of reflections emphasises the effect that preferred orientation can have during sample 
analysis.  The splitting in this case is due to crystal size.  Where larger crystals are mixed with 
smaller crystals, a variable sample height is produced, which in turn causes a shift in the PXRD 
pattern.  So in this instance, the preferred orientation of the (01-1) plane results in increased 
intensity of the 10.5
o
 2θ reflection, and the variation in sample height causes it to split (Figure 
3.26).  It should be noted that with the given instrument and experimental parameters, anisotropic 
broadening of reflections is not observed above 10
o
 2θ and therefore is unlikely to have had an 
effect in this case. 
 
 
Figure 3.26  Schematic showing the x-directional shift associated with sample height 
variance 
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The crystal size theory is confirmed by observation of the SEM for this sample (Figure 3.27), which 
clearly shows a mixture of small and large, flat-faced crystals (and the presence of surface 
nucleation).  Homogenisation of the sample (grinding in a pestle and mortar) before repeat analysis 
showed a single reflection at 10.5
o
 2, indicating that the splitting observed was as a result of 
crystal size (Figure 3.28).  Figure 3.28 also shows the disappearance of the 15.6
o
 2 (5.68Å, 
L(120) plane) reflection following sample homogenisation.  While this reflection appears as a 
major reflection prior to grinding, in a perfectly random sample, the contribution from this reflection 
would be expected to be minimal. 
 
 
Figure 3.27  SEM micrograph showing crystals produced from 80% acetone 
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Figure 3.28  PXRD pattern of crystals produced from 80% acetone analysed using a stepped 
scan, prior to- (bottom) and post (top) homogenisation (by grinding) 
 
The removal of reflections following homogenisation is of paramount importance when considering 
the use of PXRD as a means of quantification.  For example, previous attempts [26] have used 
peak area analysis including the L.H2O reflection at 16.4
o
 2θ.  Analysis of this region with a 
continuous scan shows one reflection, but in a mixed phase, preferred orientation can render the 
L contribution at 16.35
o
 2θ significant, as shown by repeat analysis using a stepped scan (Figure 
3.29).  Where there are two contributions to the reflection, the peak area is increased giving the 
potential for error in later quantification calculations.   
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Figure 3.29  Resolution of multiple contributions to the ~16.5
o
 2θ reflection with the use of a 
stepped scan (bottom) of the same sample (2θ vs counts) 
  
While preferred orientation can make quantification by PXRD difficult and potentially unreliable, it is 
also responsible for enhancing minor reflections which may be of use during phase identification.  
For example, the partial dehydration of L.H2O to LS under high quantities of methanol or ethanol 
show preferred orientation to enhance the reflection at 9.2
o
 2θ (Figure 3.20), which is unique to the 
LS phase.  Under normal analysis conditions, the expected limit of detection for a minor phase 
would be ~5wt%, however, where a minor phase exists as large crystals, it can quite easily be 
detected (below the typical limit) as a result of these preferred orientation effects. 
 
3.3.4 Application to other pharmaceutical excipients 
 
The other excipients employed in this study were selected on their ability to undergo 
(pseudo)polymorphic transitions i.e. a change in polymorph or hydration state (maintaining the 
terminology used in discussion of lactose).  For example, raffinose undergoes partial dehydration 
when treated thermally.  Eventually, complete dehydration of raffinose is achieved and an 
anhydrous amorphous form is produced due to the collapse of the crystal structure following the 
removal of water molecules [22].  Trehalose dihydrate is subject to thermal and solvent mediated 
dehydration to a stable anhydrous form [23].  Mannitol is known to exist as a hemihydrate [31], 
however its three anhydrous polymorphic forms; alpha, beta and delta are more commonly 
observed [24,25]. 
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Under the described crystallisation conditions, each of the sugars produced crystals of needle or 
plate-like habit exclusively.  Table 3.2 shows the same comparison for mannitol as was seen earlier 
for the lactose crystallisations, however the SEM micrographs show little variance in morphology 
between crystals.  As with the lactose crystallisations, particle size decreases with increasing 
antisolvent.   
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Table 3.2  SEM micrograph comparison of antisolvent crystallisation of mannitol as a function of %antisolvent in the total volume (40ml) (250x 
magnification, solutions where crystal growth was not observed are indicated by “-”)
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For comparison, the SEM micrographs for acetone antisolvent crystallisations of raffinose 
pentahydrate and trehalose dihydrate are also given (Figure 3.30 and Figure 3.31), showing 
similarity in habit to the mannitol crystals observed.   
 
 
Figure 3.30  SEM micrographs showing crystallisation products of raffinose pentahydrate 
with acetone antisolvent (150x magnification) 
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Figure 3.31  SEM micrographs showing crystallisation products of trehalose dihydrate with 
acetone antisolvent (150x magnification) 
 
Unlike the lactose products, there was no variation in crystal morphology with antisolvent or 
antisolvent content, however crystal width was shown to be variable.  Generally, at higher 
antisolvent content, the crystals produced were more needle-like than those produced at lower 
antisolvent content, which resembled wider tapes.  Agglomerate growth was also observed, where 
a single nucleation point resulted in the growth of “fanned” crystals (Figure 3.30, 50%). 
 
Some variation was also observed in the susceptibility of each excipient to crystallisation 
conditions.  For example, mannitol was very resilient to crystallisation conditions, and crystal 
growth was observed under most conditions, however this was not the case for trehalose 
dihydrate, where crystallisation was often inhibited. 
 
As a result of morphological traits, the PXRD data showed preferred orientation effects for each of 
the excipients (indicated by increased intensity of some reflections in comparison to the standard 
materials).  Phase identification highlighted no change in polymorphism or hydration state in the 
raffinose or trehalose crystallisation products, even at high proportions of dehydrating antisolvent 
(Figure 3.32).  This is perhaps to be expected in the raffinose products as the most stable form is 
the pentahydrate, however, given that trehalose is subject to solvent mediated dehydration, a 
similar behaviour to that of lactose at 95% methanol or ethanol content was expected in the form of 
partial dehydration.  PXRD analysis did, however, highlight the increased crystallinity observed 
95%90%
85%80%
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following recrystallisation, as reflections showed increased resolution and reduced broadening 
effects.   
 
 
Figure 3.32  PXRD patterns of raffinose pentahydrate and trehalose dihydrate crystals 
produced from 95% ethanol antisolvent compared to standards 
 
The antisolvent crystallisation of mannitol showed polymorphic transitions from the commercially 
available beta form to the inclusion of the delta form with increasing antisolvent content (Figure 
3.33).  This effect was, however, not observed in the crystallisation from acetonitrile antisolvent, 
where the beta form remained as a pure crystallisation product.   
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Figure 3.33  PXRD patterns of mannitol/acetone antisolvent crystallisation products 
showing mannitol polymorphism 
 
The alpha form was not observed in the PXRD data collected, though this is an acceptable 
observation given the lesser stability of this polymorph.  The preferred orientation effects in PXRD 
analysis of mannitol polymorphs have been discussed elsewhere [24] and the results collected in 
this study support their findings. 
 
These studies have highlighted the care necessary when using lactose as an excipient.  Due to its 
solution properties, its behaviour when subjected to solvent environments is much more difficult to 
predict than other excipients.   
 
3.4 Conclusions 
 
Crystallisation of lactose from aqueous solutions was promoted with the use of water-miscible 
antisolvents.  At low antisolvent content, large L.H2O crystals formed, however as antisolvent 
content increased, L became more dominant as indicated by the formation of small, needle-
shaped crystals.  The crystallisation of L seemed to be encouraged by the presence of an 
antisolvent, as L was not observed in the products crystallised from saturated solutions. 
 
It is commonly quoted that lactose naturally crystallises as a tomahawk shaped crystal.  The 
research presented here indicates that a combination of crystallisation conditions and polymorphic 
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impurities hugely influence crystal habit, and as such, it is difficult to assign a “typical morphology” 
to L.H2O as a species, though the tomahawk is one such possibility. 
 
While the effects of preferred orientation in PXRD analysis are usually considered a hindrance, this 
study has also highlighted the possibility of its use as a phase identification aid, where reflections at 
low angle can be emphasised.  However, these properties of lactose crystals also highlight that 
quantification by PXRD can be problematic for the non-specialist. 
 
These studies have emphasised the difficulty encountered when using lactose as an excipient, in 
comparison to other sugars, as the susceptibility to crystallisation environment and processing 
conditions appears to be a trait that is dominant in lactose alone.  While mannitol has also been 
shown to exhibit polymorphism under the same conditions, the same effects on particle 
morphology were not observed, as each polymorph crystallised in a needle habit.  Raffinose and 
trehalose hydrates were found to be stable under the same crystallisation conditions, again forming 
crystals of a needle habit.  Given the extensive use of lactose as an excipient, these polymorphic 
and morphological transitions must be considered throughout each stage of the formulation 
process into a pharmaceutical.    
  
Chapter 3  Crystallisation of pharmaceutical excipients 
from aqueous solutions 
Page | 92  
 
3.5 References 
 
[1] M Fujiwara, ZK Nagy, JW Chew, RD Braatz. First-principles and direct design approaches for 
the control of pharmaceutical crystallization, J.Process Control. 15 (2005) 493-504. 
 
[2] BY Shekunov, P York. Crystallization processes in pharmaceutical technology and drug delivery 
design, J.Cryst.Growth. 211 (2000) 122-136. 
 
[3] 3M Health Care Ltd, personal communication. 
 
[4] D Chiou, TAG Langrish, R Braham. The effect of temperature on the crystallinity of lactose 
powders produced by spray drying, J.Food Eng. 86 (2008) 288-293. 
 
[5] H Steckel, HG Brandes. A novel spray-drying technique to produce low density particles for 
pulmonary delivery, Int.J.Pharm. 278 (2004) 187-195. 
 
[6] G Calvert, M Ghadiri, R Tweedie. Aerodynamic dispersion of cohesive powders: A review of 
understanding and technology, Adv.Powder Technol. 20 (2009) 4-16. 
 
[7] MK Haque, YH Roos. Crystallization and X-ray diffraction of spray-dried and freeze-dried 
amorphous lactose, Carbohydr.Res. 340 (2005) 293-301. 
 
[8] TD Dincer, GM Parkinson, AL Rohl, MI Ogden. Crystallisation of α-lactose monohydrate from 
dimethyl sulfoxide (DMSO) solutions: influence of β-lactose, J.Cryst.Growth. 205 (1999) 368-374. 
 
[9] TD Dincer, MI Ogden, GM Parkinson. Crystal growth mechanisms of the (0 1 0) face of α-
lactose monohydrate crystals, J.Cryst.Growth. 311 (2009) 2427-2432. 
 
[10] MG Gänzle, G Haase, P Jelen. Lactose: Crystallization, hydrolysis and value-added 
derivatives, Int.Dairy J. 18 (2008) 685-694. 
 
[11] G Clydesdale, KJ Roberts, GB Telfer, DJW Grant. Modeling the crystal morphology of alpha-
lactose monohydrate, J.Pharm.Sci. 86 (1997) 135-141. 
 
[12] SL Raghavan, RI Ristic, DB Sheen, JN Sherwood, L Trowbridge, P York. Morphology of 
crystals of alpha-lactose hydrate grown from aqueous solution, J.Phys.Chem.B. 104 (2000) 12256-
12262. 
 
[13] TD Dincer, MI Ogden, GM Parkinson. In situ investigation of growth rates and growth rate 
dispersion of α-lactose monohydrate crystals, J.Cryst.Growth. 311 (2009) 1352-1358. 
Chapter 3  Crystallisation of pharmaceutical excipients 
from aqueous solutions 
Page | 93  
 
[14] SL Raghavan, RI Ristic, DB Sheen, JN Sherwood. The bulk crystallization of alpha-lactose 
monohydrate from aqueous solution, J.Pharm.Sci. 90 (2001) 823-832. 
 
[15] JH Kirk, SE Dann, CG Blatchford. Lactose: A definitive guide to polymorph determination, 
Int.J.Pharm. 334 (2007) 103-114. 
 
[16] D Traini, PM Young, F Thielmann, M Acharya. The influence of lactose pseudopolymorphic 
form on salbutamol sulfate-lactose interactions in DPI formulations, Drug Dev.Ind.Pharm. 34 (2008) 
992-1001. 
 
[17] A Nokhodchi, M Maghsoodi, D Hassan-Zadeh, M Barzegar-Jalali. Preparation of agglomerated 
crystals for improving flowability and compactibility of poorly flowable and compactible drugs and 
excipients, Powder Technol. 175 (2007) 73-81. 
 
[18] LTT Vu, L Huynh, JA Hourigan. Effects of solvents on characteristics of crystalline lactose 
extracted in ternary and quaternary systems, Adv.Powder Technol. 20 (2009) 251-256. 
 
[19] XM Zeng, GP Martin, C Marriott, J Pritchard. The influence of crystallization conditions on the 
morphology of lactose intended for use as a carrier for dry powder aerosols, J.Pharm.Pharmacol. 
52 (2000) 633-643. 
 
[20] SG Lim, TA Nickerson. Effect of methanol on various forms of lactose, J.Dairy Sci. 56 (1973) 
843-848. 
 
[21] TA Nickerson, SG Lim. Effect of various alcohols on lactose, J.Dairy Sci. 57 (1974) 1320-1324. 
 
[22] W Cheng, S Lin. Processes of dehydration and rehydration of raffinose pentahydrate 
investigated by thermal analysis and FT-IR/DSC microscopic system, Carbohydr.Polym. 64 (2006) 
212-217. 
 
[23] H Nagase, T Endo, H Ueda, M Nakagaki. An anhydrous polymorphic form of trehalose, 
Carbohydr.Res. 337 (2002) 167-173. 
 
[24] SN Campbell Roberts, AC Williams, IM Grimsey, SW Booth. Quantitative analysis of mannitol 
polymorphs. X-ray powder diffractometry—exploring preferred orientation effects, 
J.Pharm.Biomed.Anal. 28 (2002) 1149-1159. 
 
[25] T Yoshinari, RT Forbes, P York, Y Kawashima. Moisture induced polymorphic transition of 
mannitol and its morphological transformation, Int.J.Pharm. 247 (2002) 69-77. 
 
Chapter 3  Crystallisation of pharmaceutical excipients 
from aqueous solutions 
Page | 94  
 
[26] N DrapierBeche, J Fanni, M Parmentier, M Vilasi. Evaluation of lactose crystalline forms by 
nondestructive analysis, J.Dairy Sci. 80 (1997) 457-463. 
 
[27] H Larhrib, GP Martin, D Prime, C Marriott. Characterisation and deposition studies of 
engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate 
from dry powder inhalers, Eur.J.Pharm.Sci. 19 (2003) 211-221. 
 
[28] AS Michaels, A Vankreve. Influences of additives on growth rates in lactose crystals, Neth.Milk 
Dairy J. 20 (1966) 163-&. 
 
[29] JL Crisp, SE Dann, M Edgar, CG Blatchford. The effect of particle size on the 
dehydration/rehydration behaviour of lactose, Int.J.Pharm. 391 (2010) 38-47. 
 
[30] JL Crisp, SE Dann, M Edgar, CG Blatchford. The in-situ solid-state NMR spectroscopy 
investigation of alcoholic lactose suspensions, Solid State Nucl.Magn.Reson. 37 (2010) 75-81. 
 
[31] C Nunes, R Suryanarayanan, CE Botez, PW Stephens. Characterization and crystal structure 
of D-mannitol hemihydrate, J.Pharm.Sci. 93 (2004) 2800-2809. 
 
Solvent-Mediated Polymorphism and Characterisation of Inhaled Pharmaceuticals 
Page | 95  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4.   Ethanolic suspensions of 
lactose 
 
Chapter 4  Ethanolic suspensions of lactose  
Page | 96  
 
4.1 Introduction 
 
The use of lactose, specifically L.H2O, as an excipient in DPIs is common place to improve dose 
reproducibility.  Excipients are usually in the particle size range of 63-90m [1-5].  This particle size 
range is suitable since excipients are used as a carrier to ensure the active drug emerges from the 
drug delivery device to supply an accurate dosing, while the carrier is impacted in the 
oropharyngeal region and swallowed.  The respirable range for API particles is typically sub-5m, 
though below ~0.5m particles may be exhaled.  One of the skills of the formulators is to create a 
stable formulation with sufficient adhesion forces to keep the active attached to the carrier particles 
during storage, but to allow the particles to become separated in the event of turbulence created on 
actuation and dose delivery to the patient.  This use of an excipient has been proven to improve 
flow properties of the active into the lungs [3,6-8] as it prevents API agglomeration by reduction of 
cohesive forces between micronised particles. 
 
Some pMDI formulations are also prone to dose variation and often require refrigeration to maintain 
stability.  As a result, investigation began into the use of lactose as a stabilisation aid for pMDI 
formulations [9-11].  The importance of excipient stabilisation becomes particularly prominent with 
the use of highly potent bronchodilators such as salmeterol xinafoate, whereby a typical dose of 
6g is administered per actuation, in comparison to more common dosages of 100-200g. 
 
In order for lactose to be used in pMDIs, polymorphism effects must be taken into account.  It is 
commonly understood that L.H2O is subject to dehydration to LS in the presence of dehydrating 
solvents such as methanol and ethanol [12,13].  Given that pMDI formulations often use ethanol as 
a cosolvent, the use of L.H2O as an excipient would in an unstable formulation as in-situ 
dehydration may occur.  As a result, 3M Health Care Ltd have developed a methodology to 
produce small particles of LS suitable for use in aerosol formulations.  This has two potential 
formulation benefits: firstly, the use of LS as an excipient avoids any further dehydration issues 
and therefore provides an inherent stability; secondly, the potential for use of “nanoparticles” in this 
area avoids any issues with carrier dissociation.  In DPI formulations, it is possible for the 
dissociation of active and excipient to fail.  This is usually as a result of the active occupying an 
area of high adhesion on the excipient particle.  Where dissociation fails, both the active and 
excipient are impacted in the oropharyngeal region and swallowed, therefore reducing drug activity.  
By lowering the excipient particle size range to within the respirable range (sub-5m), the carrier 
effect can be exploited without the need for the unreliable dissociation step, hence improving 
absorption of the active in the lower lung. 
 
The small particles of LS, known as “sub-micron lactose” (SML) are produced as an ethanolic 
suspension.  As such it can easily be incorporated into pMDI formulations, therefore posing an 
advantage in terms of convenience. 
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This section of research evaluates the properties and stability of the SML suspension, forming a 
comparison to other ethanolic lactose suspensions of larger particle size.  The research focuses on 
the effect of suspension preparation method on polymorphic transitions, as well as polymorphic 
transformation during solvent removal and any effects on crystal size, shape and morphology.  It is 
important to fully understand the behaviour of the excipient in terms of binding in formulation and 
release in aerosol form, as changes in polymorph and crystal growth can be detrimental to deep 
lung penetration of the dose and shelf life of the inhaler itself.  
 
4.2 Experimental 
 
4.2.1 Preparation of ethanolic lactose suspensions 
 
SML is an ethanolic suspension of LS (produced by 3M Health Care Ltd and provided in 
suspension form).  A standard in-house method as outlined in Patent EP 1324 749 B1 [10] is used 
to produce the sub-micron suspension.  Micronised L.H2O is dispersed in anhydrous ethanol 
using a Silverson high shear mixer.  The suspension is then added to the product reservoir of an 
Avestin Emulsifier C160 homogeniser and re-circulated for 30min at 10kpsi.  The dispersion is then 
passed out of the homogeniser at 20kpsi and transferred to a sealed container.  This process gives 
a suspension of mass:volume 1:8.4. 
 
A series of suspensions suitable for comparison were also prepared.  L.H2O was suspended in 
anhydrous ethanol (previously dried for 24h over 4A molecular sieves) in a 1:10 ratio (w/v, a good 
approximation of the SML suspension).  It was important that anhydrous ethanol was used.  If 
standard ethanol (typically 96% ethanol, 4% water) were used in its place, an environment is 
presented in which LH2O is partially soluble (in the water content of the ethanol).  Under these 
aqueous conditions, LH2O would undergo mutarotation to the commonly expected L 60:40 
LH2O mixture.  Two different means of suspension preparation were employed; a high-
temperature, refluxed suspension (24h, with stirring) whereby a rapid dehydration to LS occurs, or 
a static room temperature suspension which employs a slower dehydration to LS.  These 
suspensions remained static for a prolonged period of time (tests indicated that 28d was a 
sufficient period to allow for complete dehydration to take place for even the largest particle size).  
Each suspension was stored in a sealed sample bottle. 
 
Six different grades (particle size ranges) of spray dried or micronised L.H2O (Table 4.1) were 
used to prepare the suspensions for comparison to the ethanolic sub-micron suspension.  These 
grades of L.H2O were selected to give a broad particle size range (verified by SEM analysis).   
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L.H2O Sample Approximate Particle Size (m) 
Lactochem Extra Fine Crystals 180-200 
Lactopress Spray Dried 150-180 
Lactopress Spray Dried 250 100-150 
Lactochem Fine Powder 30-50 
Lactochem Microfine 5-10 
Micronised Lactose* 2-4 
* Provided by 3M Health Care Ltd.  All other samples provided by Friesland 
Foods DOMO 
Table 4.1  Suppliers and particle sizes for suspended L.H2O 
 
Purity of the starting materials was determined by PXRD (Figure 4.1), each of which were found to 
contain only L.H2O.  This is unusual, particularly when dealing with spray dried materials, as 
water is often used as a feed solution.  Where this is the case, one would expect to find trace 
amounts of L in the final product due to the muta-rotation of L.H2O (60:40 L:L.H2O), however 
this was not apparent in the Lactopress Spray Dried and Lactopress Spray Dried 250 samples.  
Due to the processes by which the starting materials are produced, variable levels of crystallinity 
would be expected, for example, spray dried materials typically contain a higher amorphous 
content than crystallised materials.  Also in the larger particle sizes it is possible that preferred 
orientation effects may result in the observation of minor reflections, which may not be observed 
elsewhere. 
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Figure 4.1  PXRD patterns of starting materials compared to standard L.H2O.  Increasing 
particle size upwards; Micronised lactose (2-4m), Lactochem microfine (5-10m), 
Lactochem fine powder (30-50m), Lactopress spray dried 250 (100-150m), Lactopress 
spray dried (150-180m), Lactochem extra fine crystals (180-200m) 
 
4.2.2 Methods of solvent removal 
 
As discussed, characterisation of powders following solvent removal can generate key information 
regarding the success of potential drug delivery based on particle size and morphology and lactose 
polymorphism.  Methods of generating solid-state samples from the sub-micron suspension and 
comparison suspensions were employed to determine any effect on the species present. 
 
Method 1:  Solvent evaporation in air 
 
The suspension (ca. 200mg) was placed onto a watch glass and allowed to evaporate (in a 
laboratory environment) to dryness (typically 3h). 
 
Method 2:  Solvent removal by means of an absorbent medium   
 
A thin layer of suspension (ca. 60mg) was placed onto the surface of a piece of standard filter 
paper, such that the solvent was immediately absorbed (total drying time typically 5min). 
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Method 3:  Solvent evaporation in a dry atmosphere 
 
The suspension (ca. 200mg) was placed over a desiccant (self indicating silica gel) and the solvent 
allowed to evaporate to complete dryness (~3h).  Molecular sieve powder (4Å) was also used to 
aid the absorption of the solvent. 
 
Method 4:  Solvent evaporation at elevated temperatures 
 
The suspension (ca. 200mg) was placed onto a watch glass in an oven at 40
o
C for 20h.  This 
temperature increase (relative to room temperature) was sufficient to aid solvent evaporation 
without resulting in lactose degradation.  
   
Method 5:  Solvent evaporation on a warmed surface 
 
A watch glass was heated to 60
o
C before the suspension (ca. 200mg) was placed onto it to allow 
solvent evaporation.  This methodology is very similar to that of the solvent evaporation in open air, 
however, complete evaporation was achieved in typically 10min instead of ~3h.   
 
4.2.3 Characterisation of SML 
 
Following successful solvent removal, dried SML was fully characterised in the solid-state and 
compared to standard lactose polymorphs, L.H2O, L, and LS for phase identification.  
 
4.2.4 Susceptibility of SML to humidity 
 
Having isolated SML in solid form, stability testing was performed to determine its resilience to 
humidity, relative to larger particle size LS. 
 
Dried SML (0.5g) was heated (160
o
C) in a sealed Young’s tube containing deionised water (0.5ml) 
for 24h.  The LS contained within the Young’s tube was held in an open vial such that the solid 
material was exposed to water vapour without being in direct contact with water (liquid) which 
would cause dissolution.  This experiment provided a crude means to determine stability to 
humidity (Figure 4.2). 
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Figure 4.2  Experimental set-up for the humidity treatment of SML 
 
Samples of dried SML and standard particle size LS were also sent to the Institute Laue-Langevin 
(ILL) in Grenoble for in-situ hydration analysis by neutron diffraction.  A new prototype humidity cell 
under development at the ILL was used to correlate rehydration effects in the two particle size 
starting materials.  This process is possible because neutron diffraction is very sensitive to 
hydrogen as it has a high anomalous scattering length (see section 4.3.7). 
 
4.2.5 SML as a suspension aid in pMDIs 
 
Following full characterisation of the suspension, combined with an understanding of the stability 
and hydration properties, tests were performed to determine the suitability for use within pMDI 
formulations. 
 
Placebo pMDI canisters containing SML suspension only (no API) were prepared and subjected to 
accelerated storage conditions.  This is a standard testing procedure for pMDI canisters, whereby 
they are stored at 40
o
C and 75% RH for a prolonged period, in this case 20 months.  Following this 
storage period, the typical method of analysis would involve “pouching” the product prior to analysis 
for any changes in the materials present.  This is where the entire canister is emptied and the 
product collected and stored until analysis can be performed.  Given the small particle size of this 
excipient, this method of pouching renders the samples subject to rehydration depending on the 
methods employed during collection, and storage thereafter.  Consequently, a method was devised 
such that direct analysis from the actuator mouthpiece could be performed, therefore removing the 
need for pouching. 
 
Each of the test canisters were actuated (60 shots, under a dry N2 atmosphere) onto an absorbent 
substrate.  This substrate could then be mounted directly onto the back of a standard Perspex 
PXRD sample holder, to maintain a flat surface for PXRD analysis.  Using the back of the sample 
holders meant that the data collected were subject to x-directional shifting due to sample height, 
which was corrected using the PXRD software. 
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4.2.6 Ethanolic suspensions of trehalose 
 
Trehalose typically exists as a dihydrate, though examples of an anhydrous form have been 
reported [14].  Investigations show that trehalose is also subject to solvent mediated dehydration, in 
the same way as L.H2O.  Therefore, attempts were implemented at producing sub-micron 
ethanolic suspensions of trehalose using the high pressure homogenisation process. 
 
Trehalose dihydrate (Acros Organics, 99%) was initially ground with a pestle and mortar, before 
being suspended in anhydrous ethanol (1:10 w/v) and dispersed with a Silverson high shear mixer.  
The suspension was then added to the product reservoir of the microfluidiser.  By altering the size 
of the chamber through which the suspension is passed, the particle size of the suspended 
material can be reduced.  For the SML suspension, a 50m chamber is used, however, initial 
attempts at processing the trehalose suspension with this chamber resulted in immediate blockage.  
The process pressure was set to maximum, which achieved 14kpsi using a single, relatively wide 
bore (200m) module arrangement.  Samples of dispersion were removed at 10 and 20 minutes 
and due to the smooth running of the machine it was decided to attempt to increase processing 
intensity by switching back to the 50m chamber.  Reduction of the chamber size therefore 
actuated an increase in pressure, and processing continued at the now higher processing pressure 
of 30kpsi, however after a short period of time, the system blocked again.  As a result the 
processing was halted to avoid damage to the microfluidiser. 
 
During processing, samples were taken both into glass vials and also onto an absorbent substrate 
(as used in the ex-actuator analysis of the SML placebo canisters), the latter being with the aim of 
capturing the particles without the possibility of further growth.  
 
4.3 Results and discussion 
 
4.3.1 Solvent removal from SML suspension 
 
Each method of solvent removal was employed for the SML suspension to determine method 
suitability, as smaller particle sizes should be more susceptible to rehydration and particle 
agglomeration due to their higher chemical potential.  The dried products were analysed by PXRD 
to observe any polymorphic transformation (summarised in Figure 4.3 and Table 4.2). 
 
 
Chapter 4  Ethanolic suspensions of lactose  
Page | 103  
 
 
Figure 4.3  PXRD patterns showing the product of dried SML suspension following Method 
1: solvent evaporation in air, Method 2: solvent removal by means of an absorbent medium, 
Method 3: Solvent evaporation in a dry atmosphere, Method 4: solvent evaporation at 
elevated temperatures and Method 5: solvent evaporation on a warmed surface 
 
Method Description Polymorph 
1 In air L.H2O  
2 Absorbent medium LS / L.H2O  
3 Dry atmosphere LS 
4 Elevated temperature LS 
5 Warmed surface L.H2O  
Table 4.2  Summary of PXRD results for solvent removal from SML suspension 
 
It is well known that “hard” conditions are required to force the dehydration of L.H2O to the stable 
anhydrous polymorph [15].  Research shows that this is achievable by thermal dehydration 
(occurring at ~160
o
C) or solvent mediated dehydration in ethanol or methanol [12,13].  Further 
evidence of the conditions required is described by the production process of the SML suspension, 
which involves solvent (ethanol) treatment under high pressure.  Based on this information, it is 
feasible to assume that the lactose in the SML has undergone full dehydration and hence is the 
stable anhydrous polymorph, LS, therefore LS would be the expected polymorph in the powders 
produced from this suspension. 
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PXRD analysis confirmed that rehydration of LS to L.H2O was evident for the sub-micron 
suspension dried by methods 1 (complete), 2 (partial) and 5 (complete).  This rehydration (or partial 
rehydration) is an important observation as the stable anhydrous polymorph should remain 
anhydrous until subjected to relative humidities in excess of 75% [16]. 
 
The rehydration of this material under unexpected conditions must be further investigated, as when 
used in an inhaled formulation, this effect could pose potential for dose failure, an obviously 
undesirable result in pharmaceutical terms.  There are three main variables to focus on in the 
determination of cause of rehydration; particle size present within the suspension, method of 
suspension production, or the method of solvent removal.  Each variable was evaluated with the 
use of ethanolic suspensions of LH2O with a larger particle size. 
 
4.3.2 Solvent removal from refluxed and static suspensions 
 
On the basis of the SML results, three methods of solvent removal were applied to the refluxed 
ethanolic suspensions.  The methods selected were method 1, 2 and 3, as these were shown to 
give full, partial and no rehydration (respectively) of the sub-micron material.  It was hoped that the 
use of these three methods would therefore allow identification of the cause of rehydration, whether 
a factor of particle size or method of solvent removal, or a combination of both variables. 
 
After complete solvent removal from the refluxed ethanolic suspensions with the three selected 
methods, PXRD, SSNMR and SEM analysis were performed on the dry powders.  PXRD and 
SSNMR results (Figure 4.4 to Figure 4.9 and summarised in Table 4.3 in comparison to SML, 
Figure 4.3 and Figure 4.10) showed that rehydration was only observed with the sub-micron 
material and in general, not with the materials of larger particle size. 
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Figure 4.4  PXRD patterns for refluxed ethanolic suspensions dried by Method 1: solvent 
evaporation in air 
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Figure 4.5  
13
C CP MAS NMR spectra for refluxed ethanolic suspensions dried by Method 1: 
solvent evaporation in air 
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Figure 4.6  PXRD patterns for refluxed ethanolic suspensions dried by Method 2: solvent 
removal by means of an absorbent medium 
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Figure 4.7  
13
C CP MAS NMR spectra for refluxed ethanolic suspensions dried by Method 2: 
solvent removal by means of an absorbent medium 
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Figure 4.8  PXRD patterns for refluxed ethanolic suspensions dried by Method 3: solvent 
evaporation in a dry atmosphere 
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Figure 4.9  
13
C CP MAS NMR spectra for refluxed ethanolic suspensions dried by Method 3: 
solvent evaporation in a dry atmosphere 
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Figure 4.10  
13
C CP MAS NMR spectra for SML following solvent removal via Methods 1, 2 
and 3. 
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Suspension 
Approximate 
particle size of 
starting material 
(m) 
Polymorph produced after solvent 
removal 
Method 1 Method 2 Method 3 
Lactochem extra fine crystals 180-200 LS LH2O / LS LS 
Lactopress spray dried 150-180 LS LS LS 
Lactopress spray dried 250 100-150 LS LS LS 
Lactochem fine powder 30-50 LS LS LS 
Lactochem microfine 5-10 LS LS LS 
Micronised lactose* 2-4 LS LH2O / LS LS 
SML* 0.5-2 LH2O LH2O / LS LS 
* Provided by 3M Health Care Ltd.  All other samples provided by Friesland Foods DOMO 
Table 4.3  Summary of polymorphic identification following solvent removal from refluxed 
ethanolic suspensions of larger particle size L.H2O 
 
The PXRD and SSNMR data show good agreement, however, paying closer attention to the 
SSNMR data collected for the samples dried via method two, some discrepancies are highlighted.  
These samples show significant broadening, both in comparison to the solid standard LS and 
LH2O, and the samples dried via methods 1 and 3.  This is particularly evident in the case of 
Lactochem extra fine crystals and micronised lactose.  As the samples are dried onto the 
absorbent medium, it is possible that some amorphous material is formed.  It would appear that this 
is particularly prominent in these two samples, which show significant broadening, with small 
crystalline resonances (sharp peaks).  By reducing the delay time of the SSNMR experiment to 
target the faster relaxing amorphous material (as amorphous materials have an increased number 
of relaxation pathways), it was possible to collect a spectrum for the amorphous material present, 
and hence a subtraction could be performed to remove this material from the extra fine crystals 
spectrum (Figure 4.11).  This subtraction highlighted that the crystalline material present is 
predominantly LH2O, with the presence of some LS resonances, as was the case for the 
micronised lactose sample.  This is not highlighted in the PXRD data, where the patterns collected 
for both of these samples are indicative of LS dominance.   
 
Amorphous material is highly susceptible to recrystallisation effects and as a result, it is likely that 
following the formation of amorphous material on solvent removal, recrystallisation back to 
crystalline LH2O occurred.  SSNMR analysis is able to detect minor phases of amorphous 
material, whereas PXRD analysis targets crystalline material.  As a result it is possible for the two 
techniques to show differing results under these circumstances.  With the presence of amorphous 
material, one would expect to see an “amorphous halo” in the PXRD data (typically in the 5-25
o
 2θ 
region for lactose polymorphs), which can present itself as background effects in the patterns 
collected.  However, in this case it would appear that the dominant crystalline phases make any 
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amorphous effects negligible by comparison.  The PXRD data imply that the dominant crystalline 
phase is LS. 
 
The presence of low levels of amorphous material following solvent removal via method 2 was also 
emphasised in the SML SSNMR data, where considerably broader lines were observed in 
comparison to methods 1 and 3.  Again, this is not indicated as clearly in the PXRD data. 
 
 
Figure 4.11  Subtraction of amorphous signals from the ethanolic reflux of Lactochem extra 
fine crystals following solvent removal via Method 2.  Crystalline material showing 
predominantly LH2O with some presence of LS resonances. 
 
Method 3; solvent evaporation in a dry atmosphere, was selected as the method of solvent removal 
for the remaining suspensions (static dehydration).  This was because it allowed the anhydrous 
polymorph to be retained in the majority of cases, independent of initial particle size, and therefore 
was the most robust method for generating the dried powders.  This method also retained 
crystallinity in the samples produced.  Each of the powders produced were also analysed by 
PXRD, and LS presence was confirmed in each case (Figure 4.12). 
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Figure 4.12  PXRD patterns for static dehydrated ethanolic suspensions dried by Method 3: 
solvent evaporation in a dry atmosphere 
 
SEM analysis was also carried out, primarily to determine any effect each of the drying methods 
had on the particles produced, and whether this showed any correlation to the polymorph present.  
Micrographs collected for each of the larger particle size suspension samples indicated that particle 
size was affected by both high temperature and static dehydration processes, but not by the 
method of solvent removal or particle size of the starting material (Figure 4.13).   
 
 
Figure 4.13  SEM micrographs showing the products following solvent removal from 
Lactochem fine powder refluxed suspensions  
 
Suspensions dehydrated under reflux conditions showed a reduction in particle size (Table 4.4), 
with particles irregular in shape and typically 3-20m.  This irregularity in shape is not consistent 
with the expected characteristics of LS particles.  Particle morphology was not affected by analysis 
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processing (e.g. PXRD sample preparation, confirmed by SEM of non-processed material), hence 
it was concluded that production of these morphologies is most likely associated with the refluxing 
process.  Vigorous stirring and the effect of boiling solvent during refluxing produces an impact and 
attrition environment (particle size reduction produced as a result of friction and abrasion similar to 
that observed by milling), which, in comparison to the starting material, reduces the particle size 
and generates a rounded particle with smooth surfaces.   This is consistent with the appearance of 
the material from the refluxed suspensions.  
 
SEM analysis was also carried out on the dried products (via method 3 only, solvent evaporation in 
a dry atmosphere) of the static dehydration suspensions.  Results (Table 4.4) showed each of the 
samples elongated tape-like particles, with no evidence of the original starting material particle 
shapes.  This dendritic growth is of great interest, as there is no energy applied to the system to 
allow for this recrystallisation/crystal growth effect. 
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Suspension Starting Material Reflux Static 
Lactochem 
extra fine 
crystals 
 
 
 
 
 
 
Lactopress 
spray dried 
   
Lactopress 
spray dried 
250 
   
Lactochem 
fine powder 
   
Lactochem 
microfine 
   
Micronised 
lactose 
   
Table 4.4  SEM micrographs showing dried powders (Method 3: solvent evaporation in a dry 
atmosphere) from refluxed and static dehydrated suspensions compared to starting 
materials (250x magnification) 
 
SML production generates particles of a specific morphology and size due to the nature of the 
homogenisation, combined with the effects of dehydration.  Therefore, any changes in particle 
appearance can be directly correlated to the drying method used and polymorph produced.  The 
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SEM micrographs (Figure 4.14, Figure 4.15 and Figure 4.16) show the effects of rehydration or 
partial rehydration on the particle morphology of the sub-micron material.  Purely anhydrous SML 
presents as oblate spheroid or cigar shaped crystals (method 3), however, with the ingress of water 
(method 2) these needle shaped particles begin to bridge, and agglomerates form.  Under 
complete rehydration (method 1), there is no evidence of the original particles and the material 
resembles a melt or honeycomb. 
 
 
Figure 4.14  SEM micrograph showing SML following solvent removal in a dry atmosphere 
(method 3) 
 
 
Chapter 4  Ethanolic suspensions of lactose  
Page | 118  
 
 
Figure 4.15  SEM micrograph showing SML following solvent removal by means of an 
absorbent medium (method 2) 
 
 
Figure 4.16  SEM micrograph showing SML following solvent evaporation in air (method 1) 
 
4.3.3 Dendritic growth in static dehydrated suspensions 
 
The dendritic growth on dehydration of L.H2O to LS was observed further by the preparation of 
two new suspensions (as per the method used for preparation of the static dehydrated 
suspensions), followed by periodic drying via method three to generate solid powders.  These were 
then analysed by PXRD and SEM to observe the physical effects which result in the formation of 
 
Chapter 4  Ethanolic suspensions of lactose  
Page | 119  
 
these dendrites, and at what stage during the dehydration process they occur.  Suspensions were 
prepared from the smallest (micronised lactose) and the largest (Lactochem extra fine crystals) 
particle sizes observed throughout these studies. 
 
SEM results (Figure 4.17 and Figure 4.18) showed the dendritic growth in each suspension, as 
previously observed. 
 
 
Figure 4.17  SEM micrographs showing ethanol mediated dehydration of micronised lactose 
over 20d (10k x magnification) 
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Figure 4.18  SEM micrographs showing ethanol mediated dehydration of Lactochem extra 
fine crystals over 20d (1.5k x magnification) 
 
The dendrites appear to form into small “balls” at the surface of the crystals initially (Figure 4.19).  
Once the surface of the crystal is covered, the balls “unwind” to form larger networks of dendrites 
(Figure 4.20). 
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Figure 4.19  SEM micrograph showing dendrite formation into “balls” (expansion of 
Lactochem extra fine crystals after 1h) 
 
 
Figure 4.20  SEM micrograph showing dendrite balls unwinding (expansion of Lactochem 
extra fine crystals after 2d) 
 
Comparison of the SEM data to PXRD data for each sample (Figure 4.21 and Figure 4.22) shows 
that the formation of these small crystal networks occurs before dehydration is evident in the PXRD 
patterns.  PXRD data show dehydration in the micronised lactose suspension after 5-10h and after 
10h-1d in the Lactochem extra fine crystals suspension, whereas the onset of dendrite formation is 
observed after 1-2h in each case.  The limit of detection for PXRD is roughly 3-5% by weight, so it 
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is possible that in the early stages of dehydration there is not enough material for detection by this 
method, which supports the observation of dehydration more slowly in the larger particle size 
suspension.  
 
 
Figure 4.21  PXRD patterns showing ethanolic dehydration of micronised lactose over 20d 
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Figure 4.22  PXRD patterns showing ethanolic dehydration of Lactochem extra fine crystals 
over 20d 
 
The SEM images collected show the method by which the network of dendrites form, however they 
do not provide any insight into exactly how or why the particle transformation takes place. 
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4.3.4 Characterisation of SML in suspension form 
 
The application of each drying technique to the ethanolic suspensions showed that the most robust 
method for producing the anhydrous polymorph was via solvent evaporation in a dry atmosphere.  
However, this was based on the assumption that the suspension originally contained LS.  As 
previously discussed, the harsh solvent/thermal conditions mean that it is feasible to assume LS 
presence, however at this stage of the research it was necessary to verify this assumption. 
 
In order to identify polymorphism in the suspensions, a method of analysis was designed such that 
SSNMR data could be collected for lactose whilst in suspension form.  Full experimental details are 
given in Chapter 5, however it can be confirmed from these data that all of the ethanolic 
suspensions (inclusive of the sub-micron material) contained the stable anhydrous lactose 
polymorph (Figure 4.23). 
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Figure 4.23  
13
C CP MAS NMR spectrum of SML suspension in comparison to solid LS 
 
4.3.5 Method of SML rehydration 
 
The previous experimental work and associated discussions have proven that rehydration of the 
sub-micron material is possible under specific conditions, though the method of rehydration has not 
yet been discussed.  Observation of the polymorph present indicated that when a slower solvent 
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removal process was employed (i.e. slow evaporation in air, method 1) the small SML particles 
rehydrated to LH2O, despite being at a significantly lower relative humidity than that accepted to 
rehydrate LS (~75% [16]).  However, when solvent removal occurred rapidly or in a dry 
environment (i.e. in a desiccator), the anhydrous polymorph was retained. The speed at which 
solvent is removed from the suspension is critical in this instance, as LS rehydration appears to be 
a direct result of water physisorption following ethanol hydration in air.  This is more prominent in 
the SML suspension, where the smaller particles have a higher chemical potential.  
 
This theory was confirmed by a further SSNMR experiment on the sub-micron suspension.  A large 
volume of the suspension was subjected to air drying conditions (method 1) for a period of 24h.  
The large volume employed slowed down ethanol evaporation, such that after the 24h period, the 
sample was still in suspension form.  SSNMR analysis was performed in the same manner as the 
original samples for polymorphism determination (Figure 4.24).  At a first glance, the results can be 
interpreted to show LS resonances.  However, there is a significant amount of line broadening 
present within the spectrum to imply a loss of crystallinity that may be associated with the onset of 
the rehydration transition. 
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Figure 4.24  
13
C CP MAS NMR spectra of SML suspension after 24h in air, compared to SML 
suspension and solid LS 
 
4.3.6 Characterisation of dried SML 
 
Given that a suitable method of solvent removal from the SML suspension had been developed, 
and that the method by which the dried SML rehydrates was better understood, it was then 
possible to carry out full solid-state characterisation of the dried material, in comparison to standard 
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polymorphs of L.H2O in order to confirm that the material is purely LS [17].  In order to do this, 
IR, Raman, SSNMR, PXRD and TGA/DTA analysis was carried out on the dried SML material.  
The data collected (provided in Appendix 1 [17]) showed that there were no small amounts of 
contaminant polymorphs when the SML suspension was dried via method 3. 
 
4.3.7 Susceptibility of dried SML to humidity 
 
LS is so called due to its stability to “normal” conditions.  It has already been shown that the sub-
micron material can rehydrate, and this has been accredited to both particle size and the 
absorption of water by the ethanol solvent.  A series of experiments were performed to assess the 
stability of the dried LS sub-micron material.  
 
PXRD analysis (Figure 4.25) of the sample subjected to humid (crude experiment with %RH 
“greater than ambient”) conditions showed no change in polymorphism, implying stability under 
these conditions, as would be expected for LS.   
 
 
Figure 4.25  PXRD analysis of humidity treated SML 
 
This method of analysis was a crude attempt at rehydration of the solid material, however analysis 
by neutron diffraction within a humidity cell provided the opportunity to further investigate the 
rehydration of this material, in comparison to a larger particle size LS [18]. 
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Experiments were performed at 100% RH, and results show that on in the presence of humidity, 
the SML rehydrates to form L.H2O, indicated by the change in intensity of reflections associated 
with LS phase (Figure 4.26 and Figure 4.27), for example the reflection at ~15
o
 2θ grows in 
intensity as LS hydrates to L.H2O.  
 
Figure 4.26  Neutron diffraction patterns for L.H2O (blue) and LS (red).  Note that the 
change in background is due to H2O absorbance and anomalous scattering of H 
 
 
Figure 4.27  Hydration of SML 
 
During neutron diffraction, scattering is not always coherent as in PXRD.  Resonance scattering 
can occur where nuclei temporarily absorb neutrons, and release them later as background 
C
o
u
n
ts
2 – Theta Scale
C
o
u
n
ts
2 – Theta Scale
 
Chapter 4  Ethanolic suspensions of lactose  
Page | 130  
 
scattering.  This effect can be monitored and has been shown to indicate the absorption of water by 
zeolites [19,20].  Background counts increase with increasing amounts of absorbed water, as the 
major contribution to the background scattering originates from hydrogen present in absorbed 
water molecules.  This method, when observed over time, also provides an accurate measure of 
the rate of absorbance of water. 
 
This theory was applied to the absorption of water by SML and the larger particle size LS.  When 
observing the evolution of background counts over time, a rapid increase is observed for the SML, 
and a slower rate for the larger particle size LS.  The increase in background counts is directly 
proportional to the amount of water absorbed by the samples.  This shows that the sub-micron 
material rehydrates much more rapidly than the larger particle size LS, which is as expected given 
the higher chemical potential (resulting from a smaller radius) and therefore higher hygroscopicity 
of smaller particles.   
 
The comparison shown in Figure 4.28 highlights the difference in rate (and therefore kinetics) of 
water absorption by the two particle sizes.  The SML shows complete rehydration as the plot 
reaches a plateau at approximately 220min, however, after ~325min the larger particle size LS still 
has not completely rehydrated to L.H2O.    
 
 
 
Figure 4.28  Evolution of the hydrated polymorph 
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4.3.8 SML as a suspension aid in pMDIs 
 
When a pMDI is actuated, the formulation is very rapidly dispersed into droplets and the 
evaporation of the propellant and co-solvent (ethanol) takes place quickly due to their low boiling 
points.  This physical expansion causes high shear forces, which separate floccs, resulting in small 
particles in the inhalation particle size range.  It is an important part of the ex-actuator sample 
preparation technique to rapidly remove the solvent by capturing the sample on an inert and very 
absorbent substrate.  
 
The PXRD analysis from an ex-actuator sample of a SML product is given in Figure 4.29, clearly 
showing that after subtracting the background produced from the substrate, the lactose polymorph 
present is LS.  This indicates that the SML suspension remains stable under formulation 
conditions, whilst being subjected to accelerated storage conditions (40
o
C, 75% RH), therefore 
improving the suitability for use as a suspension aid in pMDIs.     
 
 
Figure 4.29  PXRD data for ex-actuator SML 
 
The observation of LS in this case also means that the actuation process removes solvent 
sufficiently quickly enough such that rehydration of SML to LH2O is not possible.  This is an 
important observation given that the previous neutron diffraction experiments showed that SML 
rehydrates at a faster rate than a larger particle size LS.  This stability also has positive 
implications on the functionality of the inhaler device, as it has already been shown that where 
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water ingress occurs, agglomeration of the SML material occurs, which would impair the 
performance of the inhaler device.  The lack of LH2O in these studies implies that the SML 
material remains as distinct particles, therefore allowing successful repeat actuation of the inhaler. 
 
4.3.9 Ethanolic suspensions of trehalose 
 
Samples of the trehalose suspension were collected in glass sample bottles and on an absorbent 
substrate at regular intervals throughout the suspension process.  The dried samples were 
analysed by SEM to observe the effects of the high pressure homogenisation on particle size.  The 
suspensions collected were then stored for a period of 3d and then subjected to solvent removal by 
solvent evaporation in a dry atmosphere (method 3, solvent evaporation in a dry atmosphere) 
before repeat analysis by SEM to determine the stability of the suspension. 
 
The SEM micrographs collected show that while particle size reduction is evident (Figure 4.30 
collected at 1000x magnification and Figure 4.31 collected at 2000x magnification), the suspension 
was clearly unstable and highly susceptible to crystal growth effects.  This gives a logical 
explanation for the system blockage observed during processing.  Where unstable particle 
reduction/growth events are observed, large particles may quite easily block the chambers.  The 
instability of the suspension was made particularly apparent following solvent removal after 3d 
where crystal growth effects result in the production agglomerates of more regular, cube-like 
crystals (Figure 4.32, 2000x magnification) or in some cases a network of needle-like crystals 
agglomerated into large particles (Figure 4.33, 1000x magnification). 
 
 
Figure 4.30  SEM micrograph showing ethanolic suspension of trehalose post high shear 
mixer (1000x magnification) 
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Figure 4.31  SEM micrograph showing ethanolic suspension of trehalose after 
microfluidisation (2000x magnification) 
 
 
Figure 4.32  SEM micrograph showing ethanolic suspension of trehalose after 
microfluidisation, following storage for 3d (2000x magnification) 
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Figure 4.33  SEM micrograph showing ethanolic suspension of trehalose after 
microfluidisation, following storage for 3d (1000x magnification) 
 
PXRD analysis of powders produced via solvent evaporation in a dry atmosphere after 3d storage 
of the suspensions indicated that static dehydration effects as observed in lactose suspensions do 
not occur as readily in trehalose.  Following storage for three days, the suspension collected post 
high shear mixing remained in the hydrated state of trehalose, however following microfluidisation 
(despite the blockage forming) dehydration was observed (Figure 4.34). 
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Figure 4.34  PXRD of trehalose following suspension in ethanol 
   
The instability of particle size and morphology within this suspension in renders it useless in terms 
of inhalation therapy.  The crystal growth effects already observed to cause blockages in the 
microfluidiser would have similar effects in an inhaler valve, most likely causing it to fail.  This study 
has also highlighted that the behaviour of different dehydrating sugars varies significantly under 
similar conditions.  While lactose and trehalose are similar in that they are capable of undergoing 
solvent mediated dehydration to form stable anhydrous polymorphs, in the case of lactose the 
microfluidiser processing actuates complete dehydration to the stable LS polymorph, while this 
does not appear to be the case for the trehalose suspension.  
 
4.4 Conclusions 
 
Given the success of the lactose carrier system employed in DPIs, and considering the instability 
associated with some pMDI formulations which rely heavily on refrigeration to maintain dose 
consistency and avoid API degradation, it is logical to consider the application of the DPI carrier 
system to suspended pMDI formulations.  In order for lactose to be used in this manner, an 
approach must be employed whereby the effects of polymorphism can be avoided.  As such, a 
sub-micron suspension of LS was developed. 
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The focus of this research was to understand the behaviour of lactose whilst in ethanolic 
suspension form.  Suspension in ethanol has been shown to have implications on polymorphism 
and particle size, which directly correspond to interactions with APIs and aerodynamic properties, 
each of which effect drug delivery to the lung.   
 
It has been proven that each of the suspensions (sub-micron and comparison suspensions) 
exhibited complete L.H2O dehydration and therefore contained LS.  The ability to rehydrate small 
particle sizes of LS below the expected RH has also been confirmed by the sub-micron material 
under some of the employed solvent removal systems, although once in solid form the material 
remained thermally and moisture stable as would be expected of the stable polymorph (though was 
subject to rehydration at a higher rate than a larger particle size LS at 100% RH).  The rehydration 
appears to be attributed to both particle size and method of solvent removal, as where the material 
was subjected to a relatively slower method of solvent removal in the presence of moisture in the 
air, rehydration or at least partial rehydration was observed.  Where rehydration (or partial 
rehydration) was evident, SEM analysis showed particle agglomeration.  This effect could 
potentially cause an inhaler to fail, as larger particle agglomerates do not have the same binding 
properties to actives, or the same flow properties with respect to smaller, more uniform particles.  
Larger particle agglomeration could also result in blockage of the inhaler valve, therefore 
rehydration effects must be minimised by the inhaler device to maintain deep lung dose delivery. 
 
Particle size, method of suspension preparation and solvent removal method were each evaluated 
to determine the cause of rehydration, with the results leading to particle size as the contributing 
factor.  Larger particle size suspensions produced by alternative means to the sub-micron material 
(reflux and static dehydration) did not undergo the same rehydration or even partial rehydration by 
any means of solvent removal. 
 
Solvent removal did not directly have an effect on the particle sizes or shapes produced from the 
suspensions.  The refluxing method of suspension preparation gave a particle reduction in 
comparison to starting materials with a morphology resembling that of a micronised material, 
whereas the static dehydration evolved particles that were considerably larger than the starting 
material, showing dendritic growth to large tape-like particles.    
 
The formation of these tape-like particles is of great interest, as the recrystallisation appears to 
occur without the need for external energy sources (for example, heat).  The methodology by which 
ethanol acts as a dehydration source is also of interest as it appears to be this process that 
generates the previously mentioned particles.  Future work will investigate this interaction of 
ethanol with L.H2O to generate the stable anhydrous polymorph. 
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It is also important to discuss the effect of solvent on the APIs used within inhalation formulations, 
so further research will discuss the effects of suspension formulation on salbutamol sulfate, a 
commonly used active for the treatment of asthma. 
 
The importance of these studies was to determine the suitability of the SML suspension for use 
within pMDI formulations.  To that extent, with the use of a novel ex-actuator method of sample 
preparation, this research has shown that the suspension remains stable following accelerated 
storage conditions. 
 
This study has also investigated the application of the high pressure homogenisation method of 
suspension to other dehydrating sugars, namely trehalose dihydrate.  It was made evident that the 
SML behaviour is highly specific to lactose.  In suspension form, it appears favourable for L.H2O 
to adopt a tape-like morphology on dehydration to LS, as shown in both the SML and static 
dehydrated suspensions, therefore giving an inherent stability.  This behaviour is not synonymous 
with trehalose dihydrate, which forms an unstable suspension prone to crystal growth effects.  For 
this reason, the trehalose suspension is not comparable to SML and therefore would not be 
considered for use as a pMDI suspension aid.   
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5.1 Introduction 
 
Alcoholic suspensions have been used for a number of years as a means to dehydrate hydrated 
sugars [1-3].  More recently, in the case of lactose, alcoholic suspensions have been introduced 
into formulations for use in pMDIs.  Alcohols capable of such dehydration behaviour include 
anhydrous ethanol and methanol, though due to its toxicity, methanol is not suitable for use in 
inhalation formulations. 
 
The use of fully dehydrated suspensions of lactose in pMDIs provides an inherent stability to the 
formulation.  Where complete dehydration of LH2O to LS has already occurred, there is little 
chance of further polymorphism in-situ.  This has already been demonstrated by the stability of 
placebo pMDI canisters containing the SML suspension over accelerated storage conditions 
(Chapter 4). 
 
Excipients and APIs used in inhaler devices, as well as the aerosol powders produced from them, 
have been heavily researched using a number of solid-state analytical techniques, such as PXRD, 
SEM and IR and Raman spectroscopy [4-8].  SSNMR spectroscopy is becoming more common as 
a standard technique in the characterisation of pharmaceuticals, though high resolution (solution-
state) NMR remains the most commonly used method [9].  In some instances preparation of 
samples in solution is not appropriate, for example, the case of lactose.  An aqueous medium 
would result in the previously mentioned mutarotation, leading to a mixture of L.H2O and L not 
representative of the original sample.  It is in cases such as this where SSNMR (also known as 
magic angle spinning NMR, MAS NMR) has proven invaluable.  While MAS NMR data do exist for 
some APIs and excipients [10,11], the use of this technique is by no means extensive in 
pharmaceutical analysis. 
 
This study determines the suitability of MAS NMR for the in-situ analysis of alcoholic lactose 
suspensions.  Though characterisation of inhaled pharmaceuticals by this technique is becoming 
more frequent, analysis of these materials in suspension form (i.e. mimicking the conditions of a 
pMDI) is a novel approach to understanding the interactions between alcohol and sugar, and 
polymorphic transitions as a result of solvent mediated dehydration [12].   
 
5.2 Experimental 
 
5.2.1 Preparation of anhydrous alcoholic lactose suspensions 
 
Full details of the methods of suspension preparation are given in section 4.2.1.  For the larger 
particle size comparison suspensions, ethanol (b.p. ~78
o
C) was also substituted for methanol (b.p. 
~65
o
C), n-butanol (b.p. ~118
o
C) and 3-methyl-2-butanol (b.p. ~102
o
C) to determine the effects of 
different solvents on polymorphism. 
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5.2.2 SSNMR analysis of suspensions 
 
Samples must be sealed in order to maintain the physical and chemical integrity of the lactose 
suspensions for the duration of a long experiment (for complete analysis, three days), in an 
unchanged environment.  A method was adopted for the MAS NMR of the suspensions, whereby 
small glass “bottles” were filled with the suspension and sealed, allowing the samples to be 
monitored over a period of several months with no exchange of atmosphere, no cross-
contamination and no loss of suspending alcohol.  On a practical MAS NMR level, sealing samples 
in glass bottles is necessary in order to allow the NMR experiment to progress at all.  If the 
standard MAS NMR rotor were to be filled with the suspensions in question and the rotor cap fitted, 
then despite the cap forming a very tight seal with the rotor wall, the centrifugal force generated by 
spinning at 5 kHz is sufficient to force the suspending alcohol from the rotor.  This is undesirable, 
as the ejected alcohol may cause the stator to be damaged, and the chemical and physical integrity 
of the lactose sample will change during the course of the NMR experiment.  
 
The hand-made glass inserts (Figure 5.1) were constructed using high-resolution solution-state 
3mm NMR tubes (Norell S-3-HT-400-7), which were cut to size and formed into bottles using a 
propane torch.  The inserts were filled using a narrow pipette to transfer the lactose suspension, 
and the solid component of the mixture compacted into the bottom of the bottle using centrifugation 
(10000 rpm for 10s), excess alcohol could then be removed, whilst maintaining the solvent 
environment, and more of the suspension added.  Several cycles of this addition and centrifugation 
produced a bottle filled with solid lactose, whilst ensuring alcohol still covered the sample.  The top 
of the bottle was cleaned and then sealed using an epoxy resin.  These home-made glass inserts 
could be easily spun at 5 kHz in the standard 4mm MAS NMR rotor.   
 
 
Figure 5.1  Photograph of the hand-made glass insert used for SSNMR analysis of 
suspensions in comparison to a standard 4mm rotor and a 5p coin 
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This type of analysis provided the opportunity for direct comparison of spectra of suspension and 
dried samples.  High-Resolution-MAS (HR-MAS) rotors could have been used to obtain similar 
results, but with two important disadvantages: firstly, evaporation of the volatile solvent could not 
be prevented over the required time frame, and secondly the sample could not be economically 
stored for several months as the HR-MAS rotors cost several hundred pounds each, whereas the 
hand-made inserts cost as little as 10-15p each. 
 
5.3 Results and discussion 
 
5.3.1 Solvent mediated polymorphism of lactose in ethanolic suspension 
 
MAS NMR spectroscopy allowed the polymorphic forms of lactose within the sub-micron lactose 
and larger particle comparison suspensions to be determined.  For each sample, four experiments 
were recorded (
1
H DP MAS, 
13
C{
1
H} (proton decoupled) DP MAS, 
13
C CP MAS, and 
13
C CP MAS 
(TOSS)) which provided detailed information about individual components in the ethanolic 
suspension.  The fundamental differences in the mechanism by which direct-polarisation (DP) and 
cross-polarisation (CP) excite nuclear spins, allows these two methods to be used as a simple filter 
to enhance or suppress the liquid or solid component of the mixture, with direct-polarisation 
exciting primarily the liquid component and cross-polarisation exciting nuclear spins within the solid 
component.   
 
The different relaxation times of 
13
C nuclei in solids and liquids allow a filter, in the form of a short 
relaxation delay, to be used for the 
1
H DP MAS (D1=10s) and 
13
C{
1
H} DP MAS (D1=60s) 
experiments.  These short relaxation delays removed the solid 
13
C signals from the spectrum, 
despite these resonances constituting the dominant component of the mixture.  
13
C nuclei in solid 
material may have relaxation times up to 360s and as such simply cannot relax completely in such 
a short period of time.  Consequently a spherical distribution of magnetisation is achieved from 
continuous pulses of non-relaxed nuclei.  This means that there is no net magnetisation for the 
solid components and as a consequence, the data collected are the 
1
H and 
13
C spectra of pure 
ethanol respectively.   
 
During a CP experiment, the transfer of nuclear magnetisation from the abundant 
1
H spins to the 
dilute 
13
C spins is achieved mainly via the 
1
H-
13
C through-space dipolar interactions, which are 
present in both solids and liquids.  In isotropic liquids these dipolar interactions are averaged to 
zero so it follows that there is no transfer of magnetisation to the 
13
C nuclei of ethanol in the 
samples, and therefore the liquid component is not detected.  The 
1
H and 
13
C nuclei in solid lactose 
material do experience dipolar interactions and so transfer of magnetisation is achieved to 
generate the 
13
C spectrum of the lactose polymorph present.   
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Despite the care taken in producing the hand-made glass inserts it was prudent not to spin the 
rotor above 5kHz.  This raised the possibility of spinning sidebands (SSBs) appearing, centred at 
multiples of 5kHz (rotor spinning speed) from each 
13
C signal in the spectrum.  Whilst the SSBs 
contain useful information about the 
13
C chemical shift anisotropy of each signal, it was decided 
that a clean spectrum free from SSBs would be useful in identifying subtle changes in lactose 
polymorphism which may have been masked by the presence of SSBs, therefore the “Total 
Suppression of Spinning Sidebands” 
13
C CP MAS (TOSS) NMR spectrum was also recorded.  The 
13
C signals actually displayed a small chemical shift anisotropy and few SSBs, therefore the 
spectra produced for the 
13
C CP MAS and 
13
C CP MAS (TOSS) NMR experiments are the same. 
 
Spectra obtained for these four experiments for the sub-micron suspension are shown for example 
in Figure 5.2 and Figure 5.3.  Each of the larger particle size suspensions showed a comparable 
set of data, indicating the ethanol component in the 
1
H DP MAS and 
13
C{
1
H} DP MAS, and the solid 
components in the CP MAS experiments. 
 
 
Figure 5.2  SSNMR experiment 1 for the SML suspension (
1
H DP MAS) 
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Figure 5.3  SSNMR experiments 2 (
13
C DP MAS, top), 3 (
13
C CP MAS, middle) and 4 (
13
C CP 
MAS (TOSS), bottom) for the SML suspension 
 
Comparison of the 
13
C CP MAS (TOSS) suspension data to standard L.H2O and LS (Figure 5.4, 
Figure 5.5 and Figure 5.6) indicated that each of the suspensions underwent complete dehydration 
of the L.H2O starting material to the stable anhydrous polymorph, LS.  This implies that the 
refluxing method, static dehydration and the high pressure homogenisation method of suspension 
production each proved efficient in mediating the ethanolic dehydration of L.H2O.  These results 
also confirm the previous hypothesis (section 4.3.5) that the method of solvent removal was 
responsible for the rehydration of SML, and disproves the theory that the suspension originally 
contained LH2O.   
 
406080100 ppm
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Figure 5.4  
13
C CP MAS (TOSS) NMR of refluxed ethanolic suspensions compared to LS 
30405060708090100 ppm
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Figure 5.5  
13
C CP MAS (TOSS) NMR of static dehydrated ethanolic suspensions compared 
to LS 
30405060708090100 ppm
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Extra fine crystals
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Fine powder
Spray dried 250
Spray dried
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Figure 5.6  
13
C CP MAS (TOSS) NMR of SML suspension (top) compared to LS 
 
5.3.2 Surface interactions of ethanol and lactose 
 
Close scrutiny of the 
13
C CP MAS (TOSS) NMR spectra of the ethanolic suspensions highlighted 
extra peaks anomalous to LS.  The 
13
C CP MAS experiment should only record resonances from 
solid material, however, peaks consistent with liquid ethanol were also observed in some spectra 
(~24 and 57ppm).  This implies a surface solid-liquid interaction exists with dynamic exchange 
30405060708090100 ppm
LS
SML 
suspension
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rates sufficiently slow as to impart a solid-like behaviour to surface bound ethanol.  The location of 
surface bound solvent, defects and nanostructures (which may be a source of solid-state phase 
change) is of interest for the function of the suspension within the inhalation system.   
 
The observation of strong ethanol resonances corresponding to bound surface ethanol is perhaps 
unexpected considering the relative proportions of surface bound ethanol to bulk lactose, however, 
this surface enhanced effect has previously been observed in water absorption studies of both 
mono- and multi-later polymeric species [13-15].  In these studies, the strength of water binding 
has been related to both the arrangement of polymer chains and the number and type of 
electrostatically bound cations associated with the polymer chain.  In this study, the presumed 
origin of the enhanced ethanol resonances is the strong hydrogen bonding between the bound 
water molecules and the dehydrating solvent.   
 
To further investigate these solid-like interactions, an insert containing only ethanol was prepared 
and analysed using the same data collection parameters.  Results of the 
13
C CP MAS (TOSS) 
experiment showed resonances associated with ethanol, however the intensities were significantly 
lower than those observed in the spectra of the suspensions analysed.  This effect is put into 
context by considering the filling volume of ethanol is only ~10% (after centrifugation during sample 
preparation) for the suspension samples and 100% for the pure ethanol insert.   
 
It is possible that some magnetisation transfer occurs to the ethanolic 
13
C nuclei during CP which 
can give a low intensity signal, but this does not explain the presence of peaks with very high 
intensity in the suspension spectra as such effects should be consistent for all samples.  Further 
investigation focussed on the presence of these peaks and what factors determine their intensity, 
as it did not remain constant between suspensions.   
  
There was no correlation in intensity of ethanol resonances with particle size, as emphasised by 
the sub-micron suspension.  Having the smallest particle size and therefore largest surface area, it 
would be expected that solvent interaction is at a maximum within this system, however, the 
ethanol peaks are barely visible.  Likewise, one of the largest particle sizes (and therefore 
comparatively small surface area), Lactopress spray dried 250 (static dehydration) had the greatest 
intensity, considerably larger than the lactose resonance itself.  Thus specific surface features and 
defect sites that initiate the solid-state phase change are likely to be linked to the method of 
formation, vide infra. 
 
Repeat analysis of one suspension insert four months after original analysis enabled the effect of 
time on ethanol peak intensity to be established.  A dramatic decrease in surface bound ethanol 
was observed in comparison to the original analysis after four weeks (Figure 5.7).   
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Figure 5.7  
13
C CP MAS (TOSS) NMR of Lactopress spray dried 250 static dehydrated 
ethanolic suspension after 4m storage (top) and 1m storage (middle) compared to LS 
 
30405060708090100 ppm
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There are two feasible hypotheses that may account for the decrease in detected ethanol.  It is 
possible that ethanol actively “strips” out water molecules from the lactose lattice (e.g. one 
molecule per interaction with ethanol molecule) so as dehydration becomes more complete, 
ethanol-lactose surface binding becomes less prominent and therefore ethanol 
13
C nuclei become 
less detectable (Figure 5.8(a)).  The second plausible occurrence is that the removal of one water 
molecule from the lactose lattice (following an interaction with an ethanol molecule) results in a 
cascade diffusion effect of the remaining water molecules within that particle to the surface, such 
that subsequent ethanol molecules may repeat the dehydration process (Figure 5.8(b)).  This 
theory would effect the same reduction in detectable ethanol in the 
13
C CP MAS (TOSS) 
experiment.  The discussed methods of solvent dehydration show correlation to earlier studies of 
Garnier et al. [1], who discuss destructive or cooperative removal of water molecules from the 
crystal structure of L.H2O and the subsequent effects these may have on polymorphic form, i.e. 
generation of the stable or hygroscopic anhydrous polymorph. 
 
 
Figure 5.8  Hypotheses for the mode of solvent mediated dehydration of L.H2O 
 
These theories of water removal also correspond to the particle size phenomenon occurring in the 
sub-micron suspension.  If the intensity of ethanol peak in the spectrum corresponds to extent of 
dehydration (i.e. the more complete dehydration, the less detectable ethanol) it would be expected 
that the smallest particle size and therefore largest surface area would undergo complete 
dehydration more readily than the larger particle sizes.  This is confirmed with the almost complete 
absence of ethanol resonances for the sub-micron material.  As time increases and more water 
molecules have desorbed from the L.H2O (to form LS), the ethanol resonance effect becomes 
HO-CH2CH3
LH2O bulk
H2O molecule
Site of solid-state transition
(a)
(b)
HO-CH2CH3
LH2O bulk
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less pronounced, presumably as the water molecules are lost from the crystallite matrix and 
become part of the solution.   
 
5.3.3 Solvent mediated polymorphism of lactose in methanolic and butanolic 
suspension 
 
Substitution of the ethanol for shorter (methanol), longer (n-butanol) and more hindered (3-methyl-
2-butanol) alkyl chain alcohols provided the opportunity to assess the necessary conditions for the 
dehydration of L.H2O.   
 
Methanol showed the same dehydrating nature as exhibited in the ethanolic suspensions.  
13
C CP 
MAS (TOSS) NMR showed both dehydration of L.H2O to LS and peaks attributable to methanol 
resonances in the spectrum (Figure 5.9).  This is to be expected as methanol has a smaller alkyl 
chain length than ethanol and so more likely to form the interactions necessary to facilitate 
dehydration. 
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Figure 5.9  
13
C CP MAS (TOSS) NMR of Lactopress spray dried 250 refluxed suspension in 
methanol, ethanol and n-butanol (surface bound solvent indicated by an asterisk) 
 
The main problem encountered with the methanolic suspensions occurred when sealing the glass 
inserts.  Due to the lower boiling point of methanol (~65
o
C in comparison to ethanol; ~78
o
C) the 
solvent evaporates more quickly than the epoxy resin sets, causing the solvent vapours to bubble 
through the resin and form a hole in the seal.  This issue was overcome with the use of a sealing 
wax before covering with the epoxy. 
30405060708090100 ppm
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The use of n-butanol (also shown previously for the Lactopress spray dried 250 suspension in 
Figure 5.9) showed that longer alcohol chains do not have the same dehydration effect on L.H2O, 
as the static dehydration preparation route generated L.H2O suspensions (i.e. no polymorphic 
transformation, even in smaller particle sized starting materials, Figure 5.10) and the refluxed 
methodology gave a polymorphic mixture of LS and L(Figure 5.11)The presence of Lcan be 
attributed to the higher temperature necessary to reflux n-butanol (b.p. ~118
o
C compared to 
ethanol; b.p. ~78
o
C), as well as the slower rate of removal of water, which were significant enough 
to facilitate mutarotation to the beta anomer.  The same dehydration pattern was observed in the 3-
methyl-2-butanol refluxed suspensions (Figure 5.12).  Resonances associated with bound solvent 
(3-methyl-2-butanol) were also present in the refluxed suspensions.  This observation is expected 
as some dehydration occurred on heating the suspensions. 
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Figure 5.10  
13
C CP MAS (TOSS) NMR of static dehydrated n-butanolic suspensions 
compared to LS, L and L.H2O 
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Figure 5.11  
13
C CP- MAS (TOSS) NMR of refluxed n-butanolic suspensions compared to 
LS, L and L.H2O 
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Figure 5.12  
13
C CP MAS (TOSS) NMR of 3-methyl-2-butanolic refluxed suspensions of 
Lactochem extra fine crystals compared to L LS and L.H2O 
 
The level of dehydration observed in the suspensions can also be linked to the ability of each 
alcohol to incorporate water from the L.H2O crystal structure into the bulk.  Methanol and ethanol 
are both highly miscible with water and hygroscopic, whereas n-butanol and 3-methyl-2-butanol 
have less affinity for water.  Put simply, as the carbon chain length of the alcohol increases, the 
alcohol takes on a more non-polar nature owing to the presence of increasing amounts of 
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hydrocarbon units, resulting in significantly reduced miscibility with water in n-butanol and 3-methyl-
2-butanol than in methanol and ethanol.  Combining this fact with the steric hindrance discussed 
earlier, the likelihood of butanolic dehydration of L.H2O under static, room temperature conditions 
is considerably lower than that of the methanolic or ethanolic dehydration observed.  At elevated 
temperatures the miscibility of water with longer chain alcohols increases, which conclusively 
explains the observed presence of LS under refluxed conditions in butanolic suspensions. 
 
5.3.4 Characterisation in the solid-state 
 
Each of the suspensions were subjected to solvent removal in a dry atmosphere (section 4.2.2, 
Method 3) to determine solvent effects on particle size and shape and to further confirm the 
polymorphic transformations observed in the SSNMR analysis in suspension form.  Solid-state 
analysis was in the form of PXRD and SEM analysis. 
 
5.3.4.1 PXRD analysis 
 
PXRD analysis of the dried powders (Figure 5.13 and Figure 5.14) showed that the methanolic 
dehydration gave similar products to the ethanolic suspensions, however the presence of a L 
minor phase was observed in some powders (Lactochem extra fine crystals, Lactochem spray 
dried micronised lactose) following refluxing.  This is a possible outcome for refluxed dehydration 
over 24h, though is lesser observed in ethanolic refluxes.  This effect was not observed in the static 
dehydration suspensions as the muta-rotation to form L requires thermal mediation, therefore the 
dried materials show full dehydration to LS. 
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Figure 5.13  PXRD patterns of powders produced from refluxed methanolic suspensions 
following solvent evaporation in a dry atmosphere 
 
 
Figure 5.14  PXRD patterns of powders produced from static methanolic dehydration 
following solvent evaporation in a dry atmosphere 
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The PXRD data for the solid material produced from the butanolic suspensions (Figure 5.15 and 
Figure 5.16) show good agreement with the SSNMR data collected for the suspensions.  The 
refluxing preparation route generates a dehydration and muta-rotation effect, producing a mixture 
of L and LS (also seen in the 3-methyl-2-butanol refluxed suspensions, Figure 5.17), whereas the 
static, room temperature preparation has no dehydration effect on the L.H2O.   
 
 
Figure 5.15  PXRD patterns of powders produced from refluxed n-butanolic suspensions 
following solvent evaporation in a dry atmosphere 
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Figure 5.16  PXRD patterns of powders produced from static dehydrated n-butanolic 
suspensions following solvent evaporation in a dry atmosphere 
 
 
Figure 5.17  PXRD patterns of powders produced from refluxed 3-methyl-2-butanolic 
suspensions following solvent evaporation in a dry atmosphere 
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5.3.4.2  Physical effects of solvents on lactose particles determined by SEM 
 
SEM analysis revealed that as with the ethanolic suspensions, refluxing generated a particle size 
reduction effect for both methanolic and butanolic suspensions (Figure 5.18 and Table 5.1).  This 
particle size reduction has already been attributed to the impact and attrition environment of the 
stirred reflux.   
 
 
Figure 5.18  SEM micrographs showing powders produced from 3-methyl-2-butanol refluxed 
suspensions of Lactochem extra fine crystals (left) and micronised lactose (right) 
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Suspension Ethanol Methanol n-Butanol 
Lactochem 
extra fine 
crystals 
 
 
 
 
 
 
Lactopress 
spray dried 
   
Lactopress 
spray dried 
250 
   
Lactochem 
fine powder 
   
Lactochem 
microfine 
   
Micronised 
lactose 
   
Table 5.1  SEM micrographs comparing products from refluxed suspensions 
 
Dendritic growth in the static dehydrated suspensions was observed with the methanolic 
suspensions (Table 5.2) however this effect was limited in the butanolic suspensions.  Dendritic 
growth is associated with the formation of LS, however this crystal arrangement is observed in the 
static dehydrated butanolic suspensions.  The implication of dehydration in these suspensions 
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does not correlate with the SSNMR or PXRD results presented, which show no dehydration in the 
dried products of the static suspensions, or surface bound butanol in the SSNMR of the 
suspensions.  Following the hypothesis that the formation of these crystals is associated with 
solvent mediated dehydration to the stable anhydrous polymorph, it is possible that the dehydration 
process is occurring in the butanolic suspension, however at a markedly slower rate in comparison 
to the methanolic and ethanolic suspensions, such that any presence of LS is too small a quantity 
for instrumental detection at this stage.  Assuming that the dehydration mechanism is sterically 
controlled (as previously discussed), it is logical that as the steric hindrance of the alcohol 
increases, the time taken for dehydration to be achieved should also increase.  This theory was 
reinforced by repeat PXRD analysis of the dried products from the static dehydrated butanolic 
suspensions of Lactopress spray dried and Lactochem extra fine crystals one year after 
suspension preparation (those showing signs of dendritic growth).  A typical limit of detection for 
PXRD is 3-5% by weight, therefore, as the data collected show L.H2O presence only (Figure 
5.19), any dehydration in these systems should be considered minimal. 
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Suspension Ethanol Methanol Butanol 
Lactochem 
extra fine 
crystals 
 
 
 
 
 
 
Lactopress 
spray dried 
   
Lactopress 
spray dried 
250 
   
Lactochem 
fine powder 
   
Lactochem 
microfine 
   
Micronised 
lactose 
   
Table 5.2  SEM micrographs comparing products from static dehydrated suspensions 
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Figure 5.19  PXRD comparison of static dehydrated butanolic suspensions dried after 
approximately one year 
 
5.3.5 The in-situ ethanolic dehydration of L.H2O 
 
The final stage of this research was to determine whether the dehydration of L.H2O to LS could 
be monitored in-situ.  Here, solid L.H2O was placed into the glass inserts along with anhydrous 
ethanol.  Following sealing, the insert was placed immediately into the SSNMR for analysis over a 
number of days in the hope that the transition from L.H2O to LS could be observed. 
 
The first consideration for these experiments was of particle size of L.H2O.  Typically, each of the 
static dehydrated suspensions were stored for four weeks before use to allow for complete 
dehydration in the larger particle sizes.  In order for these experiments to be successful given the 
length of time necessary to collect high quality data via SSNMR analysis, and accounting for the 
necessary time for the epoxy seal to set completely (~12-24h), the particle size of L.H2O used 
was required to be large enough that a sufficiently slow rate of dehydration was employed. 
 
The data acquisition time for the suspended samples already discussed was 5d per sample in 
order to achieve a suitable signal quality.  Analysis of the in-situ dehydration samples for this length 
of time was not appropriate, as it was possible that any dehydration may occur within this period.  
Therefore, the number of scans collected was reduced from 4000 to 100 initially (Figure 5.20).  
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Each of the data sets were analysed using the 
13
C CP MAS (TOSS) NMR experimental parameters 
outlined previously, and were compared to solid standards for phase identification.  Initial attempts 
used the largest particle size from the comparison suspensions, Lactochem extra fine crystals, 
which was prepared in approximately a 1:2 (w/v) L.H2O:ethanol ratio.   
 
 
Figure 5.20  In-situ dehydration of Lactochem extra fine crystals (data collection following 
12h sealing period, repeat analysis over 14d period) 
 
30405060708090100 ppm
LS
L.H2O
Extra fine crystals in ethanol
Chapter 5  The in-situ solid-state NMR investigation of 
lactose suspensions 
Page | 168  
 
The data collected showed a signal of sufficient quality for phase identification, however showed no 
signs of dehydration after a period of 14d.  Given that this grade of lactose has been shown to 
dehydrate in 10h-1d (section 4.3.3), it was unlikely that dehydration would occur at all and so 
further analysis was halted.   
 
When filling the glass inserts with pre-suspended material, the volume of ethanol present was not 
critical as dehydration had already occurred.  Therefore centrifugation allowed the insert to be 
packed with a sufficient amount of material to allow for a high quality signal to be recorded, whilst 
remaining under ethanolic environment.  For in-situ dehydration, the ethanolic content was critical.  
The original comparison suspensions were produced in a 1:10 L.H2O:ethanol (w/v) ratio, though it 
was shown in the SML suspension that a ratio of 1:8.4 (w/v) would also facilitate dehydration in 
micronised material.  It was necessary to attempt to replicate these ratios in the glass inserts to 
facilitate dehydration.  Due to the significantly lower solid:solvent ratio used in the larger particle 
size sample, it was acceptable that dehydration did not occur. 
 
Repeat attempts used a smaller particle size (micronised lactose) and a larger solvent ratio 
(approximately 1:4).  The solid:solvent ratio could not match the original comparison samples, as 
this would not have provided the necessary quantities of solid material for detection.  It has already 
been shown (section 4.3.3) that dehydration of this particle size L.H2O can occur in 5-10h, so it 
was possible that full dehydration would occur during the period required to ensure complete 
sealing of the insert.  Analysis using the same parameters as the larger particle size sample, 
generated a very poor signal, and so the number of scans collected was increased from 100 to 
400, giving a total data acquisition time of ~7h.  Following analysis under these conditions, the 
quality of signal achieved showed some improvement, however there were no signs of dehydration 
of L.H2O after another 14d (Figure 5.21). 
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Figure 5.21  In-situ dehydration of micronised lactose (data collection following 12h sealing 
period, repeat analysis over 14d period) 
 
The data collected also showed a resonance associated with liquid ethanol.  The peak has a very 
small integral, from which it can be assumed that this is an artefact and that some liquid (and not 
surface bound) ethanol has been detected.  Resonances as sharp and intense as these are 
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commonly attributed to solution-state analysis where the rapid tumbling of liquid molecules cancels 
out dipolar interactions, resulting in very sharp signals. 
 
Observation of the insert following removal from the instrument showed that centrifugal forces had 
acted upon the solid L.H2O present within the insert.  During spinning, the solid L.H2O had been 
pulled to the outer edge of the insert, forming a uniform coating.  This reduces the surface area of 
the L.H2O particles significantly, and so is likely to reduce the probability of any dehydration 
effects.    
 
Another insert was prepared in the same manner and stored for 10d prior to analysis, with 
occasional mixing of the suspension via gentle shaking.  It has already been shown that 
dehydration would occur at a significantly slower rate due to the reduced ethanol content, however 
the intention was that an initial storage period would promote the onset of dehydration and 
suspension prior to analysis. 
 
Results (Figure 5.22) showed little distinguishing features from the previous sample, again with no 
signs of dehydration.   
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Figure 5.22  In-situ dehydration of micronised lactose following a 10d storage period 
 
On removal of the sample, it was again observed that centrifugal forces had come into action, 
meaning that the 10d storage period was not sufficient to facilitate the production of a stable 
suspension. 
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These physical effects of centrifugal forces on suspensions have not been previously observed.  
Each of the comparison suspensions, and the SML remained fully suspended following analysis 
with spinning at 5kHz.  These effects give another insight into the suspension capabilities of SML.  
Studies [16] have shown that SML (as a suspension aid) forms a network of interlocked particles, 
capable of “locking” micronised API particles into formulation (Figure 5.23, reproduced with 
author’s permission from [16]).  It is this nature which prevents the separation and agglomeration of 
API particles in formulation. 
 
 
Figure 5.23  SML and mironised API particle 
 
It is possible that these interlocking particles can withstand the centrifugal forces exerted on the 
glass inserts when spun at 5kHz, allowing the lactose particles to remain fully suspended 
throughout the analysis period.  The same effect would apply to the comparison suspensions, 
which showed the formation of much larger dendrites in comparison to the SML material when 
dried under static conditions. 
 
5.4 Conclusions 
 
SSNMR is becoming increasingly accepted as a major characterisation technique for both actives 
and excipients.  The development of this technique pushes the boundaries of use such that this 
characterisation ability can now include suspensions.  This is ideal for inhalation therapy, as 
formulations for pMDIs already exist in suspension form.  This section of research has shown that a 
great deal more than simple species identification is obtainable using this technique, and solid-
solvent interactions can be monitored. 
 
API SML
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Application of MAS NMR aided by glass inserts to the monitoring of ethanol-lactose interactions 
specifically has given further insight into solvent mediated polymorphism, and in particular that the 
sterically controlled interactions and hence dehydration process can be monitored over time by the 
presence of ethanol resonances in the 
13
C CP MAS (TOSS) NMR spectrum.  
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6.1 Introduction 
 
There are three classes of bronchodilators, 2-adrenergic receptor agonists, methylxanthines, and 
anticholinergic agents [1].  Of these, salbutamol (also known as “albuterol”) sulfate belongs to the 
2-adrenergic receptor (or “2-adrenoceptors”) agonists, and is one of the most commonly 
administered treatments for asthma.  Activation of the 2-adrenoceptor proteins usually occurs by 
interaction with R-epinephrine, which is naturally produced in the body, however drugs such as 
salbutamol sulfate, ([C13H21NO3]2SO4, SS) are able to mimic this interaction.  
 
Various investigations into physicochemical and biological effects of SS have been performed, in 
particular, paying attention to the effects of each of the enantiomers.  API compounds are required 
to have a particular conformation in order to interact with the specific binding sites on the 2-
adrenoceptor proteins [2].  As a result, recent discussion of SS has indicated that the R-enantiomer 
(also known as levalbuterol) shows anti-inflammatory properties resulting in the relaxation of 
contracted bronchial tissue, whereas the S-enantiomer appears inactive in this role [3].  The R-
enantiomer also shows approximately a 100-fold increase in affinity for the 2-adrenoceptor sites in 
comparison to the S-enantiomer [3], and a markedly higher rate of metabolism.  It has even been 
hypothesised that, as the S-enantiomer is retained in tissues for a longer period than the R-
enantiomer, eventually hyperreactivity to bronchoconstricting stimuli ensues, therefore 
compromising the efficacy of the R-enantiomer [4-6].   
 
Following research into the preferential activity of levalbuterol, a number of papers and patents 
have arisen discussing the separation of the two enantiomers [7-11].  In spite of these studies, 
levalbuterol is not readily available commercially (for research purposes), and salbutamol is often 
still used pharmaceutically in the racemate form owing to the increased costs associated with 
enantiomeric resolution prior to formulation.  As a result, the characterisation that follows here is 
concerned with the racemate. 
 
SS may be administered in solution form in pMDIs, or in powder form for example in the Ventolin 
Accuhaler (GlaxoSmithKline), however, characterisation of this material in the solid-state, and in 
formulation is lacking.  Single crystal XRD data were collected in 1978 [12], and since then the only 
comprehensive attempts at solid-state characterisation have been carried out by Palacio et al. in 
2007 [13]. 
 
Studies into SS have also included methods of particle engineering suitable for inhalation purposes 
[14-17].  These methods often rely on crystallisation of SS from aqueous solutions with the use of 
antisolvents, however, research into the effects of these antisolvents is also not available.  It has 
recently been shown that when crystallising pharmaceutical excipients from aqueous solutions, the 
presence of antisolvents can affect polymorphism and crystal habit [18], properties which also 
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affect the suitability of APIs for use in inhaled formulations.  These studies include discussion of the 
effects of crystallisation on SS. 
 
Studies of SS by PXRD are already available [13], however SSNMR data are not, and as such 
these have been collected.  These studies also show that SS resonances can be isolated from SS/ 
L.H2O mixtures, a property unique to salbutamol as an API, and not observed in all common APIs 
used in the treatment of asthma. 
 
6.2  Experimental 
 
6.2.1 Crystallisation of SS from aqueous solutions 
 
SS (~0.1g, racemate, 3M Health Care Ltd, 99.9%) was dissolved in distilled water (~1ml) at room 
temperature.  Different antisolvents (2, 4, 6 or 8ml) were added to the SS solution without stirring or 
agitation.  The crystallisation vessels were covered to avoid solvent evaporation, and left 
undisturbed for three days to allow crystallisation to occur, however in most cases crystals were 
formed within ~12h.  The crystals were recovered and analyzed for polymorphism effects by single 
crystal X-ray diffraction.  Acetone, tetrahydrofuran, acetonitrile, ethanol, ethylene glycol, dimethyl 
sulfoxide, and dioxane (Fisher Scientific Ltd.) were selected as antisolvents. 
 
6.2.2 SSNMR investigation of SS 
 
Alongside the standard 
13
C CP MAS and 
13
C CP MAS (TOSS) experiments outlined in previous 
chapters, a series of experiments were performed such that the spectra of SS (3M Health Care Ltd, 
Alfa Aesar 99%) could be fully elucidated using solid-state methods.  
13
C and 
1
H T1 relaxation 
delays were also estimated.   
 
Non-quaternary suppression (NQS) [19] techniques, which use a dipolar-dephasing delay prior to 
acquisition decoupling, were applied to determine the positions of resonances associated with non-
protonated carbon nuclei, and phase inversion (PI) techniques [20] aided the assignment of CH2 
groups within the structure.  The two unassigned CH2 groups were then distinguished using 
solution-state heteronuclear multiple quantum coherence (HMQC) data.  
 
The saturation-recovery method, measured using the 
13
C signal intensity via CP MAS, allowed the 
proton relaxation time in SS to be determined.  A rapid series of 32 proton pulses created a 
spherical distribution of magnetisation (saturation) after which a recovery-delay allowed the 
magnetisation to relax towards equilibrium, then a standard CP excitation, ramped for the proton 
frequency, transferred the magnetisation to the 
13
C nuclei and these signals were acquired under 
conditions of proton decoupling (time proportional phase modulation, TPPM).  A series of 8 
recovery-delays were set between 0.1s and 5.0s and these were plotted against the resulting 
13
C 
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signal intensities for each NMR signal in the spectrum and then fitted with the saturation-recovery 
function:  
))exp(1]([][
1
0
T
t
tItI

    Equation 6.1  Saturation-recovery function 
(where I[t] = intensity at a given time, and I[t0] = intensity at time zero) to provide the 
1
H T1 of each 
signal in the spectrum (Figure 6.1).  
13
C T1 was determined using the Torchia method [21,22].  
During the T1 and CP MAS experiments samples were spun at 10kHz, CP MAS (TOSS) data were 
collected at 5kHz in order to comply with previous suspension analyses. 
 
 
Figure 6.1  Saturation-recovery plot of 
13
C signal intensity against relaxation delay time to 
produce 
1
H T1 values 
 
SSNMR experiments were performed on inhalable formulations of SS, typically 2% SS, 98% 
lactose and SS relaxation was compared to commercial salmeterol xinafoate (SX, 3M Health Care 
Ltd) and fluticasone propionate (FP, 3M Health Care Ltd) in the same manner. 
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6.3 Results and discussion 
 
6.3.1 Crystallisation of SS from aqueous solutions 
 
Crystallisation of SS from the slow evaporation of aqueous solution allowed the preparation of 
crystals for the redetermination of the crystal structure at 150K by single crystal X-ray diffraction 
(Figure 6.2, full details given in Appendix 2). 
 
 
Figure 6.2  Asymmetric unit of SS as determined by single crystal XRD (chiral centres 
indicated by stars) 
 
All atoms of the sulfate ion are disordered over two sets of positions with major occupancy of 
62.0(8)%.  The OH and H groups at C(8) and C(21) (the chiral centres) are also two-fold disordered 
with major occupancies 72.4(7) and 94.2(7)% respectively.  This disorder is due to the racemic 
nature of the compound; the atomic positions librate with a change in conformation between the co-
crystallised R- and S-enantiomers.  Atom O(6X) was refined with a fixed Uiso value of 0.03Å
3
 in the 
final refinement cycles.  The cations and anions link into 2D-sheets via H-bond interactions (Figure 
6.3).  Those involving NH2
+
, OH and SO4
2-
 are strong links whereas those involving CH are weaker. 
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Figure 6.3  Perspective view down b of the unit cell of SS showing packing 
 
6.3.2 Antisolvent crystallisation of SS 
 
Antisolvent precipitation was not successful in all cases.  Crystal growth was observed from 
acetone, tetrahydrofuran and ethanol antisolvents, however not in acetonitrile, dimethyl sulfoxide, 
ethylene glycol or dioxane.  Where crystal growth was successful, needle-shaped crystals formed, 
independent of crystallisation conditions, i.e. antisolvent presence, type of antisolvent used or 
volume of antisolvent.  The quantity of crystals produced was significantly smaller than those 
produced during the lactose crystallisations, therefore difficulties in recovery meant that PXRD and 
SEM analysis were not possible.   
 
Notwithstanding the change in appearance of the material produced on recrystallisation i.e. from 
micronised material (Figure 6.4) to crystals of a needle habit, single crystal XRD analysis showed 
some interesting modifications to the crystal structure of these samples.  Where the materials were 
crystallised from acetone and tetrahydrofuran, inclusion of solvent molecules into the crystal 
structure was observed (Figure 6.5 and Figure 6.6, full details given in Appendix 2). 
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Figure 6.4  SEM micrograph of micronised SS 
 
 
Figure 6.5  Asymmetric unit of acetone solvate of SS as determined by single crystal XRD 
(acetone molecules indicated by stars) 
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Figure 6.6  Asymmetric unit of tetrahydrofuran solvate of SS as determined by single crystal 
XRD (tetrahydrofuran molecules indicated by stars) 
 
In the acetone solvate, the H and OH groups at C(8) are two-fold disordered with the major 
component occupancy refined to 90.3(3)%.  The minor component oxygen was refined 
isotropically.  S(1) and O(4) lie on a 2-fold axis, while O(5) is two-fold disordered with 50/50 
occupancy across this axis.  In the tetrahydrofuran solvate the sulfate ion is also two-fold 
disordered with O(7) common to both components.  The major component occupancy is 54.4(9)%.  
The OH and H groups at C(8) and C(21) are disordered as in the pure SS structure, with major 
components occupied 92.1(7) and 80.3(9)% respectively.  Atom O(3X) was refined isotropically.  
Disorder was modelled with restraints on geometry and displacement parameters.  The disorder 
observed at atoms C(8) and C(21) arises from non-enantiomerically pure starting material, as seen 
in the redetermined SS structure. 
 
In both of the solvates, solvent molecules “cap” the hydrogen bonding in the b-direction, however 
not in the a-direction, leaving channels in the structure as wide tapes or ladders are formed running 
parallel to the b-direction (Figure 6.7 and Figure 6.8).  In non-solvated SS this is not the case 
where hydrogen bonding forms longer chains of interlinked molecules. 
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Figure 6.7  Perspective view down b of the unit cell of the acetone solvate of SS showing 
packing (top) and packing via H-bonding along b (bottom) 
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Figure 6.8  Perspective view down b of the unit cell of the tetrahydrofuran solvate of SS 
showing packing (note, for clarity only one sulfate group position is presented) 
 
The solvent molecule capping of hydrogen bonding in the OH groups was further investigated with 
the use of dioxane and ethylene glycol antisolvents (Figure 6.9).  Both of these antisolvents are 
able to form multiple hydrogen bonds, and therefore it was hypothesised that should solvation 
occur, bridging over these channels may result, thus facilitating the linking of salbutamol molecules 
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in the b-direction.  Unfortunately, this theory was not proven as crystal growth from these systems 
did not occur. 
 
Figure 6.9  Structures of dioxane (left) and ethylene glycol (right) 
 
The final system where crystallisation was observed was that which used ethanol as an antisolvent.  
This is pharmaceutically important as ethanol is commonly used as a cosolvent in the production of 
pMDIs.  Crystal growth was observed, and again, the crystals produced were needle-like in habit, 
however, single crystal XRD showed no indication of solvation.  The crystals analysed showed no 
signs of decomposition during analysis, implying that the solvate did not form at all, not that the 
crystals desolvated or degraded in air during analysis.  A number of different crystallisation 
techniques are possible (for example solvent evaporation methods, or diffusion techniques) for the 
production of samples for single crystal XRD, however, due to time constraints, these were not 
explored.  At this stage it can be concluded that under the specified conditions, ethanolates were 
not observed, however this is by no means definitive for SS. 
 
6.3.3 SSNMR investigation of SS  
 
13
C CP MAS and 
13
C CP MAS (TOSS) NMR data are presented for SS (Figure 6.10) in Figure 
6.11.  The TOSS data show the removal of some SSBs.  A change in resolution is also observed, 
along with some background effects, for example, resolution of the broad peak at ~128ppm is 
given to show two clear contributions in the TOSS data.    
 
 
Figure 6.10  Structural representation of salbutamol (non-stoichiometric) 
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Figure 6.11  
13
C CP MAS and 
13
C CP MAS (TOSS) NMR of SS 
 
NQS and PI experiments were carried out to determine the positions of resonances associated with 
non-protonated carbons and CH2 groups respectively (Figure 6.12 and Figure 6.13).  The NQS 
experiment highlights the 4 quaternary carbons in the SS structure (highlighted in Figure 6.12).  At 
higher ppm (110-160ppm) are the aromatic 
13
C signals (typically found in this region), of which 
there are 3 quaternary carbons, as indicated.  Therefore the quaternary at ~59ppm is associated 
140 120 100 80 60 40 20 ppm
13C CP MAS (TOSS)
13C CP MAS
 
Chapter 6  Characterisation of salbutamol sulfate  
Page | 188  
 
with the central carbon of the tertiary butyl (
t
Bu) group.  The NQS experiment also shows the 
t
Bu 
methyl groups, which are observed due to averaging over the CH couplings as a result of the high 
mobility of the group.  
 
 
Figure 6.12  NQS experiment highlighting quaternary carbons 
140 120 100 80 60 40 20 ppm
13C CP MAS (TOSS)
NQS
Q
Q
Q
Q
tBu
Q
Q
Q Q
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Figure 6.13  PI experiment highlighting positions of CH2 groups 
 
The PI experiment results in a change in intensity of peaks associated with CH and CH3 groups, 
such that, on subtraction from the original CP experiment (as shown in Figure 6.13), specific 
signals are removed completely.  These signals are consistent with CH2 resonances.   
 
A single SS unit contains 13 carbons, of which there are 4 quaternary, 3 CH3, 2 CH2 and 4 CH 
groups.  The data collected so far have elucidated the positions of each of the quaternary, CH3 and 
CH2 carbons, meaning those left must be associated with CH groups. 
140 120 100 80 60 40 20 ppm
13C CP MAS (TOSS)
PI (subtraction)
Q
Q
Q
Q
tBu
CH2
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The solution-state HMQC experiment (Figure 6.14) shows correlation of 
13
C and 
1
H spectra.  
13
C 
data are presented as a distortionless enhancement by polarisation transfer (DEPT) experiment, 
meaning that quaternary carbons are omitted, CH and CH3 groups are positive, and CH2 groups 
are negative.  Comparison of the HMQC data to the solid-state PI data indicates that the 
elucidation of the CH2 peak positions was correct.  Full assignment was possible by considering 
splitting due to coupling of the protons in solution-state (i.e. CH2 “A” has no proton neighbours to 
couple to, which would result in splitting, and therefore appears as a singlet, however CH2 “B” 
couples to a CH group giving a multiplet).  In the same manner, the full assignment of the CH 
groups can be performed.  The aromatic proton “X” has no proton neighbours, meaning it appears 
as a singlet.  Aromatic protons “Y” and “Z” neighbour each other (three bonds apart) and so couple 
to each other, and hence both appear as doublets.  These shifts also appear in the aromatic 
region, leaving only the CH-OH group multiplet unassigned. 
 
 
Figure 6.14  HMQC for SS in solution-state (in D2O) 
 
To summarise, Figure 6.15 shows the solid-state data again with each of the 
13
C resonances 
assigned. 
 
H2O
A
B
X
Y
Z
tBu
CH3
CH2
CH2
CH
CH
2x CH
A
BX Y
Z
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Figure 6.15  
13
C CP MAS (TOSS) NMR of SS with full assignment 
 
6.3.3.1 T1 relaxation of SS 
 
Analysis of SS using the saturation-recovery (
1
H) and Torchia (
13
C) techniques indicated a 
remarkably low 
1
H and 
13
C relaxation delay (Figure 6.16 and Figure 6.17).  This relaxation is 
comparable to a liquid sample, and as such is rarely seen in crystalline solid materials.  In the 
liquid-state, 
1
H relaxation times are typically 1-5s and 
13
C 2-20s.  In contrast, the same sample in 
solid-state (crystalline) can be expected to have a relaxation time of 60-300s for 
1
H and 60-3000s 
for 
13
C.  Proton relaxation times can be readily determined in the solid-state using these saturation-
recovery methods.  
13
C relaxation is notoriously difficult to quantify due to the considerable amount 
of NMR time required for their acquisition, however, with the use of Torchia methods, these data 
are accessible.  
1
H relaxation is particularly important to these studies, as most 
13
C data are 
collected via CP methods, which rely on the relaxation of protons (Chapter 2).  
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Figure 6.16  Comparison of 
13
C CP MAS data using a D1 delay time of 2s and 60s 
 
140 120 100 80 60 40 20 ppm
13C CP MAS D1 = 60s
13C CP MAS D1 = 2s
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Figure 6.17  T1 relaxation data for non-micronised SS 
 
A number of different sources of SS were investigated; micronised, non-micronised, and samples 
subjected to particle engineering techniques, in order to determine whether the short relaxation 
was some experimental artefact.  Micronised material is likely to contain higher levels of 
amorphous material which would show significantly faster relaxation times in comparison to 
crystalline material.  Comparisons were formed by collection of SSNMR, PXRD and SEM data for 
each source of SS (Figure 6.17 to Figure 6.29).   
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Figure 6.18  SEM micrograph of non-micronised salbutamol SS 
 
 
Figure 6.19  T1 relaxation data for Alfa Aesar SS 
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Figure 6.20  SEM micrograph of Alfa Aesar SS 
 
 
Figure 6.21  T1 relaxation data for micronised SS 
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Figure 6.22  SEM micrograph of micronised SS 
 
 
Figure 6.23  T1 relaxation data for micronised SS (2nd pass) 
 
 
Chapter 6  Characterisation of salbutamol sulfate  
Page | 197  
 
 
Figure 6.24  SEM micrograph of micronised SS (2nd pass) 
 
 
Figure 6.25  T1 relaxation data for SS Sample 1 – prepared by 3M using a proprietary particle 
engineering process 
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Figure 6.26  SEM micrograph of SS Sample 1 – prepared by 3M using a proprietary particle 
engineering process 
 
 
Figure 6.27  T1 relaxation data for SS Sample 2 - prepared by 3M using a proprietary particle 
engineering process 
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Figure 6.28  SEM micrograph of SS Sample 2 - prepared by 3M using a proprietary particle 
engineering process 
 
 
Figure 6.29  PXRD data for each SS sample 
 
PXRD data show no impurity phases, and very little variation in the samples with the exception of 
the non-micronised material, which shows improved resolution, as would be expected of a more 
crystalline sample.  Optical rotation studies were also performed and showed the materials to be 
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racemic (samples supplied by 3M are also known to be racemic), though, comparison of these 
PXRD data to the data presented in Palacio et al. [13] would imply (incorrectly) that the SS 
samples are R-enantiomeric “form 1”.   
 
SEM studies show variation in particle size distribution and morphology depending on the method 
of processing applied, again, as would be expected.  The samples produced by 3M using a 
proprietary particle engineering process are typically smooth particles and smaller than the 
micronised materials.  These samples are particularly interesting as small, smooth particles, for 
example those produced by spray drying, are often observed to have a layer of amorphous 
material at their surface.  If the short relaxation times observed are related to amorphous content, 
samples such as these would show a shorter relaxation than the highly crystalline non-micronised 
materials. 
 
Comparison of SSNMR data indicated that the short T1 relaxation was inherent to SS, as each of 
the different sources showed similar results.  For clarity, the 
13
C CP MAS (TOSS) NMR spectra are 
shown, annotated with the relaxation times of protons (
1
H T1) associated with these carbon nuclei, 
i.e. the bonded protons which are therefore coupled to these carbons and allow net magnetisation 
transfer during the CP experiment.  The 
13
C T1 relaxation times are also presented, and show 
remarkably short T1 times for a crystalline material (by comparison, the relaxation of 
13
C in lactose 
is typically 360s with the 
1
H relaxation time typically 60s).   
 
The variation in calculated T1 across the compound is related to the nature and environment of the 
protons and carbons in the crystalline material.  For example, the relaxation time of the highly 
mobile 
t
Bu group would be expected to be much shorter than for a less mobile aromatic moiety, 
and this is reflected in the measured T1 values.  These results are summarised in Table 6.1 and 
Table 6.2, where 
1
H and 
13
C relaxation is compared across the compound for each source of SS.  
Comparison of the 
1
H T1 data shows little variation, with an approximate T1 of 1s, independent of 
proton environment.  This is not the case for the 
13
C data, where a markedly shorter T1 is observed 
for the 
t
Bu CH3 carbons, the central carbon of the 
t
Bu group, and the carbon of the CH2 group 
adjacent to the NH group (CH2 “B”, Figure 6.14).  The highly mobile nature of the 
t
Bu group can 
impart a fast relaxing nature onto the central carbon, and it is possible that being adjacent to a 
quadrupolar 
14
N nucleus can have a similar effect on the CH2 group, therefore significantly 
reducing the T1 values to 3-4s.  At this point it should be noted that the Torchia methods produce 
notoriously poorer data fits than the saturation-recovery methods, and as such the 
13
C data should 
be used as an approximation, whereas the 
1
H data can be considered more accurate. 
 
In general, molecular motion within a solid crystal will give rise to a short T1.  Adamantane is used 
as a SSNMR standard due to its short T1 times, which are induced by molecular motion.  The rigid 
adamantane cages librate, which affects the whole molecule and therefore the 
13
C and 
1
H T1 
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relaxation times.  In contrast, SS has distinctly different regions in the structure, each capable of 
displaying different libration modes, and it is this motion that can be detected using T1 times. 
 
Source 
Peak position (ppm) 
153 135 129 126 118 68 59 57 52 26 
Q Q CH Q CH CH CH2 Q CH2 
t
Bu 
Non-
micronised 
981 993 960 976 860 990 1s 982 944 980 
Alfa Aesar 774 571 166 804 279 876 828 826 551 797 
Micronised 830 783 937 826 587 987 986 939 1s 959 
Micronised 
(2
nd
 pass) 
862 885 545 875 811 899 1s 771 818 1s 
3M sample 1 831 582 165 709 572 825 759 831 872 821 
3M sample 2 734 697 489 838 426 967 840 826 524 1s 
Table 6.1  Summary of 
1
H T1 relaxation data (ms unless otherwise stated).  Note “Q” denotes 
a quaternary (non-protonated) carbon 
 
Source 
Peak position (ppm) 
153 135 129 126 118 68 59 57 52 26 
Q Q CH Q CH CH CH2 Q CH2 
t
Bu 
Non-
micronised 
61 32 39 53 36 26 4 4 23 21ms 
Alfa Aesar 30 29 * 262 4 25 3 7 27 24ms 
Micronised 84 154 36 24 * 24 3 4 19 24ms 
Micronised 
(2
nd
 pass) 
464 91 101 73 68 35 4 4 31 24ms 
3M sample 1 8 6 12 7 18 20 3 4 62 24ms 
3M sample 2 84 22 102 38 262 31 4 4 15 662ms 
Table 6.2  Summary of 
13
C T1 relaxation data (s unless otherwise stated).  Note “Q” denotes 
a quaternary (non-protonated) carbon 
* a poor data fit was observed and therefore the calculated T1 was unreliable 
 
Spinning samples at 5-10kHz induces stress on the sample which may have a physical effect 
similar to micronisation, and therefore could have resulted in misinterpretation of these data if the 
samples had changed during analysis.  In order to determine any change or loss of crystallinity in 
the samples, PXRD analysis was repeated after SSNMR analysis (Figure 6.30).  The samples 
were also exposed to air for a number of days post NMR measurement and initial PXRD analysis 
(Figure 6.31) to highlight any modified or improved crystallinity which may coincide with moisture 
induced recrystallisation processes. 
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Figure 6.30  PXRD of micronised (2
nd
 pass) SS after NMR 
 
 
Figure 6.31  PXRD of micronised (2nd pass) SS before NMR 
 
The data collected highlight that there were no changes in any of the SS materials, independent of 
sample source or processing, prior to or post NMR, therefore implying that the short T1 times 
observed are an inherent property of crystalline SS and not an artefact of amorphous material 
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content.  This conclusion should have been further verified by repeat T1 analysis of the samples 
after exposure to air. 
 
6.3.3.2  SS/L.H2O mixtures 
 
The API content in an inhaled formulation is typically a few percent by weight (~2%), therefore 
observing APIs in-situ in a commercial product is difficult due to the presence of excess lactose.  
Simple subtraction of spectra is possible, however accurate subtraction involves data collection for 
two samples subjected to the same processing methods; one containing the excipient, and one 
omitting it.  These methods also require a significant amount of SSNMR instrument time, as the 
spectra recorded must display excellent signal to noise for the subtraction to be successful.  This 
often proves difficult as such samples are rarely available, and SSNMR instrument time is 
expensive in comparison to solution-state where data can be collected in a matter of minutes.   
 
The short T1 relaxation observed for SS suggested further investigation into the isolation of these 
resonances from SS/L.H2O mixtures may be possible.  L.H2O is a typical solid in SSNMR terms, 
in that it has a 
1
H relaxation time of ~60s, significantly greater than the observed T1 for SS of ~2s 
(note that 
1
H relaxation times are quoted as these are used in the CP experiments).  This means 
that the careful choice of parameters could allow the faster relaxing, minor API component to be 
detected amongst the excipient bulk (slow relaxing). 
 
Filtering of signals has already been discussed in reference to solid and liquid material in the 
lactose suspensions.  The different relaxation times of 
13
C nuclei in solids and liquids allowed a 
filter, in the form of a short relaxation delay, to be used for 
1
H DP MAS (D1=10s) experiments 
which biased the measured data and hence targeted ethanol resonances, whereas 
13
C{
1
H} DP 
MAS (D1=60s) experiments biased the measured data and hence targeted solid material, ignoring 
the liquid content of the samples.  Short relaxation delays removed the solid 
13
C signals from the 
spectrum, despite these resonances constituting the dominant component of the mixture. 
 
These methods can be applied to mixtures of materials that possess markedly different relaxation 
times, even when studying solid-state material alone.  An optimum relaxation delay (D1) of 60s 
allows the signals of SS and L.H2O to relax, thus signals are added coherently with each 
successive scan, and the resulting spectrum shows similarly intense signals from both 
components.  A significantly shorter D1 will have no effect on the fast relaxing SS, but will affect the 
L.H2O signals.  Without complete relaxation, the successive scans will not be added coherently 
for the L.H2O signals, and therefore the signal-to-noise ratio for L.H2O will not improve, 
independent of the number of scans acquired.  Figure 6.32 shows the 
13
C CP MAS (TOSS) NMR of 
a 50:50 SS:L.H2O blend, with a relaxation delay of 60s.  Clearly evident are the resonances from 
both L.H2O and SS.  When this relaxation delay is reduced to 2s (Figure 6.33 and Figure 6.34), 
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i.e. consistent with full relaxation of SS but incomplete relaxation of L.H2O, a filter is applied to 
remove most resonances from L.H2O. 
 
 
Figure 6.32  
13
C CP MAS (TOSS) NMR of a 50:50 SS:L.H2O mixture, D1=60s. * denotes the 
presence of L.H2O resonances 
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50:50 SS:L.H2O  
D1 = 60s
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Figure 6.33  
13
C CP MAS (TOSS) NMR of a 50:50 SS:L.H2O mixture, D1=2s.  * denotes the 
presence of L.H2O resonances 
 
140 120 100 80 60 40 20 ppm
SS
L.H2O
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Figure 6.34  
13
C CP MAS (TOSS) NMR of a 50:50 SS:L.H2O mixture applying the T1 filter to 
reduce L.H2O component of the spectrum.  * denotes the presence of L.H2O resonances  
 
These studies are pharmaceutically relevant as SS may be administered in DPI form, where it is 
mixed with L.H2O as an excipient.  Use of these simple analytical techniques allows the 
characterisation of API materials in-situ.  A typical inhaled formulation (e.g. Inhalac 70, provided by 
3M Health Care Ltd) consists of 2% API (in this case SS) in 98% L.H2O.  Ordinarily, a sample of 
approximately 100mg, which is sufficient to fill the rotor, is required for detection by SSNMR 
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methods, and as such, detection of small contents of API was expected to be difficult in the 
presence of bulk lactose.   
 
Figure 6.35 shows the 
13
C CP MAS NMR of the 2% SS sample using a D1 of 60s in comparison to 
2s.  The longer delay again allows all of the L.H2O material to relax fully, and therefore signals are 
detected.  In this instance, SS resonances are not detected, purely because the dominant phase 
present is that of L.H2O, i.e. there is simply not enough SS (for the given number of scans used) 
to be detected amongst the L.H2O bulk.  When the delay is reduced to 2s, the bias favours the 
fast relaxing SS.  Even though resonances of both L.H2O and SS are observed, it is important to 
note that the API is present at only 2%, and comparison of these data to those collected for the 
50% sample using a D1 of 60s, shows little spectral difference between the samples. 
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Figure 6.35  
13
C CP MAS NMR of Inhalac 70 (2% SS), filtered using the T1 delay.  D1 = 2s 
compared to D1 = 60s 
 
The importance of these NMR results, in particular for the 2% SS blend, is emphasised when 
comparing these data to PXRD data for the same samples (Figure 6.36).  PXRD is a traditional 
characterisation method applied to pharmaceuticals, however, for applications such as the 
detection of low level APIs in inhaled formulations, the limit of detection simply does not allow for 
full characterisation of the composition.  
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Figure 6.36  PXRD comparison of SS/L.H2O blends 
 
By PXRD the SS content of the Inhalac 70 sample is not detected at all, and in the 50% SS 
sample, reflections appear as a minor phase.  Preferred orientation effects in this instance prove 
problematic in the detection of SS, as the intensity of the major L.H2O reflections are increased 
and mask the SS resonances.  These studies show the potential flaws in analysis of inhalation 
blends by PXRD in comparison to SSNMR techniques.  
 
SSNMR analysis of inhaled formulations is also applicable to suspended forms of SS/lactose 
mixtures.  The 50% SS/L.H2O blend was suspended in ethanol such that static dehydration of the 
L.H2O to LS could take place.  The preparation of the suspension allowed two lines of 
investigation; firstly, static dehydration methods have been shown to result in the dendritic growth 
of LS particles [23].  The preparation of suspended SS/L.H2O would also allow any changes in 
particle morphology associated with suspension in ethanol to be observed.  Analysis in suspension 
form using the glass inserts also provides a means for the in-situ analysis of pMDI formulations (i.e. 
those containing SML). 
 
SEM analysis of the SS/L.H2O blend following the standard static dehydration period of 4w 
showed the typical dendritic growth associated with dehydration of L.H2O to LS.  SS particles 
remained as micronised material, physically unchanged by the presence of ethanol (Figure 6.37 
and Figure 6.38). 
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Figure 6.37   SEM micrograph of 50:50 SS:L.H2O blend 
 
 
Figure 6.38  SEM micrograph showing 50:50 SS:L.H2O following suspension in anhydrous 
ethanol for 4w (and therefore dehydration to LS), followed by solvent evaporation in a dry 
atmosphere 
 
SSNMR analysis of the suspended SS/LS showed similarities to the solid mixture, with the 
addition of ethanol resonances as observed in Chapter 5.  Again, by altering the D1 relaxation 
delay from 60s to 2s, different components of the suspension could be isolated (Figure 6.39).  
While dehydration was observed in the lactose material, SS showed no signs of polymorphism in 
suspended form.  
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Figure 6.39  
13
C CP MAS NMR of suspended SS/LS 
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6.3.4 Application to other APIs 
 
SS is a short acting 2-adrenoceptor agonist, used typically for the treatment of asthma during an 
attack, however salmeterol xinafoate (SX, Figure 6.40(a)) and formoterol fumarate (FF, Figure 
6.40(b)) are long acting 2-adrenoceptor agonists, which would typically be administered as 
preventatives.  Fluticasone propionate (FP, Figure 6.40(c)) is a corticosteroid and belongs to a 
second group of drugs commonly administered for the treatment of asthma.  
 
 
Figure 6.40  Structural representations of (a) SX, (b) FF and (c) FP 
 
(a)
(b)
(c)
1/2
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The relaxation of FF has previously been discussed by Apperley et al. [24], and was found to relax 
similarly to lactose with long 
1
H and 
13
C T1 times, therefore a relaxation time (D1) filter would not be 
selective in this case.  The NQS pulse program, which removes all CH resonances (CH, CH2 and 
CH3), was therefore applied to select the quaternary signals from blends of FF and L.H2O.  The 
disadvantage of using pulse sequences such as these are that any CH resonances from the API 
are also removed.  The filter applied by varying the D1 time allows full spectral detail to be 
resolved. 
   
Application of the T1 relaxation studies to SX and FP indicated that SX shows similar relaxation 
behaviour to that expected of crystalline solids, i.e. a longer T1 value (Figure 6.41).  The 
1
H data 
showed a good fit to the saturation-recovery function, and an accurately measured T1 of ~20s.  
Comparison of spectra collected with a relaxation delay of 2, 20 and 60s (Figure 6.42) indicated 
little spectral difference between the two longer delay times, however relaxation was incomplete for 
the 2s D1, indicated by the significantly poorer signal-to-noise ratio. 
 
 
Figure 6.41  
1
H T1 relaxation data for SX 
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Figure 6.42  
13
C CP MAS NMR of SX using a D1 of 2, 20 and 60s 
 
The experimental 
13
C T1 relaxation data collected using the Torchia methods provided poor signal-
to-noise over a D1 range of 1 to 60s.  These data did not fit the theoretical function well, as the 
delay times applied were not long enough to monitor the SX relaxation, and therefore the estimated 
13
C T1 values have large associated errors.  Where compounds relax over such long periods in this 
manner, the T1 is typically approximated as ten times 
1
H T1, therefore ~200s.  The 
13
C T1 relaxation 
160 140 120 100 80 60 40 20 ppm
SX D1 = 2s
SX D1 = 60s
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times provide information on the crystallinity of the sample, and the mobility of specific parts of a 
molecule.  Unfortunately, collection of the 
13
C T1 data requires the use of very long delays, even 
when using CP methods. 
 
Crystalline FP was shown to have similar relaxation properties to SS, and the saturation-recovery 
T1 relaxation experiments showed a typical 
1
H relaxation of ~1s, with a good data fit by the 
saturation-recovery methods (Figure 6.43). 
 
 
Figure 6.43  
1
H T1 relaxation data for FP 
 
The 
13
C T1 data were again collected using the Torchia method, though similarly to SX, not all data 
provided acceptable correlation to the fit function.  Of the well fitted data, two T1 times were 
generated, one showing very short relaxation (similar to the 
t
Bu group in SS), and one showing a 
longer relaxation (more akin to lactose and FF).  By comparison of these data to those collected for 
SS, it is understood that the structure of the API plays a large role in the relaxation times observed.  
The highly mobile 
t
Bu group in SS relaxed much quicker than the aromatic region, and similar 
effects are observed in FP.  The structure of FP (Figure 6.40(c)) shows multiple bonded ring 
structures with aliphatic regions protruding from the pentane ring.  It is likely that the shortest of the 
T1 values calculated are associated with these more mobile (and therefore less ordered) groups.  
Similarly to SX, poor correlation of the data to the Torchia function made a accurate 
13
C T1 
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calculation difficult. Therefore the same approximation method as in SX is applied (
13
C T1 = ~10 x 
1
H T1), giving a 
13
C T1 of ~20s.      
 
As with the SS studies, both samples were checked for crystallinity by PXRD (Figure 6.44) to 
ensure that the presence of amorphous material was not having an effect on relaxation.  PXRD 
indicated crystallinity in both cases (with little indication of any appreciable amounts of X-ray 
amorphous material) , which is to be expected as neither of the samples had been micronised. 
 
Figure 6.44  PXRD patterns for SX and FP 
 
6.3.4.1 API/L.H2O mixtures 
 
FP was prepared as a 2% L.H2O blend, for comparison to the Lactohale 70 sample.  FP was 
mixed (w/w) with micronised L.H2O, using a stirring and shaking method.  The samples were not 
ground together to avoid the formation of amorphous material.  Analysis of the blend by PXRD  
showed predominantly L.H2O (Figure 6.45), as was observed in the SS/L.H2O blends.  It is 
possible that some of the FP reflections are observed (e.g. ~10
o
 2θ), though these are very difficult 
to distinguish from background noise. 
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Figure 6.45  PXRD of 2% FP blend compared to pure FP and L.H2O.  * denotes the presence 
of FP minor phase reflections 
 
When the same sample was analysed by 
13
C CP MAS NMR with a D1 of 2 and 60s, similar results 
were observed to that of the Lactohale 70 sample (Figure 6.46).  The 
1
H T1 relaxation of these 
materials is dramatically different (FP ~2s, L.H2O ~60s), therefore the short relaxation delay acts 
as a filter to suppress the intensities of the long-relaxing L.H2O, as was seen in the SS/L.H2O 
blends.  At 60s, only L.H2O is detected, as this material forms the bulk and relaxes fully, therefore 
there is simply not enough material for the FP to be detected.  Where D1 = 2s, the FP contribution 
to the spectrum is approximately 50% as FP relaxes fully, and L.H2O relaxation is suppressed 
sufficiently to allow the 2% abundant FP to be detected clearly. 
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Figure 6.46  
13
C CP MAS NMR of 2% FP blend 
 
FP and SX are often combined in inhaled formulations, as the two APIs provide different means of 
treatment; FP provides anti-inflammatory action, while SX aids in bronchodilation [25-28].  Given 
the previous success in filtering L.H2O signals from API/L.H2O blends, and the differing 
relaxation behaviour of FP, SX and the excipient L.H2O, experimentation continued to determine 
whether signals from each component of a formulation could be isolated. 
2%FP 98%L.H2O
D1 = 2s
2%FP 98%L.H2O
D1 = 60s
FP
L.H2O
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A blend of FP (2% w/w/w) and SX (2% w/w/w) combined with L.H2O (96% w/w/w) was prepared 
using the stirring and shaking methodology applied to the preparation of FP/L.H2O and 
SS/L.H2O blends.  This tertiary blend was analysed by both PXRD and SSNMR.  PXRD analysis 
(Figure 6.47) showed similar results to that of the FP/L.H2O blend, with no detection of SX in the 
presence of L.H2O and FP (some minor phase FP reflections were again apparent, as indicated 
by the single asterisk).  The minor reflection indicated with the double asterisk (~17
o
 2θ) may be 
attributed to all three components of the blend.  The reflection found at this angle in the L.H2O 
pattern is a minor reflection, rarely attributed with preferred orientation effects [18], and as such, 
the likelihood is that this reflection is attributed to one of the API compounds.   
 
 
Figure 6.47  PXRD of a 2%FP 2%SX 96%L.H2O blend 
 
The 
13
C CP MAS NMR data (Figure 6.48) were collected with a relaxation delay D1 of 2s (FP 
relaxation), 20s (SX relaxation) and 60s (L.H2O relaxation) in the hope that different components 
of the blend could be isolated by biasing the data collection.  Results showed that where the 
relaxation delay was 60s, the 96% abundant L.H2O was the dominant component of the 
spectrum, as has been observed in the SS and FP blends.  When D1 = 20s, L.H2O again 
dominated the spectrum, with some resonances of FP being observed, however, there was no 
detection of the SX component.  When the relaxation delay was significantly reduced such that D1 
= 2s, FP resonances were clearly observed in the spectrum at approximately 50% of the signal 
intensity of the L.H2O signals, as was seen in the FP/L.H2O blend. 
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Figure 6.48  
13
C CP MAS NMR of 2%FP 2%SX 96% L.H2O blend applying the T1 filter.  Note 
the resonances observed in the SX spectrum above ~170ppm are SSBs 
 
Analysis of the pure SX sample shown in Figure 6.42 shows that a relaxation delay of 20s allows 
full relaxation of the pure material, however, in a L.H2O blend, relaxation of the major component 
is sufficient to prevent detection of the SX contribution.  The “long” relaxation time of both the SX 
406080100120140160180 ppm
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and L.H2O prevent selective filtering of the NMR signals in the tertiary blend on this basis, 
therefore, as L.H2O signals are suppressed, unfortunately so are the SX signals.  
 
As the SX contribution to the sample remained undetected using the relaxation D1 filter, an 
alternative method was attempted based on the FF investigations performed by Apperley et al. 
[24].  NQS experiments were performed in an attempt to isolate the quaternary carbons associated 
with SX, essentially to prove that it is present in the blend.  D1 delays of 20s and 2s were also 
applied to these experiments.  The 2s D1 was expected to emphasise the faster relaxing FP 
signals, and the 20s D1 the slower relaxing SX signals as well as the fully relaxed (and equally 
abundant) FP signals. 
 
In reality, detection of the SX component was not possible (Figure 6.49).  Applying a D1 of 2s 
highlighted the mobile CH3 groups of FP (similar to those observed in the SS NQS experiment), as 
well as resonances associated with quaternary carbons.  When the D1 was increased to 20s, a 
spectrum consistent with lactose was generated, which is unusual for NQS data.  The protonated 
carbons of lactose experience large 
1
H-
13
C dipolar couplings and therefore, if decoupling is 
switched off (the NQS turns off decoupling for a fraction of a second prior to acquisition) these 
signals should be suppressed.  Therefore, all 
13
C signals of L.H2O should be removed from the 
spectrum to leave quaternary signals and highly mobile 
13
C resonances in the SX and FP 
components, which are equally abundant at 2% by mass. 
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Figure 6.49  NQS experiment using delay times of 2 and 20s for the 2%FP 2%SX 96% L.H2O 
sample 
 
With more time, further investigation into the detection of SX could have included a 50% blend of 
SX and L.H2O in order to optimise the delay times applied to the NQS experiments. 
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6.4 Conclusions 
 
SS, FP, and SX are all typical APIs administered for the treatment of asthma, however solid-state 
characterisation of these materials is relatively poorly explored.  The most common drug used for 
treatment, SS, has previously been characterised by PXRD, but SSNMR data are not available, 
therefore 
13
C CP MAS NMR data have been provided, interpreted, and assigned providing 
information such as the peak positions associated with the functional groups of the structure.   The 
13
C MAS NMR data have also shown key results not available from other methods. 
 
A number of techniques for the production of small particles of SS for inhalation are available.  The 
effects of these techniques on particle size, morphology and amorphicity are generally understood, 
however, the susceptibility of SS to crystallisation effects has not been considered until now, and 
the potential for inclusion of antisolvent molecules into the crystal structure has been 
demonstrated.   
 
This investigation has also highlighted a common pharmaceutical problem; characterisation of APIs 
in blends with L.H2O, where the API occupies a small percentage (typically 2%) by mass.  
Analysis of these blends by PXRD is unsuitable as low levels of API cannot be reliably detected 
amongst the L.H2O bulk, therefore other solution-state techniques are commonly employed such 
as high-performance liquid chromatography (HPLC) [29].  While solution-state analysis is accepted 
for the characterisation of APIs, it is not a suitable method for the characterisation of inhaled 
formulations (containing L.H2O) due to the solvent mediated polymorphism effects of L.H2O.  As 
such, SSNMR was investigated as an alternative method of analysis. 
 
One of the fundamental advantages of SSNMR is the ability to tailor experiments to the properties 
of a particular material or blend of materials, such that a wealth of information can be acquired 
where other analyses are unsuitable.  The data collected targets an inherent property of all solid 
materials; the T1 relaxation.  Investigation into the 
1
H and 
13
C T1 relaxation of SS, FP and SX 
showed that SS and FP in the solid-state behave similarly to a mobile liquid phase or amorphous 
solid phase with very short T1 relaxations.  SX was found to behave as a typical crystalline 
material, with a significantly longer relaxation akin to L.H2O. 
 
T1 was also observed to be heavily correlated to the API structure, showing that highly mobile parts 
of the molecule (e.g. 
t
Bu groups) result in a significantly shorter relaxation than observed in less 
mobile parts of the structure (e.g. aromatics). 
 
These variable T1s were used as a filter to bias the NMR spectrum towards a particular component 
in the analysis of inhalable formulations.  2% SS, FP and SX/FP blends with L.H2O were prepared 
and analysed using different D1 relaxation delay times to selectively isolate different components in 
the blends.  With a relaxation delay of 60s, the spectra collected were dominated by the bulk 
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material, L.H2O, which has a highly crystalline behaviour and therefore slow relaxation.  When 
this D1 was reduced to 2s, relaxation of the APIs (with the exception of SX) was targeted, and at 
levels as low as 2%, the API component of the spectrum was observed at ~50% of the L.H2O 
intensity. 
 
SX was observed to have a 
1
H T1 of approximately 20s, which is not too dissimilar to L.H2O at 
60s, thus, when blends containing FP and SX were analysed, the spectra were dominated by either 
L.H2O or FP/L.H2O.  NQS experiments as used by Apperley et al. [24] were applied to identify 
the presence of SX, however these data remained swamped with signals associated with L.H2O.  
Further experimentation into the isolation of SX components in FP/L.H2O blends was required.  
 
Continuation of these studies was also to include the single enantiomeric R-form of SS, which is 
known to be the active enantiomer.  In particular, these studies were to include investigation into 
crystallisation susceptibility as seen in the racemate, but more importantly, continuation of the T1 
relaxation studies.  Mobility within the structure is responsible for the incredibly short relaxation 
times observed, and the crystal structures obtained show disorder around the chiral centres within 
the salbutamol molecule.  This disorder arises as the positions of the protons and OH groups 
librate.  It is possible that this is the initiation point for the mobility observed within the structure, 
and hence studies of the R-enantiomer were to determine whether the physical effect of locking SS 
into one conformation results in an increase in the T1.  Unfortunately, the single enantiomeric form 
of SS was not available at the time of these studies (known suppliers were non-responsive, and 
enantiomeric resolution attempts [7,30] proved unsuccessful), and therefore these data could not 
be collected. 
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7.1 Introduction 
 
In previous chapters, the components of pMDIs have been discussed, along with the popularity of 
salbutamol sulfate as a treatment for asthma.  Concern has also been shown for the effects of 
solvents on formulation components, and even the potential for polymorphic transitions as 
suspension aids exit the inhaler.  However, so far, there has been no discussion of the role of 
inhaler canisters on inhaler performance, or the detrimental effects they may have on dose 
reproducibility. 
 
Salbutamol sulfate is well known as a “sticky” drug, in that it is highly susceptible to adhesion to 
surfaces or carrier particles, or cohesion to form large agglomerates [1-3].  A key area of concern is 
the permanent deposition of salbutamol onto the inside of the pMDI canister during an inhaler 
lifetime, and formulations often have to compensate for this lack of deliverable API.  As a result, a 
number of different coatings (often silicon based, though all have “code names” to distinguish 
between manufacturer) have been produced in order to minimise this deposition. 
 
Typical deposition studies involve filling a coated canister with a salbutamol formulation, then 
evacuating the canister to dryness.  The canister can then be cut open and analysed for deposition 
(visually, by mass etc.) in comparison to other coatings or uncoated canisters. 
 
Discussed here is the application of 3D SEM to viewing the adhesion of salbutamol to different 
canister coatings.  Visualisation of adhesion sites is often difficult, therefore this study investigated 
the suitability of 3D SEM analysis to these samples, and determined the significance of any 
information pertaining to adhesion sites that could be obtained.  
 
7.2 Experimental 
 
7.2.1 Particle adhesion 
 
Micronised SS was dispersed in decafluoropentane (approximately 1:64 w/w) and the mixture was 
sonicated for 1min.  The suspension was dispensed into each of three of a selection of test canister 
types and the canisters were then immediately placed on a horizontal rolling mixer operating at 35 
revolutions per minute (RPM), for 10min, after which the decafluoropentane carrier fluid had 
evaporated and the micronised particles had formed an even coating on the canister internal 
surface.  The canisters were then placed in an oven at 50
o
C for 5min to complete the particle 
adhesion process by driving off any moisture. 
 
 
 
 
Chapter 7  3D SEM analysis of salbutamol sulfate 
deposition in coated inhaler canisters 
Page | 230  
 
7.2.2 Canister coatings 
 
Four different coatings were analysed for comparison, 3M proprietary coating A, 3M proprietary 
coating A 40/75 (subjected to accelerated storage conditions of 40
o
C and 75% RH), 3M proprietary 
coating B and a fluorinated ethylene propylene (FEP) coating.  The FEP coating is a commonly 
applied coating to inhaler canisters, and the novel 3M coatings were used as a comparison point. 
 
Canister coatings are applied via a plasma coating methodology [4].  A dense “diamond-like glass”, 
typically ~1000nm thick comprising carbon, silicon, hydrogen and oxygen is applied to the surface 
of the canister as a bonding layer or “pre-coating”.  Once in place, secondary layers can be applied 
for example by curing perfluorosilanes in-situ. 
 
Sections of each canister were cut and mounted on 12mm aluminium sample stubs (using Agar 
silver Dag to maintain conductivity) for SEM analysis (Figure 7.1). 
 
 
Figure 7.1  Photograph showing the removal of canister sections for sample preparation 
 
This method of sample preparation subjects the cross sections to contamination with aluminium 
filings from the cutting process, however, these would be easily identifiable in the SEM due to the 
highly conductive nature of metals and so would not compromise the results obtained. 
 
7.2.3 SEM analysis 
 
Canister analysis comprised the collection of SEM images indicating sites of salbutamol adhesion, 
followed by the removal of deposited salbutamol, and repeat analysis of the area of adhesion.  It 
was hoped that the images collected might show any surface defects or give some indication of 
why deposition occurs in these areas specifically. 
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SEM analysis was performed using a focussed ion beam (FIB) field emission gun (FEG) SEM.  
This system offers improved flexibility in terms of sample analysis, with the inclusion of a FIB as 
well as the standard electron beam.  The FIB works in a similar way to a standard SEM beam, 
however where an SEM uses an electron beam, the FIB uses ions, typically gallium.  This means 
that it has the potential to be destructive, and FIBs are commonly used for site specific analysis or 
ablation of materials. 
 
3D SEM is a novel technique whereby standard SEM images are amalgamated by computer 
software (MeX, developed by Alicona) to produce 3D “projections”.  In order to collect data for 3D 
amalgamation, three separate images must be collected per sample, with the sample stage tilted to 
10, 0 (horizontal) and -10
o
.  This is deceptively difficult, as the image in question must move only 
through this tilt axis, not in any lateral direction, as the software builds the projection from a central 
point.  To enable this, a eucentric stage is used, however, maintaining a fixed point (eucentric 
point) for analysis becomes increasingly difficult with small particles which may be influenced by 
interaction with the beam. 
 
7.3 Results and discussion 
 
7.3.1 Sample conductivity 
 
It was hoped that the analysis of aluminium (and therefore conductive) canisters would negate the 
need for gold coating.  The lack of coating would allow EDX analysis to be performed in 
combination with SEM image collection, therefore providing species identification.  Analysis without 
gold coating would also allow the easy removal of salbutamol following image collection, as 
deposited particles could simply be washed away. 
  
However, once the samples were placed into the electron beam, it was found that not only were 
particles charging, but charge build-up was also causing significant damage to the coated surface 
(Figure 7.2).  Where materials are non-conductive (i.e. insulating), a charge build up is observed in 
the form of a bright halo, as seen in the SEM images.  In extreme cases this halo can make particle 
imaging very difficult, as the edges of the sample become indistinguishable from the charging halo.  
The charging observed implied that the coatings applied to the canisters rendered them non-
conductive. 
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Figure 7.2  SEM micrograph showing damage to the coating surface 
 
Distinct, individual particles approximately 1-2m in size (Figure 7.3) interacted with the beam in a 
detrimental manner, i.e. they were “blown away”.  This was as a result of a simple charge repulsion 
effect as charge built up in both the particles and the coated surface. 
 
Chapter 7  3D SEM analysis of salbutamol sulfate 
deposition in coated inhaler canisters 
Page | 233  
 
 
 
Figure 7.3  SEM micrograph showing small particles susceptible to interaction with the ion 
beam 
 
As a result, the voltage of the electron beam was lowered from 10 to 5kV, and the samples were 
gold (sputter) coated to prevent charging.  This showed a reduction in surface damage, however, 
the beam interaction problem in small particles was not rectified.  Applying a thicker layer of gold to 
the samples was undesirable, and as such, focus had to be moved to larger particles or 
agglomerates, in order to allow image collection.  Usually larger particles would be subject to 
charge effects more so than smaller particles, however in this case, the charge build up was not 
sufficient to cause physical effects in the larger particles. 
 
7.3.2 SEM imaging 
 
Initial observations of the samples highlighted that there was significantly more material deposited 
on the 3M proprietary coating A 40/75 and FEP coatings, than on the 3M proprietary coating A and 
3M proprietary coating B coatings. 
 
Collecting images of agglomerates proved problematic in terms of locating a eucentric centre, 
because individual particles were still subject to charge build-up effects and hence movement 
under the electron beam.  It is important for a central point to be established such that, when the 
sample is tilted, the eucentric point does not move.  Each sample was imaged at 10, 0 and -10
o
 tilt 
(Figure 7.4).  The figure shows that the tilt angle is so negligible that very little difference is 
Chapter 7  3D SEM analysis of salbutamol sulfate 
deposition in coated inhaler canisters 
Page | 234  
 
observed by eye in the images produced (though when overlayed this becomes more obvious).  
This slight difference allows the 3D software to create projections based on the images provided. 
 
 
Figure 7.4  Three SEM images collected at -10, 0 and 10
o
 
 
After the images had been collected, it was important to leave a marker such that the area of 
adhesion could be found for repeat imaging following the removal of salbutamol.  The FIB was 
used as a destructive tool to ablate small areas, such that markers in the surface were created.  It 
was then possible to measure the distance from the marker to the particle or agglomerate of 
interest.  These measurements, at the correct magnification, allow the exact position of adhesion 
sites to be located following particle removal (Figure 7.5 to Figure 7.8). 
 
 
Figure 7.5  3M proprietary coating A 40/75 marker 
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Figure 7.6  3M proprietary coating A marker 
 
 
Figure 7.7  FEP marker 
Chapter 7  3D SEM analysis of salbutamol sulfate 
deposition in coated inhaler canisters 
Page | 236  
 
 
 
Figure 7.8  3M proprietary coating B marker 
 
The 3M proprietary coating B sample in particular highlights the susceptibility of the surface coating 
to beam deformation, though this varied between samples.  Where the ion beam was used to 
create the marker, significant damage to the surrounding area was observed.  This sample also 
highlighted the difficulty in particle imaging observed due to charge build-up effects.  As a result, 
the particles imaged were significantly larger than those expected and observed in other samples.  
It was suspected that these “particles” may in fact be defects in the surface coating, however as the 
samples were gold coated, this could not be confirmed by EDX analysis at this stage.  Due to the 
in-situ polymerisation which takes place in order to form these coatings, it is possible that in areas 
of excess material, uneven areas in the coating may appear. 
 
7.3.3 Generation of 3D images 
 
Each set of images were edited together using the 3D software (MeX), to generate 3D “projections” 
of the areas of interest (Figure 7.9 to Figure 7.20). 
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Figure 7.9  3M proprietary coating A 40/75 area of interest 
 
 
Figure 7.10  3M proprietary coating A 40/75 area of interest projection 
 
 
Chapter 7  3D SEM analysis of salbutamol sulfate 
deposition in coated inhaler canisters 
Page | 238  
 
 
 
Figure 7.11  3M proprietary coating A 40/75 area of interest 3D “projection” 
 
The 3M proprietary coating A 40/75 area of interest was in the form of a large agglomerate of 
particles in the region of 2m.  The 2D SEM images collected show the particulate detail, however 
this is lost in the 3D “projections”, where the particles appear to be “smoothed” together. 
   
 
Figure 7.12  3M proprietary coating A area of interest 
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Figure 7.13  3M proprietary coating A area of interest projection 
 
 
Figure 7.14  3M proprietary coating A area of interest 3D “projection” 
 
The particle selected from the 3M proprietary coating A sample is significantly larger by comparison 
to the 40/75 sample at ~80m in length.  The 3D “projections” here show a better representation of 
the surface detail of the particle, for example the adhesion of smaller particles. 
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Figure 7.15  FEP area of interest 
 
 
Figure 7.16  FEP area of interest projection 
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Figure 7.17  FEP area of interest 3D “projection” 
 
Similarly to the 3M proprietary coating A 40/75 area of interest, the FEP sample shows image 
collection from a smaller agglomerate, this time with individual particles of approximately 5m.  
Again, the morphological detail of the distinct particles that make up the agglomerate is lost during 
the 3D processing. 
 
 
Figure 7.18  3M proprietary coating B area of interest 
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Figure 7.19  3M proprietary coating B area of interest projection 
 
 
Figure 7.20  3M proprietary coating B area of interest 3D “projection” 
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The final area of interest, observed in 3M proprietary coating B, was a significantly larger mass 
(~150m), however, similar effects in the loss of surface detail were observed. 
 
Where a eucentric centre could not be maintained due to beam interactions and charge build-up in 
the particles, amalgamation of the images into 3D “projections” was unsuccessful.  Figure 7.21 
shows the images collected at three tilt angles.   
 
 
Figure 7.21  Isolated particle on the FEP coating showing lateral movement due to 
interaction with the ion beam 
 
In this instance it can clearly be seen that there is movement in the particle in a lateral direction.  
Therefore when processed by MeX, the 3D projection becomes flattened as all height information 
is lost, and does not show a genuine representation of the particle viewed due to distortion of the 
image (Figure 7.22 and Figure 7.23) 
 
 
Figure 7.22  FEP area of interest 2 projection 
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Figure 7.23  FEP area of interest 2 3D “projection” 
 
The 3D “projections” shown indicate that, due to the tilt angles employed, 3D imaging does not 
provide any useful information on how or where the particles or agglomerates bind to the canister 
coating.  Sampling at shallow tilt angles such as these only gives an image from above the areas of 
interest.  Under these conditions, it is not possible for the software to form a projection of the base 
of the particles, and as such the image is blended into the surface (Figure 7.24).   
 
 
Figure 7.24  Schematic of 3D SEM limitations 
 
It was hoped that more information regarding deposition sites would be obtained following 
salbutamol removal. 
 
 
-10o 10o
0o
3D View
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7.3.4 Removal of salbutamol sulfate 
 
Removal of deposited salbutamol sulfate was made increasingly difficult by the need for the 
samples to be gold coated.  As salbutamol is readily soluble in water, removal without gold coating 
would have simply involved washing the samples, then drying in air to avoid surface damage prior 
to repeat analysis.  With the application of gold to the surface of the canister samples, the method 
of removal was required to be harsh enough to remove the layer of conducting gold, without 
causing any damage to the coated canister surface. 
 
Initial attempts at salbutamol removal involved washing the samples with water and methanol, and 
using cotton wool to wipe the surface.  This method proved far too destructive as the surface of the 
canister was subjected to significant amounts of damage (Figure 7.25). 
 
 
Figure 7.25  SEM micrograph showing damage to canister coating 
 
Washing twice with water and then methanol only (no harsh abrasion) also proved unsuccessful as 
the particle remained, with sufficient gold coating to reduce particle charging on repeat analysis 
(Figure 7.26).  Repeating this process again gave a slightly improved degree of removal, however 
the agglomerate of interest remained, again with sufficient gold coating to prevent particle charging 
(Figure 7.27). 
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Figure 7.26  SEM micrograph showing unsuccessful removal of gold coating and 
salbutamol sulfate 
 
 
Figure 7.27  SEM micrograph showing repeat of unsuccessful washing 
 
Washing repeatedly with water and methanol (again, no harsh abrasion) also proved unsuccessful.  
The gold coating and salbutamol were removed, along with the location marker left by the FIB.  The 
marker only appears to be “gold coat” deep, meaning that removal of the salbutamol would not be 
possible whilst remaining able to locate the area of interest. 
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In the 3M proprietary coating B sample, significant damage was caused to the surface coating 
when leaving the location marker using the FIB.  However, with the difficulty observed in imaging 
small, individual particles, it was unlikely that any genuine salbutamol particles were observed, and 
hence the success of the marker was irrelevant. 
 
7.3.5 Ablation and EDX analysis 
 
It was discussed previously that the agglomerates imaged on the 3M proprietary coating B sample 
coating were significantly larger than those expected for this level of deposition.  It is therefore 
likely that these “agglomerates” were in fact defects in the coating applied to the canister.  In order 
to investigate this further, the FIB was used to prepare a cross section of one of the agglomerates, 
which could then be analysed by EDX. 
 
Before the FIB can ablate the material in question, a platinum layer is applied to the surface, which 
has two functions during ablation.  Firstly the platinum layer acts as a protection barrier from the 
gallium ions during ablation, such that the area to be analysed is not damaged during sample 
preparation.  Secondly, the presence of a platinum layer induces a consistent cutting rate across 
the feature.  For example, where a material consists of hard and soft areas at the surface, the 
softer material would be ablated quicker than the harder material, leaving an inconsistent surface.  
The presence of the platinum layer ensures that etching occurs at the same rate, regardless of the 
underlying material.  EDX analysis requires a flat surface for accurate elemental analysis, and as 
such, the Pt layer aids the production of clean surfaces for analysis (Figure 7.28, Figure 7.29 and 
Figure 7.30). 
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Figure 7.28  Preparation of cross-section 
 
 
Figure 7.29  Cross-section (image collected using the electron beam) 
Chapter 7  3D SEM analysis of salbutamol sulfate 
deposition in coated inhaler canisters 
Page | 249  
 
 
 
Figure 7.30  Cross-section (image collected using the ion beam) 
 
 
Figure 7.31  EDX projections of the cross-section 
 
Figure 7.31(a) shows the total aluminium content within the area analysed (where a brighter colour 
indicates higher content), highlighting that the cross section shows the aluminium canister at the 
base of the feature.  Figure 7.31(b) and Figure 7.31(c) show total oxygen and silicon content 
respectively, therefore confirming that the area of interest in this sample was, as suspected, a 
defect in the surface coating, and not a deposition of salbutamol sulfate.  Point EDX analysis was 
also performed for each layer present, with the results outlined in Table 7.1.  The point analysis 
reinforces the area analysis shown in Figure 7.31, as the dominant species in the base layer is 
aluminium from the canister, and the surface layer shows a silicone phase. 
 
(a) (b) (c)
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Element 
Top layer Bottom layer 
Weight % Atomic % Weight % Atomic % 
O 18.22 (± 0.31) 28.02 2.61 (± 1.28) 4.33 
Al 10.24 (± 0.21) 9.33 96.75 (± 0.06) 95.07 
Si 71.54 (± 0.07) 62.65 0.64 (± 7.4) 0.60 
Total 100 100 100 100 
Table 7.1  EDX results for the cross-section 
 
Looking closer at Figure 7.29 and Figure 7.30 the images clearly show phase boundaries within the 
deformity.  For example, the base of the image clearly shows a boundary to the aluminium canister, 
and obvious layers of the coating material where the deformation has occurred. 
 
7.4 Conclusions 
 
This study highlights the development of software to maximise the use of techniques already in 
existence, however, also shows the importance of having samples that are “fit-for-purpose”. 
 
In this instance, 3D imaging did not provide any useful information pertaining to the sites of 
adhesion of salbutamol sulfate.  Due to the tilt angles employed during sample analysis, the 
images obtained do not include detail from underneath the particles of interest.  Under these 
conditions, it is not possible for the software to postulate the environment underneath the particle, 
and as such the particle image is blended into the canister surface.   
 
While unsuccessful in this instance, the study is encouraging, and with more time and funding, 
investigation into the necessary thickness of gold coating to prevent charge build-up effects would 
be possible, along with methods by which this coating can be removed in a non-destructive 
manner.  Investigation into the preparation of location markers would also require review, such that 
successful markers deeper than the gold coating layer could be produced, allowing repeat analysis 
of the areas where adhesion was prominent.  It should also be noted at this point, that as the 3D 
imaging is both time consuming and difficult in samples of this nature, given the results achieved, 
the use of this technique for further analysis is not justified.  Much better quality and more useful 
data could be collected with the use of a standard SEM technique.  
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In order to successfully administer an inhaled drug for the treatment of asthma or chronic 
obstructive pulmonary disease (COPD), the device from which the dose is delivered and the drug 
formulation itself must both be optimised.  Technological advancements have shown the 
improvement of dry powder and pressurised metered dose inhaler (pMDI) devices, and formulation 
science has shown improvements with the inclusion of excipients.   These improvements in drug 
formulations have therefore generated a wealth of characterisation data for inhaled 
pharmaceuticals. 
 
Of the studies presented in this thesis, the crystallisation of excipients has been investigated, as 
the effects of particle size, morphology and polymorph are shown to cause variation in the 
delivered dose.  In these studies, crystallisation of lactose from aqueous solutions was promoted 
with the use of water-miscible antisolvents.  At low antisolvent content, large alpha lactose 
monohydrate (L.H2O) crystals formed, however as antisolvent content increased, beta lactose 
(L) became more dominant as indicated by the formation of small, needle-shaped crystals.  The 
crystallisation of L seemed to be encouraged by the presence of an antisolvent, as L was not 
observed in the products crystallised from saturated solutions. 
 
A common misconception is that lactose naturally crystallises as a tomahawk shaped crystal.  The 
research presented here indicated that a combination of crystallisation conditions and polymorphic 
impurities hugely influenced crystal habit, therefore assigning a “typical morphology” to L.H2O as 
a species is difficult, though the tomahawk is one such possibility. 
 
The discussed susceptibility of excipients to crystallisation environment appears to be a trait that is 
dominant in lactose alone, making its use as an excipient more complex.  While mannitol has also 
been shown to exhibit polymorphism under the same conditions, similar effects on particle 
morphology were not observed, as each polymorph crystallised in a needle habit.  Raffinose and 
trehalose hydrates were found to be stable under these crystallisation conditions, again forming 
crystals of a needle habit.  Given the extensive use of lactose as an excipient, these polymorphic 
and morphological transitions must be considered throughout each stage of the formulation 
process into a pharmaceutical, due to possible effects on dose accuracy and efficiency. 
 
Application of antisolvent crystallisation conditions to active pharmaceutical ingredient (API) 
compound salbutamol sulfate (SS) showed that APIs are also susceptible to solvent environments.  
Morphological transformations were observed, with materials recrystallised from a typical 
micronised powder, adopting a needle-like habit.  Specifically in the case of acetone and 
tetrahydrofuran antisolvents, the formation of SS solvates was observed.  This solvation is of 
particular interest when considering ethanol antisolvents, as ethanol is often used as a cosolvent in 
pMDI formulation.  In these studies, ethanol presence was shown to promote crystallisation, 
however ethanolates were not observed.  Further possible studies could include more in-depth 
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discussions of ethanol promoted crystallisation, and a similar investigation into the pure 
enantiomeric forms of SS, given that the R-form is shown to be the active form.   
 
With in-depth formulation studies come solid-state characterisation methods such as powder X-ray 
diffraction (PXRD) and solid-state nuclear magnetic resonance spectroscopy (SSNMR).  PXRD is a 
commonly used analytical tool for inhaled pharmaceuticals, both API and excipient alike, however 
data interpretation can prove problematic where samples are atypical (i.e. non-homogenous) such 
as those produced from crystallisation methods.  The effects of preferred orientation in PXRD 
analysis are usually considered a nuisance, however, these studies highlighted the possibility of its 
use as a phase identification aid, where reflections at low angle can be emphasised.   
 
Given the success of the lactose carrier system employed in dry powder inhalers (DPIs), and 
considering the instability associated with some pMDI formulations which rely heavily on 
refrigeration to maintain dose consistency and avoid API degradation, it is logical to consider the 
application of the DPI carrier system to suspended pMDI formulations.  In order for lactose to be 
used in this manner, an approach must be employed whereby the effects of polymorphism can be 
avoided.  As such, a sub-micron suspension of LS (sub-micron lactose, SML) was developed and 
investigated as a potential pMDI excipient in comparison to suspensions of larger particle size. 
 
In ethanolic suspension, L.H2O of varied particle size (2-200m, and SML) was shown to exhibit 
complete dehydration to LS.  The ability to rehydrate small particle sizes of dried LS below the 
expected RH was also confirmed by the sub-micron material, and the rate of water uptake was 
observed to be increased in comparison to a larger particle size LS at 100% RH.   
 
Particle size, method of suspension preparation and solvent removal method were each evaluated 
to determine the cause of rehydration in the SML, with the results leading to particle size as the 
contributing factor.  Larger particle size suspensions produced by alternative means to the sub-
micron material (reflux and static dehydration) did not undergo the same rehydration or even partial 
rehydration by any means of solvent removal. 
 
The method of solvent removal applied to each type of suspension did not directly affect the 
particle sizes or shapes produced in the dry powders.  The SML method of suspension produced 
particles of an oblate spheroid, or cigar shape; a morphology unique to the SML suspension.  The 
refluxing method of suspension preparation gave a particle size reduction in comparison to starting 
materials with a morphology resembling that of a micronised material, whereas the static 
dehydration evolved particles that were considerably larger than the starting material, showing 
dendritic growth to large tape-like particles.    
 
The formation of these tape-like particles is of great interest, as the recrystallisation appears to 
occur without the need for external energy sources (for example, heat).  This growth would be 
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detrimental to an inhaled formulation as in-situ morphological transitions could result in blockage of 
the device valve and therefore inhaler failure.  The methodology by which ethanol acts as a 
dehydration source is also of interest as it appears to be this process that generates the previously 
mentioned particles.  Extensions of this work therefore investigated the interaction of ethanol with 
L.H2O to generate the stable anhydrous polymorph. 
 
SSNMR is becoming increasingly popular as a major characterisation technique for both actives 
and excipients.  This technique is advantageous in comparison to analysis in the solution-state, as 
sample recovery is possible, and analysis is carried out on samples in their natural state.  This is 
particularly beneficial when considering the polymorphism of APIs and excipients in solution, for 
example, the muta-rotation of lactose.  Development of this technique pushes the boundaries of 
use such that this characterisation ability can now include suspensions.  This is ideal for inhalation 
therapy, as formulations for pMDIs already exist in suspension form.  This section of research 
showed that a great deal more than simple species identification is obtainable using this technique 
as solid-solvent interactions were monitored. 
 
Application of MAS NMR aided by hand-made glass inserts to the monitoring of ethanol-lactose 
interactions specifically gave further insight into solvent-mediated polymorphism in SML and the 
larger particle size suspensions.  In particular the sterically controlled interactions and hence 
dehydration process can be monitored over time by the presence of ethanol resonances in the 
13
C 
CP MAS NMR spectrum.  These studies indicated that the method of SML production results in a 
complete state of dehydration, unlike the larger particle sizes.  This gives the suspension an 
inherent stability in formulation terms, as no further dehydration or dendritic growth is observed on 
storage. 
 
SSNMR characterisation of inhaled formulations can also be applied to DPIs.  SS, fluticasone 
propionate (FP), and salmeterol xinafoate (SX) are all typical APIs administered for the treatment of 
asthma, however characterisation in their solid-states is relatively unexplored.  The most commonly 
used treatment, SS, has previously been characterised by PXRD, but SSNMR data, until now, 
have not been available. 
 
This investigation draws attention to a common problem in the analysis of pharmaceuticals; the in-
situ characterisation of APIs formulated into L.H2O blends, where the API occupies only 2% by 
mass.  Analysis of these blends by PXRD is unsuitable as low levels of API cannot be detected 
amongst the L.H2O bulk (PXRD limit of detection is typically 3-5% by mass), however the 
application of SSNMR has proven capable of API detection at these levels. 
 
The data collected targets an inherent property of all solid materials; the T1 relaxation.  
Investigation into the 
1
H and 
13
C T1 relaxation of SS, FP and SX showed that SS and FP in the 
solid-state behave similarly to a mobile liquid phase or amorphous solid phase with very short T1 
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relaxations.  SX was found to behave as a typical crystalline material, with a significantly longer 
relaxation, akin to L.H2O.  T1 was observed to be heavily correlated to the API structure, showing 
that highly mobile parts of the molecule (e.g. 
t
Bu groups) result in a significantly shorter relaxation 
than observed in less mobile parts of the molecule (e.g. aromatics). 
 
These variable T1s were used as a filter to bias the NMR spectrum towards a particular component 
in the analysis of inhalable formulations.  2% SS, FP and SX/FP blends with L.H2O were prepared 
and analysed using different D1 delay times to isolate different components in the blends.  With a 
relaxation delay of 60s, the spectra collected were dominated by the bulk material, L.H2O, which 
has a crystalline behaviour and therefore slow relaxation.  When this D1 was reduced to 2s, 
relaxation of the APIs (with the exception of SX) was targeted, and at levels as low as 2%, the API 
component of the spectrum was observed at ~50%.  The scope for this technique is broadened 
when considering the application of glass inserts as a sample preparation method.  These analyses 
could therefore also be applied to suspended pMDI formulations. 
 
The majority of the studies presented focussed on the behaviour of materials in formulation, and 
the in-situ detection of low level APIs, however, the inhaler device itself plays a large role in drug 
delivery.  Of equal importance to formulation developments are the improvements in device 
technology, in particular when paying attention to the adhesive nature of SS.  Inhaler canisters are 
often coated to provide a “non-stick” surface to maximise drug release from a formulation.  In the 
final set of studies presented, a developmental 3D SEM technique was applied to investigate the 
adhesion of deposited SS to coated surfaces of inhaler canisters.  It was hoped that images could 
be produced to expose the methods of surface adhesion by SS particles. 
 
In this instance, 3D SEM imaging did not provide any useful information pertaining to the sites of 
adhesion of SS.  While unsuccessful in this instance, investigation into more adequate sample 
preparation methods and data collection could result in the generation of insightful images, 
however, as 3D imaging is both time consuming and difficult in samples of this nature, given the 
results achieved, the use of this technique for further analysis is not justified.  
 
Through investigation into the solid-state properties of pharmaceutical APIs and excipients, or 
development of characterisation techniques, novel analyses of inhaled formulations have been 
presented.  The data collated have also provided simple resolutions to common industrial 
problems, namely the collection of formulation data in-situ. 
 
8.1 Future studies 
 
The body of research presented in this thesis highlights a number of areas for possible further 
investigation.  Of these, consideration of the behaviour of SS in formulation, and the detection of 
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low level APIs in the presence of lactose are probably of most interest, with considerable 
importance to the pharmaceutical industry and academic research. 
   
The studies presented indicate that solvation of SS is possible, and as such the potential for 
ethanolate formation should be further investigated.  Research has also indicated the preference of 
the R-enantiomer for use as a treatment for asthma, and as such investigation into solvation 
properties of single enantiomers should be considered.  
 
These studies have also indicated a route to the detection of low level APIs in the presence of bulk 
lactose using SSNMR methods.  This method of analysis is pharmaceutically important, as sample 
integrity is maintained whilst providing full phase characterisation.  Further studies in this field 
should target SX detection in the presence of FP and L.H2O.  Comparative studies with FF, which 
shows a similar T1 relaxation to SX, have shown success in detection below 2% by mass, and as 
such it can be speculated that optimisation of experimental conditions would provide similar 
successes in SX detection. 
 
These studies have shown that, while inhaled pharmaceuticals have been available for a number of 
years, there remains a wealth of opportunity for the development of formulations, and the 
consequent development of analysis techniques to aid the understanding of their function and 
stability.   
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A1.1 PXRD 
 
The PXRD patterns produced indicate distinct differences between the L.H2O, LS and L 
samples.  The patterns are compared to SML in Figure A1.1 [1]. 
 
The L.H2O pattern shows the major reflections occurring at the following d-spacings; 4.46Å, 4.54Å 
and 4.64Å (19.88, 19.48 and 19.04
o
 2θ respectively).  The reflection with d-spacing 4.46Å is 
particularly characteristic of L.H2O, hence its absence from the other patterns implies that there is 
no L.H2O presence within the other samples.   
 
The d-spacings for the major reflections of the L pattern occur at 4.28Å, 8.35Å and 4.22Å (20.73, 
10.55 and 20.99
o
 2θ respectively).  The reflection with d-spacing 8.35Å is indicative of the L 
polymorph as none of the other polymorphs show reflections of this intensity in this range of the 
pattern.  Again, the absence of this peak from the SML sample implies that there is no L present. 
 
The LS polymorph also has a well known PXRD pattern.  The d-spacings of the three major 
reflections occur at 4.55Å, 4.63Å and 4.89Å (19.37, 19.05 and 17.97
o
 2θ respectively).  The pattern 
also has a characteristic reflection at approximately 9
o
 2θ.  Other polymorphs do not exhibit 
reflections at such low angles, and hence this reflection can be used to detect even small quantities 
of LS.  
  
When comparing the LS pattern to that of the SML sample it is apparent that there are distinct 
crystallographic similarities.  The absence of all characteristic reflections for the other lactose 
polymorphs discounts them as a crystallographic match.  Consequently it can be concluded from 
the obtained data that SML consists of the LS polymorph and is not contaminated with L.H2O.    
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Figure A1.1  PXRD comparison of SML to standard lactose polymorphs 
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A1.2 SSNMR 
 
The resonances of L.H2O and LS have previously been documented and assigned to the 
corresponding part of the lactose molecule [2].  Comparison of the spectra produced indicates that 
SML shows agreement with the other methods of analysis, and a clear match to LS (Figure A1.2 
[1]). 
 
Figure A1.2  
13
C CP MAS NMR comparison of SML to standard lactose polymorphs 
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A1.3 IR 
 
Previous study into the IR spectra of lactose polymorphs has shown that the main diagnostic region 
is 800-1000cm
-1 
[3].  It is here where distinct differences between each of the polymorphs can be 
identified.  The spectra collected indicate the characteristic vibrational bands for each polymorph. 
 
By comparing the SML sample to the standards, it is clear that a match to the LS spectrum is seen 
(Figure A1.3 [1]).   
 
Across the full range of the spectra, there are many similarities between the polymorphs.  The 
spectra mainly comprise of a series of low wavenumber vibrations, though each have a strong 
vibrational band at ~3200cm
-1
, indicative of the intermolecular OH groups which show stretching 
frequencies in this range.  One distinct difference between the L.H2O spectrum and the 
anhydrous polymorphs are the vibrational bands at ~1650 and ~3500cm
-1
.  These stretches are 
indicative of the free water molecules within the lattice. 
 
 
Figure A1.3  IR comparison of SML to standard lactose polymorphs 
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A1.4 Raman 
 
The spectra for L.H2O, L and LS are shown in Figure A1.4 [1] along with a comparison to SML.  
Characterisation of lactose using Raman spectroscopy has been well documented since the 1970s 
[4].  It is well known that the spectra obtained for L.H2O and its anomer, L, are significantly 
different.  A change in conformation leads to alteration of C-O-H vibrations, which has a marked 
effect (through coupling) on the vibrational behaviour of the ring structure.  However, it should also 
be observed that the characteristic stretching and bending frequencies of the C-O-C glycosidic 
bond (the bond linking the two sugar moieties) are present in both spectra (~1100 and ~350cm
-1
). 
 
With regards to the SML sample, it is reasonable to expect similarities in the spectrum to that of its 
parent compound, L.H2O.  The spectrum produced is a good match to the known LS sample, 
and also shows the characteristic C-O-C stretching and bending frequencies.      
 
 
Figure A1.4  Raman comparison of SML to standard lactose polymorphs 
 
A1.5 TGA/DTA 
 
The TGA and DTA traces for each form of lactose are shown in Figure A1.5 to Figure A1.8 [1]. 
 
The differences between L.H2O and the anhydrous samples become apparent when paying 
particular attention to the number of endotherms observed in the results.  L.H2O undergoes two 
transitions, indicated by two mass decreases and corresponding endotherms in the plot.  The first 
is due to loss of water.  A natural assumption would be that this phase occurs at the boiling point of 
water, however due to interactions within the lattice, the boiling point effectively increases to 
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overcome any forces of attraction.  The transition is hence observed at approximately 120
o
C.  The 
second endotherm indicates the decomposition of the sample to oxides of carbon.   
 
For the anhydrous samples (LS, SML and L), there is no loss of water, hence a single mass loss 
is observed in the plot.  This endotherm is consequently associated with the direct decomposition 
of the samples. 
 
There are distinct similarities between the known LS sample and the sub micron lactose, such as 
the temperature of decomposition (onset at approximately 220
o
C), hence strengthening the 
argument that the sample is in fact LS and not L.H2O. 
 
 
Figure A1.5  TGA/DTA data for L.H2O 
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Figure A1.6  TGA/DTA data for L 
 
 
Figure A1.7  TGA/DTA data for LS 
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Figure A1.8  TGA/DTA data for SML 
 
  
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
-20
0
20
40
60
80
100
120
0 100 200 300 400 500 600
D
e
ri
v.
 W
e
ig
h
t 
(%
/o
C
)
W
e
ig
h
t 
(%
)
Temperature (oC)
Weight %
Deriv. Weight %/°C
 
Appendix 1   Characterisation of SML 
Page | 267  
 
A1.6 References 
 
[1] JL Crisp, SE Dann, M Edgar, CG Blatchford. The effect of particle size on the 
dehydration/rehydration behaviour of lactose, Int.J.Pharm. 391 (2010) 38-47. 
 
[2] WL Earl, FW Parrish. A cross-polarization—magic-angle sample spinning n.m.r. study of several 
crystal forms of lactose, Carbohydr.Res. 115 (1983) 23-32. 
 
[3] JH Kirk, SE Dann, CG Blatchford. Lactose: A definitive guide to polymorph determination, 
Int.J.Pharm. 334 (2007) 103-114. 
 
[4] H Susi, JS Ard. Laser-raman spectra of lactose, Carbohydr.Res. 37 (1974) 351-354. 
 
Solvent-Mediated Polymorphism and Characterisation of Inhaled Pharmaceuticals 
 
Page | 268  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2.  Single crystal XRD of 
salbutamol sulfate 
  
 
Appendix 2  Single crystal XRD of salbutamol sulfate 
Page | 269  
 
Table A2.1  Crystal data and structure refinement for SS 
 
Chemical formula  C26H44N2O10S 
Formula weight  576.69 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, Cc 
Unit cell parameters a = 27.928(3) Å  = 90° 
 b = 6.1797(7) Å  = 98.8662(19)° 
 c = 16.7859(19) Å  = 90° 
Cell volume 2862.4(6) Å
3
 
Z 4 
Calculated density  1.338 g/cm
3
 
Absorption coefficient  0.171 mm
1
 
F(000) 1240 
Crystal colour and size colourless, 0.35  0.10  0.06 mm
3
 
Reflections for cell refinement 2180 ( range 2.46 to 22.60°) 
Data collection method Bruker APEX 2 CCD diffractometer 
  rotation with narrow frames 
 range for data collection 2.46 to 27.50° 
Index ranges h 36 to 36, k 7 to 8, l 21 to 21 
Completeness to  = 27.50° 99.9 %  
Intensity decay 0% 
Reflections collected 13270 
Independent reflections 6369 (Rint = 0.0391) 
Reflections with F
2
>2 4314 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.943 and 0.990 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0471, 0.0231 
Data / restraints / parameters 6369 / 214 / 425 
Final R indices [F
2
>2] R1 = 0.0439, wR2 = 0.0942 
R indices (all data) R1 = 0.0760, wR2 = 0.1095 
Goodness-of-fit on F
2
 1.025 
Absolute structure parameter 0.36(16) i.e. not reliably determined. 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.222 and 0.269 e Å
3
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Table A2.2  Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) for 
SS.  Ueq is defined as one third of the trace of the orthogonalized U
ij
 tensor. 
 
      x      y      z      Ueq 
C(1) 0.58112(18) 0.7363(8) 0.2621(3) 0.0260(12) 
C(2) 0.57711(18) 0.9437(9) 0.2317(3) 0.0273(13) 
C(3) 0.61462(19) 1.0341(9) 0.1979(3) 0.0291(13) 
C(4) 0.65658(18) 0.9164(9) 0.1956(3) 0.0225(12) 
C(5) 0.66193(18) 0.7038(8) 0.2266(3) 0.0244(11) 
C(6) 0.62225(18) 0.6221(9) 0.2609(3) 0.0275(12) 
O(1) 0.69405(12) 0.9984(6) 0.1588(2) 0.0271(9) 
C(7) 0.70602(18) 0.5759(8) 0.2230(3) 0.0270(13) 
O(2) 0.70053(13) 0.4267(6) 0.1546(2) 0.0307(9) 
C(8) 0.53936(17) 0.6430(9) 0.3031(3) 0.0282(12) 
O(3) 0.5418(2) 0.4273(9) 0.3018(5) 0.075(3) 
O(3X) 0.5001(3) 0.626(2) 0.2548(6) 0.031(2) 
C(9) 0.54062(18) 0.7472(8) 0.3829(3) 0.0289(13) 
N(1) 0.49436(13) 0.7016(7) 0.4168(2) 0.0219(9) 
C(10) 0.4948(2) 0.7430(8) 0.5070(3) 0.0263(12) 
C(11) 0.5152(2) 0.9683(9) 0.5276(3) 0.0349(14) 
C(12) 0.44150(19) 0.7324(9) 0.5176(3) 0.0336(13) 
C(13) 0.5252(2) 0.5675(10) 0.5562(4) 0.0434(16) 
C(14) 0.27458(19) 0.7384(8) 0.3850(3) 0.0257(12) 
C(15) 0.27672(19) 0.9504(9) 0.4171(3) 0.0277(13) 
C(16) 0.23926(19) 1.0371(9) 0.4505(3) 0.0248(12) 
C(17) 0.19759(18) 0.9146(8) 0.4546(3) 0.0240(12) 
C(18) 0.19409(16) 0.7088(9) 0.4228(3) 0.0219(11) 
C(19) 0.23150(17) 0.6206(8) 0.3893(3) 0.0245(11) 
O(4) 0.16008(13) 0.9934(6) 0.4897(2) 0.0310(9) 
C(20) 0.14880(17) 0.5700(9) 0.4258(3) 0.0274(13) 
O(5) 0.15416(13) 0.4290(6) 0.4934(2) 0.0303(9) 
C(21) 0.31435(19) 0.6486(9) 0.3472(3) 0.0346(13) 
O(6) 0.31030(16) 0.4207(6) 0.3380(3) 0.0565(14) 
O(6X) 0.3606(11) 0.636(10) 0.393(3) 0.030 
C(22) 0.31402(18) 0.7504(8) 0.2637(3) 0.0263(12) 
N(2) 0.35866(14) 0.7064(6) 0.2304(2) 0.0225(9) 
C(23) 0.3578(2) 0.7521(8) 0.1410(3) 0.0256(12) 
C(24) 0.3374(2) 0.9772(8) 0.1225(4) 0.0366(15) 
C(25) 0.4101(2) 0.7421(9) 0.1274(3) 0.0383(14) 
C(26) 0.3280(2) 0.5789(9) 0.0936(3) 0.0329(14) 
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S(1) 0.42365(11) 0.1974(6) 0.3401(2) 0.0384(7) 
O(7) 0.4247(7)  0.0364(15) 0.3298(10) 0.031(3) 
O(8) 0.4731(3) 0.2737(11) 0.3733(5) 0.0439(19) 
O(9) 0.4070(3) 0.3065(12) 0.2609(4) 0.046(2) 
O(10) 0.3909(2) 0.2388(11) 0.3982(4) 0.0510(19) 
S(1X) 0.43144(12) 0.1954(6) 0.3093(3) 0.0127(10) 
O(7X) 0.4296(10)  0.042(2) 0.3167(16) 0.021(3) 
O(8X) 0.4483(5) 0.3098(19) 0.3832(6) 0.034(3) 
O(9X) 0.3833(3) 0.2778(18) 0.2743(6) 0.028(2) 
O(10X) 0.4657(3) 0.2253(13) 0.2519(5) 0.027(2) 
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Table A2.3  Crystal data and structure refinement for SS acetone solvate. 
 
Chemical formula C32H56N2O12S 
Formula weight  692.85 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, C2/c 
Unit cell parameters a = 28.445(3) Å  = 90° 
 b = 6.1414(7) Å  = 107.3986(15)° 
 c = 22.007(2) Å  = 90° 
Chemical formula C32H56N2O12S 
Cell volume 3668.6(7) Å
3
 
Z 4 
Calculated density  1.254 g/cm
3
 
Absorption coefficient  0.149 mm
1
 
F(000) 1496 
Crystal colour and size colourless, 0.49  0.33  0.14 mm
3
 
Reflections for cell refinement 5977 ( range 2.79 to 30.42°) 
Data collection method Bruker APEX 2 CCD diffractometer 
 rotation with narrow frames 
 range for data collection 1.94 to 31.35° 
Index ranges h 40 to 40, k 8 to 8, l 30 to 32 
Completeness to  = 30.00° 99.8 %  
Intensity decay 0% 
Reflections collected 20618 
Independent reflections 5731 (Rint = 0.0271) 
Reflections with F
2
>2 4553 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.931 and 0.980 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0614, 2.3098 
Data / restraints / parameters 5731 / 47 / 240 
Final R indices [F
2
>2] R1 = 0.0467, wR2 = 0.1215 
R indices (all data) R1 = 0.0603, wR2 = 0.1303 
Goodness-of-fit on F
2
 1.039 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.413 and 0.484 e Å
3
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Table A2.4  Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) for 
SS acetone solvate.  Ueq is defined as one third of the trace of the orthogonalized U
ij
 tensor. 
 
      x      y      z      Ueq 
C(1) 0.17413(4) 0.6110(2) 0.31059(6) 0.0262(2) 
C(2) 0.18149(4) 0.4009(2) 0.33463(6) 0.0288(3) 
C(3) 0.22839(5) 0.3117(2) 0.35518(6) 0.0269(2) 
C(4) 0.26895(4) 0.43293(19) 0.35191(5) 0.0229(2) 
O(1) 0.31569(3) 0.35150(14) 0.37175(5) 0.0304(2) 
C(5) 0.26248(4) 0.64599(19) 0.32837(5) 0.0224(2) 
C(6) 0.21482(4) 0.7306(2) 0.30751(6) 0.0252(2) 
C(7) 0.30569(5) 0.7841(2) 0.32649(6) 0.0287(3) 
O(2) 0.32316(3) 0.91780(15) 0.38247(5) 0.0336(2) 
C(8) 0.12230(4) 0.7013(2) 0.28438(7) 0.0316(3) 
O(3) 0.12362(4) 0.9259(2) 0.29407(9) 0.0664(6) 
O(3X) 0.1001(3) 0.7508(16) 0.3182(4) 0.029(3) 
C(9) 0.10282(4) 0.6359(2) 0.21490(6) 0.0256(2) 
N(1) 0.04926(3) 0.68480(15) 0.18726(4) 0.01980(18) 
C(10) 0.02744(4) 0.65638(18) 0.11562(5) 0.0230(2) 
C(11)  0.02799(5) 0.6747(3) 0.10244(7) 0.0441(4) 
C(12) 0.04730(7) 0.8354(2) 0.08270(7) 0.0428(4) 
C(13) 0.04064(6) 0.4328(2) 0.09672(6) 0.0345(3) 
S(1) 0.0000 0.18634(7) 0.2500 0.03702(14) 
O(4) 0.0000 0.42642(19) 0.2500 0.0314(3) 
O(5) 0.00856(10) 0.0892(3) 0.19815(10) 0.0428(5) 
O(6) 0.04844(8) 0.1332(4) 0.31056(10) 0.0391(5) 
O(5X) 0.03982(8) 0.1100(3) 0.22827(12) 0.0373(4) 
O(7) 0.37585(4) 0.65917(18) 0.48226(5) 0.0404(2) 
C(14) 0.35746(6) 0.5370(3) 0.51198(7) 0.0388(3) 
C(15) 0.30844(8) 0.5830(5) 0.52060(11) 0.0728(6) 
C(16) 0.38294(9) 0.3354(3) 0.54193(11) 0.0664(6) 
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Table A2.5  Crystal data and structure refinement for SS tetrahydrofuran solvate. 
 
Chemical formula  C34H60N2O12S 
Formula weight  720.90 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, Cc 
Unit cell parameters a = 28.154(2) Å   = 90° 
 b = 6.1756(5) Å   = 116.2099(11)° 
 c = 24.0401(19) Å  = 90° 
Cell volume 3750.0(5) Å
3
 
Z 4 
Calculated density  1.277 g/cm
3
 
Absorption coefficient  0.148 mm
1
 
F(000) 1560 
Crystal colour and size colourless, 0.46  0.13  0.08 mm
3
 
Reflections for cell refinement 3884 ( range 2.93 to 26.03°) 
Data collection method Bruker APEX 2 CCD diffractometer  
 rotation with narrow frames 
 range for data collection 1.61 to 28.32° 
Index ranges h 37 to 37, k 8 to 8, l 32 to 32 
Completeness to  = 28.32° 99.9 %  
Intensity decay 0% 
Reflections collected 18413 
Independent reflections 9153 (Rint = 0.0306) 
Reflections with F
2
>2 6528 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.935 and 0.988 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0514, 1.8241 
Data / restraints / parameters 9153 / 167 / 506 
Final R indices [F
2
>2] R1 = 0.0465, wR2 = 0.1093 
R indices (all data) R1 = 0.0718, wR2 = 0.1231 
Goodness-of-fit on F
2
 1.035 
Absolute structure parameter 0.28(17) 
Largest and mean shift/su 0.005 and 0.001 
Largest diff. peak and hole 0.426 and 0.279 e Å
3
 
  
 
Appendix 2  Single crystal XRD of salbutamol sulfate 
Page | 275  
 
Table A2.6  Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) for 
SS tetrahydrofuran solvate.  Ueq is defined as one third of the trace of the orthogonalized U
ij
 
tensor. 
 
      x      y      z      Ueq 
C(1) 0.79228(17) 1.0190(8) 0.3935(2) 0.0249(10) 
C(2) 0.80326(17) 0.8123(9) 0.4177(2) 0.0271(10) 
C(3) 0.85202(17) 0.7169(8) 0.4357(2) 0.0251(10) 
C(4) 0.89320(17) 0.8318(8) 0.43198(19) 0.0237(10) 
O(1) 0.94207(12) 0.7413(5) 0.44987(15) 0.0273(8) 
C(5) 0.88376(17) 1.0421(7) 0.40880(19) 0.0222(9) 
C(6) 0.83435(18) 1.1337(8) 0.3899(2) 0.0247(10) 
C(7) 0.92893(18) 1.1764(8) 0.4076(2) 0.0267(10) 
O(2) 0.95394(13) 1.3105(5) 0.46104(15) 0.0309(8) 
C(8) 0.73760(17) 1.1185(8) 0.3672(2) 0.0292(11) 
O(3) 0.74125(16) 1.3420(7) 0.3738(2) 0.0550(14) 
O(3X) 0.7209(8) 1.163(3) 0.4055(9) 0.002(5) 
C(9) 0.70831(16) 1.0410(8) 0.3013(2) 0.0254(10) 
N(1) 0.65080(13) 1.1010(6) 0.27364(15) 0.0203(8) 
C(10) 0.62008(16) 1.0769(7) 0.20513(19) 0.0241(9) 
C(11) 0.6285(2) 0.8548(8) 0.1848(2) 0.0359(12) 
C(12) 0.6374(2) 1.2579(8) 0.1732(2) 0.0379(13) 
C(13) 0.56156(19) 1.1018(9) 0.1908(2) 0.0382(12) 
C(14) 0.42697(17) 0.0235(8) 0.2768(2) 0.0264(10) 
C(15) 0.41885(19)  0.1904(8) 0.2544(2) 0.0263(10) 
C(16) 0.36920(18)  0.2846(8) 0.2344(2) 0.0254(10) 
C(17) 0.32840(17)  0.1718(7) 0.23881(19) 0.0210(9) 
C(18) 0.33528(18) 0.0441(7) 0.26062(19) 0.0238(9) 
C(19) 0.38653(17) 0.1330(8) 0.28030(19) 0.0244(10) 
O(4) 0.27897(12)  0.2576(5) 0.22120(16) 0.0290(8) 
C(20) 0.29229(19) 0.1727(8) 0.2630(2) 0.0284(10) 
O(5) 0.26680(12) 0.3114(5) 0.20875(15) 0.0286(7) 
C(21) 0.48258(18) 0.1134(7) 0.3023(2) 0.0285(10) 
O(6) 0.48034(16) 0.3373(7) 0.2949(3) 0.0509(18) 
O(6X) 0.5047(6) 0.137(4) 0.2690(7) 0.072(7) 
C(22) 0.51256(17) 0.0466(8) 0.3700(2) 0.0253(10) 
N(2) 0.56978(13) 0.0997(6) 0.39675(15) 0.0207(8) 
C(23) 0.60190(17) 0.0819(7) 0.46774(18) 0.0252(10) 
C(24) 0.5844(2) 0.2563(9) 0.4972(2) 0.0352(13) 
C(25) 0.5924(2)  0.1456(7) 0.4870(2) 0.0348(12) 
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C(26) 0.65869(18) 0.1100(10) 0.4791(2) 0.0356(12) 
O(7) 0.61037(19) 0.84169(18) 0.3353(2) 0.0313(3) 
S(1) 0.61893(18) 0.6058(5) 0.3439(2) 0.0260(8) 
O(8) 0.5760(3) 0.5234(11) 0.3602(4) 0.0399(19) 
O(9) 0.6708(2) 0.5574(11) 0.3984(3) 0.0374(19) 
O(10) 0.6186(4) 0.5129(11) 0.2895(3) 0.050(3) 
S(1X) 0.5990(2) 0.6018(7) 0.32317(19) 0.0316(8) 
O(8X) 0.6032(4) 0.5059(15) 0.3817(4) 0.046(2) 
O(9X) 0.6442(3) 0.5138(14) 0.3159(4) 0.047(2) 
O(10X) 0.5494(3) 0.5578(13) 0.2716(3) 0.040(2) 
O(11) 0.96612(15) 1.1171(7) 0.56841(16) 0.0425(9) 
C(27) 0.9196(2) 1.1585(11) 0.5773(3) 0.0536(15) 
C(28) 0.9208(3) 1.0077(12) 0.6255(3) 0.0691(17) 
C(29) 0.9607(3) 0.8472(10) 0.6324(4) 0.118(3) 
C(30) 0.9882(2) 0.9143(10) 0.5975(2) 0.0486(15) 
O(12) 0.25373(14) 0.1178(6) 0.10150(15) 0.0383(9) 
C(31) 0.23003(19)  0.0828(8) 0.0716(2) 0.0341(11) 
C(32) 0.2735(2)  0.1949(8) 0.0621(2) 0.0494(10) 
C(33) 0.3049(3)  0.0122(11) 0.0567(4) 0.100(3) 
C(34) 0.2983(2) 0.1630(9) 0.0905(3) 0.0550(16) 
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